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ABSTRACT  
 
 
Characterization of the Substrate Specificity and Mechanism of Protein Arginine 
Methyltransferase 1 
 
by 
 
 
Whitney Wooderchak, Doctor of Philosphy 
 
Utah State University, 2008 
 
 
Major Professor:  Joan M. Hevel, Ph.D. 
Department:  Chemistry and Biochemistry 
 
 
Protein arginine methyltransferases (PRMTs) posttranslationally modify protein 
arginine residues.  Type I PRMTs catalyze the formation of monomethylarginine (MMA) 
and asymmetric dimethylarginine (ADMA) via methyl group transfer from S-adenosyl 
methionine onto protein arginine residues.  Type II PRMTs generate MMA and 
symmetric dimethylarginine.  PRMT-methylation affects many biological processes.  
Although PRMTs are vital to normal development and function, PRMT-methylation is 
also linked to cardiovascular disease, stroke, multiple sclerosis, and cancer.   
Thus far, nine human PRMT isoforms have been identified with orthologues 
present in yeast, plants, and fish.  PRMT1 predominates, performing an estimated 85% of 
all protein arginine methylation in vivo.  Yet, the substrate specificity and catalytic 
mechanism of PRMT1 remain poorly understood.   
Most PRMT1 substrates are methylated within repeating ‘RGG’ and glycine-
arginine rich motifs.  However, PRMT1 also methylates a single arginine on histone-H4 
 iii
that is not embedded in a glycine-arginine motif, indicating that PRMT1 protein 
substrates are not limited to proteins with ‘RGG’ sequences.  In order to determine if 
PRMT1 displays broader substrate selectivity, I first developed a continuous 
spectrophotometric assay to measure AdoMet-dependent methyltransferase activity.  
Using this assay and a focused peptide library based on a sequence derived from the in 
vivo PRMT1 substrate fibrillarin, we observed that PRMT1 demonstrates amino acid 
sequence selectivity in peptide and protein substrates.  PRMT1 methylated eleven 
substrate motifs that went beyond the ‘RGG’ and glycine-arginine rich paradigm, 
suggesting that the methyl arginine proteome may be larger and more diverse than 
previously thought. 
PRMT1 methylates multiple arginine residues within the same protein to form 
protein-associated MMA and ADMA.  Interestingly, ADMA is the dominant biological 
product formed and is a predictor of mortality and cardiovascular disease.  To understand 
why PRMT1 preferentially forms ADMA in vivo, we began to 1) probe the mechanism of 
ADMA formation and 2) examine the catalytic role of certain active site residues and 
their involvement in ADMA formation.  We found that PRMT1 dissociatively methylated 
several peptide substrates and preferred to methylate mono-methylated substrates over 
their non-methylated counterparts.  Methylation of a multiple arginine-containing 
substrate was systematic (not random), a phenomenon that may be important 
biologically.  All in all, our data help explain how PRMT1 generates ADMA in vivo.   
(204 pages) 
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CHAPTER 1 
 
INTRODUCTION 
 
 
Protein arginine methyltransferase (PRMT) enzymes are involved in a wide 
variety of cellular communication in eukaryotes.  In addition to phosphorylation, 
acetylation, and glycosylation, protein arginine methylation is one more post translational 
modification that enables organisms to expand upon their limited genome.  PRMT-
methylation affects many biological processes including RNA processing, signal 
transduction, DNA repair, transcriptional regulation (reviewed in [1]), viral infection [2], 
chromatin remodeling [3], and neuronal cell differentiation [4].    The molecular basis for 
these events lies in the fact that methylation of protein arginine residues has the ability to 
enhance or disrupt certain protein-protein interactions, protein-DNA interactions, and 
protein-RNA interactions (described further in Chapter 2).   
Thus far, eleven PRMT isoforms have been identified in humans (PRMT1-11) 
with orthologs present in yeast, protozoa, Caenorhabditis elegans, Drosophila 
melanogaster, plants, and fish.  The breadth of these enzymes indicates the vital 
biological importance of arginine methylation across the plant and animal kingdoms.  
The significance of protein arginine methylation has also been demonstrated in PRMT1 
null mice that died early during embryonic development [5] and PRMT4 null mice that 
showed incorrect cell differentiation [6].  Although PRMTs are vital to survival, protein 
arginine methylation has been linked to carcinogenesis [7], viral pathogenesis [2], 
multiple sclerosis [8], spinal muscular atrophy [9], lupus [10], cardiovascular disease 
[11], and stroke [12].  Therefore, the elucidation of the regulation and mechanism of 
these enzymes will prove invaluable.   
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PRMTs transfer a methyl group from S-adenosyl methionine (AdoMet/SAM) 
onto a positively charged arginine residue in the protein substrate, and S-adenosyl 
homocysteine (AdoHcy/SAH) is produced.  Type I PRMTs (PRMT1, 3, 4, 6, and 8) 
catalyze the formation of monomethylarginine (MMA) and asymmetric dimethylarginine 
(ADMA) via the transfer of a methyl group from S-adenosyl methionine (AdoMet/SAM) 
onto protein arginine residues.  PRMT5 and 7, both type II enzymes, generate MMA and 
symmetric dimethylarginine (SDMA).  Opposing biological consequences result from 
whether a protein has been asymmetrically or symmetrically dimethylated [reviewed in 
1]. 
Although much research has been performed on PRMTs since their cloning a little 
over ten years ago, the substrate specificity of PRMT1 (the most predominant PRMT 
isoform that performs over 85% of all protein arginine methylation) [13], remains 
unclear.  Few in vivo PRMT1 protein substrates have been identified, and the mechanism 
of PRMT1 remained uncharacterized until recently [14].  Importantly, in order to 
understand how PRMTs impact biology, we must first understand how these enzymes 
select certain substrates over others and perform catalysis.  The purpose of this 
dissertation is to add to the overall understanding of PRMT catalysis and substrate 
specificity by characterizing the mechanism and substrate selection of the most 
predominant PRMT isoform, PRMT1.   
In Chapter 3, I helped develop the first continuous spectrophotometric assay for 
AdoMet-dependent methyltransferases and demonstrated the utility of this assay with 
PRMT1.  Prior to this assay, PRMTs were assayed with peptide substrates and 
radioactively-labeled AdoMet.  Radioactively-methylated peptide was then hydrolyzed 
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and analyzed by HPLC [15].  Because this method is laborious and expensive, it is not 
practical for screening many peptides.  In order to perform the types of kinetic analyses 
needed to address PRMT1 substrate specificity, we needed a more robust, higher 
throughput assay. In collaboration with Dr. Sunny Zhou, we developed a continuous 
spectrophotometric coupled assay (see Chapter 3) to measure AdoMet-dependent 
methyltransferase activity.  Our assay employs two recombinant coupling enzymes, 
AdoHcy nucleosidase and adenine deaminase.  AdoHcy nucleosidase hydrolyzes 
AdoHcy, a product and inhibitor of methyltransfer, into adenine and S-ribosyl 
homocysteine.  Adenine is then converted into hypoxanthine via adenine deaminase 
which results in a decrease at 265 nm that can be monitored continuously with time.  This 
assay was used repeatedly in several chapters of this dissertation. 
In Chapter 4, we investigated the substrate specificity of PRMT1.  Before 2007, 
little was known regarding the substrate specificity of PRMT1 other than the fact that 
PRMTs methylate arginine residues in glycine/arginine rich areas of proteins within 
‘RGG’ and ‘RXR’ motifs.   From recent studies, it is now known that 1) certain 
negatively charged surface residues of PRMT1 are important for substrate binding [16], 
2) substrate positive charge positioned near the active site is important for PRMT1 
catalysis [17], and 3) the N-terminus of PRMT1 influences substrate specificity [18].  
Our study advanced the current understanding of PRMT1 substrate selection by 
examining the primary amino acid sequence determinants of PRMT1 substrates.  Using 
the continuous assay (discussed in Chapter 3) and a focused peptide library based on a 
sequence derived from the in vivo PRMT1 substrate fibrillarin, we showed that PRMT1 
displays substrate sequence selectivity at the amino acid level (see Chapter 4).  We report 
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that PRMT1 has the ability to methylate eleven motifs that go beyond the ‘RGG’ and 
‘RXR’ glycine/arginine rich paradigm suggesting that the methyl arginine proteome may 
be larger and more diverse than previously thought.   
In Chapter 5, we tried to understand why PRMT1 predominantly forms ADMA in 
vivo by investigating how PRMT1 dimethylates substrate arginine residues 
mechanistically.  Although PRMT1 is capable of forming both MMA and ADMA, most 
PRMT1 substrates are found in vivo in the dimethylated state with multiple dimethylated 
arginines on the same protein.  Numerous studies have shown a relationship between 
elevated ADMA concentration and cardiovascular disease [19], and PRMT1 has been 
shown to be overexpressed in myocardial tissue taken from coronary heart disease 
patients [20].  Two possible ways to explain the predominance of ADMA formation are 
1) preference for the mono-methylated substrate over the nonmethylated substrate or 2) 
processive methylation.  Our data indicate that PRMT1 dissociatively methylates single 
arginine-containing peptides despite any increase in peptide length.  PRMT1 
preferentially methylated monomethylated substrates over unmodified substrates, a 
preference that would inevitably increase the amount of ADMA.  Interestingly, 
methylation of a multiple arginine-containing substrate was shown to be systematic 
wherein one arginine was preferentially methylated over another.  This is important 
because the biological response may change depending on which protein arginine residue 
is methylated first.  Finally, PRMT1 was shown to dissociatively methylate a multiple 
arginine-containing substrate.  Based on these results, the predominance of dimethylated 
protein substrates in vivo is likely due to the ability of PRMT1 to preferentially methylate 
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monomethylated versus unmodified arginine-containing proteins (see Chapter 5), a 
phenomenon that may depend on substrate sequence.   
In Chapter 6, we investigated certain PRMT1 active site residues and their 
catalytic roles.  Cheng and coworkers proposed that a conserved methionine residue 
among type I PRMTs (M155 in the PRMT1 active site) may ensure the formation of 
ADMA due to steric hindrance afforded by a bulky methionine residue [21].  Type II 
PRMTs such as PRMT5 have a smaller alanine residue at this site and form SDMA.   
When analyzing the methylation products formed from M155A-PRMT1, a mutant 
PRMT1 that alleviated any steric hindrance afforded by this active site methionine 
residue, no SDMA was present.  This suggests that Met155 does not affect asymmetric 
versus symmetric dimethylation formation (see Chapter 6).  Another conserved active site 
methionine residue (M48 in PRMT1) adjacent to AdoMet and the substrate arginine in 
the PRMT1 crystal structure was shown to be very important in catalysis.  M48A-
PRMT1 was nearly catalytically inactive while M48L-PRMT1 demonstrated a catalytic 
efficiency approximately half that of WT-PRMT1.  These results indicated that the length 
of this amino acid residue is important in PRMT catalysis based on its proximity to the 
substrate arginine (see Chapter 6).  Further product analysis from an extended reaction 
with M48L-PRMT1 revealed that this mutant was also not capable of generating SDMA.  
Thus, removing steric bulk afforded by Met155 or Met48 in the PRMT1 active site is not 
by itself sufficient to transform PRMT1 into a Type II PRMT.   
Chapter 7 includes experimental results from several projects that have yet to be 
completed.  In one project, we found that the amino acid sequence of certain peptide 
substrates directly affects the extent that a particular substrate is mono- and dimethylated.  
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Furthermore, we noticed that substrate inhibition of PRMT1 occurred at high substrate 
concentrations when using an ‘RGA’-containing fibrillarin-based peptide versus one 
housing an ‘RGG’ sequence.  Together, these data indicate how the composition of the 
substrate sequence can alter the extent that a particular substrate is methylated.  Next, I 
examined the importance of an interaction between the substrate and the conserved THW 
loop among PRMTs by mutating two residues (H293 and W294 to an alanine on 
PRMT1) and assessing the activity of each with several substrates.  In another project, I 
showed how the AdoMet/AdoHcy ratio present in healthy and diseased individuals 
affected PRMT1 activity.  Finally, I determined the Ki for a fibrillarin-based peptide 
containing ADMA. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
METHYLATION 
 
After DNA is transcribed into mRNA in the nucleus, processed mRNA can be 
translated into amino acids by the ribosomal complex in the cytosol.  After the emerging 
string of amino acids from the ribosome is folded into a three-dimensional protein, this 
protein can then be post translationally modified.  While an organism’s genome has the 
ability to code for a variety of proteins, post translational modifications such as 
phosphorylation, acetylation, glycosylation, and methylation enable organisms to expand 
upon their limited genomes.   
Methylation requires the presence of 1) a methyl donor such as S-adenosyl 
methionine (AdoMet/SAM) or tetrahydrofolate (THF) and 2) a methyl acceptor.  AdoMet 
is the second most widely used enzyme substrate in the cell [1].  The preference for 
AdoMet over other methyl donors such as THF results from the favorable energetics of 
the AdoMet-dependent methyltransferase reaction (-17 kcal/mol).  This amount of energy 
is more than twice the amount released during ATP hydrolysis.  This energy does not 
come without a cost.  The de novo biosynthesis of AdoMet costs the cell twelve 
equivalents of ATP making AdoMet the most expensive metabolic compound on a per 
carbon basis [2].  (Note, recycling AdoMet from AdoHcy costs the cell only 1 ATP.) 
Thus far, five families of AdoMet-dependent methyltransferases have been 
identified (Classes I through V) suggesting five independent evolutionary paths to 
methyltransferases [3].  Classes I and V contain most of the protein methyltransferases 
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while the other classes are comprised of small molecule, DNA, and RNA 
methyltransferases.  Although enzymes from the different families have diverse structural 
requirements for the way in which they bind AdoMet, they all share the same basic 
mechanism (Fig. 2-1).  First, the positively charged sulfur moiety of AdoMet causes the 
S-CH3 bond to be polarized.  This polarization facilitates the nucleophilic attack of the 
“+CH3” group by an electron rich nitrogen, oxygen, or carbon target atom.  Ultimately, 
the electrons push towards the sulfur moiety in AdoMet resulting in the formation of the 
methylated target atom and S-adenosyl homocysteine (AdoHcy/SAH) [4].   
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     Fig. 2-1.  General reaction mechanism for AdoMet-dependent methyltransferases.  A 
general base (B:) abstracts a proton from the target atom (X=N, O, or C) prior to or 
during the course of the SN2 reaction mechanism.  A transition state is forms from the 
nucleophilic attack of the polarizable target atom onto the methyl group carbon of 
AdoMet.  Ultimately, electrons push towards the sulfur moiety in AdoMet resulting in the 
formation of AdoHcy and X-CH3.  
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Among protein methyltransferases, nitrogen is the most dominant nucleophile.  
N-methylation of exposed lysine and arginine residues does not alter the positive charge 
of the amino acid, but it does increase the hydrophobicity and steric bulk of the residue 
which can disturb the way in which the modified protein interacts with certain biological 
molecules.  Lysines can be mono, di, or tri-methylated, whereas the guanidino nitrogens 
of arginine can be mono- or dimethylated.  In addition to lysine and arginine, the 
imidazole ring of histidine and the side chain amide nitrogens of glutamine and 
asparagine can be methylated.  The methylation of protein histidine, glutamine, and 
asparagine residues is not readily reversible under physiological conditions.  On the other 
hand, methyl groups transferred onto the nitrogens of DNA bases are readily removed 
through enzymatic oxygenation resulting in the formation of formaldehyde and the 
starting base [5].  
In addition to nitrogen, proteins can also be methylated on oxygen atoms to form 
methyl esters.  O-methylation of surface protein aspartates and glutamates neutralizes the 
negative charge on the carboxylate side chain and adds hydrophobicity to the protein 
surface.  This modification is readily reversible, and the hydrolysis of protein methyl 
esters is often used as a signal during bacterial chemotaxis [6].        
Although nitrogen and oxygen containing amino acid side chains are most 
commonly methylated, certain Archaeal methanogenic bacteria methylate proteins on 
electron-rich carbon and sulfur atoms.  To date, methanogenic bacteria are the only 
organisms on earth that have the ability to C-methylate protein arginyl and glutamyl side 
chains.  The methanogenic enzyme methyl-coenzyme M reductase, which helps catalyze 
the last step in the formation of methane, was shown crystallographically to contain C-
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methylated arginine and glutamine side chains, an N-methylated histidine, and an S-
methylated cysteine residue [7].  The function of these peculiar modifications in 
methanogens is unknown. 
 
PROTEIN ARGININE METHYLATION 
 
  Arginine residues were first shown to contain methyl groups in 1967 [8].  Since 
then, arginine methylation has been shown to be a vital, relatively abundant 
posttranslational modification.  Two percent of all protein arginine residues are 
asymmetrically dimethylated in rat liver nuclei [9], and approximately 12% of all 
arginine residues isolated from heterogeneous nuclear ribonucleoproteins (hnRNPs) are 
asymmetrically dimethylated [10].   
The enzymes responsible for methylating protein arginine residues in both the 
nucleus and cytoplasm are the protein arginine methyltransferases (PRMTs).  Thus far, 
eleven PRMT isoforms have been identified in humans with homologues present in yeast, 
protozoa, Caenorhabditis elegans, Drosophila melanogaster, plants, and fish [11].  The 
breadth of these enzymes indicates the vital biological importance of arginine 
methylation across the plant and animal kingdoms.  The significance of protein arginine 
methylation has also been demonstrated in PRMT1 null mice that died early during 
embryonic development [12] and PRMT4 null mice that showed incorrect cell 
differentiation [13].   
PRMTs perform the general SN2 reaction mechanism characteristic of most 
AdoMet-dependent methyltransferases where an active site glutamate residue is proposed 
to abstract a proton from the substrate arginine residue (see Fig. 2-1).  Methylation of 
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positively charged protein-arginine residues occurs via the attack of the terminal 
nucleophilic guanidino nitrogen onto the methyl group of AdoMet forming monomethyl 
arginine (MMA) and AdoHcy (Fig. 2-2).  PRMTs can transfer another methyl group onto 
MMA resulting in the dimethylation of certain protein-arginine residues.  Type I PRMTs 
(PRMT1, 3, 4, 6, and 8) transfer a second methyl group onto the previously modified 
guanidino nitrogen to form asymmetric dimethylarginine (ADMA).  Type II PRMTs 
(PRMT5 and 7) transfer another methyl group to the unmodified guanidino nitrogen 
creating symmetric dimethylarginine (SDMA).   
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     Fig. 2-2. Reactions catalyzed by PRMTs.  PRMTs catalyze the S-adenosylmethionine 
(AdoMet) dependent methylation of a protein substrate arginine residue to form 
monomethyl arginine (MMA).  Type I methyltransferases, PRMT1, 3, 4, 6, 8, and 10  
dimethylate arginine asymmetrically to form asymmetric dimethyl arginine (ADMA).  
Type II methyltransferases, PRMT5, 7, and 9 catalyze the formation of symmetric 
dimethyl arginine (SDMA) where each guanidino nitrogen is modified.   
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PROTEIN ARGININE METHYL- 
TRANSFERASE FAMILY 
 
Despite the discovery of protein arginine methylation thirty years ago, the PRMTs 
were not cloned until recently.    Thus far, eleven PRMT isoforms have been identified 
(see Fig. 2-3).  The most predominant mammalian type I methyltransferase, PRMT1, was 
discovered based on its homology to the yeast arginine methyltransferase Hmt1/Rmt1 
[14].  PRMT2 was recognized due to its homology to PRMT1 [15] while PRMT3 was 
isolated as a PRMT1 binding partner in a yeast two-hybrid screen [16].  PRMT4/CARM1 
was identified in a yeast two-hybrid screen bound to the p160 steroid receptor coactivator 
GRIP1 [17].  PRMT5 was cloned as a Jak2-binding protein [18].  PRMT6 and PRMT8 
were identified based on their homology to other type I PRMTs [19 and 20], and PRMT7 
was discovered in a genetic screen looking for suppressor elements conferring resistance 
to a topoisomerase II inhibitor [21].  PRMT9 was identified through a protein database 
search using a consensus query sequence corresponding to the conserved PRMT AdoMet 
binding domain.  However, PRMT9 is structurally distinct from all other known PRMTs 
[22].  PRMT10, a type I PRMT, was identified in plants and was shown to preferentially 
asymmetrically dimethylate histone H4 in vitro [23].  PRMT11 was identified most 
recently through a yeast two-hybrid screen bound to the methyl-DNA-binding 7 (MBD7) 
protein in plants [24]. 
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     Fig. 2-3.  Protein arginine methyltransferases.  PRMT1-PRMT11 are aligned based 
upon their characteristic THW loop (in black) and AdoMet methyltransferase motifs I, 
post I, post II, and post III (also in black).  PRMT2 has an SH3 domain while PRMT3 has 
a Zn2+ finger domain.  PRMT7 and PRMT10 contain a repeat of the methyltransferase 
motifs.  PRMT11 has an F box domain near the N-terminus.   
 
 
 
PRMT SUBSTRATES 
 
With PRMTs present throughout the plant and animal kingdoms, the significance 
of protein arginine methylation is evident.  Yet, the methyl arginine proteome has only 
recently begun to be characterized using mass spectrometry techniques [25], and the 
substrate specificities of the different PRMT isoforms remain ill-defined.  In general, 
PRMTs methylate arginines located in glycine arginine rich (GAR) areas of proteins in 
‘RGG’ or ‘RXR’ motifs.  Type I methyltransferases (PRMT1, 3, 6, and 8) mainly 
methylate arginines located within GAR sequences.  PRMT4, on the other hand, displays 
a different degree of specificity and does not typically methylate GAR sequences.  Type 
II methyltransferases, PRMT5 and 7, methylate isolated arginines as well as arginines 
within GAR motifs.  PRMT9 has been shown to symmetrically dimethylate maltose 
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binding protein (MBP) [22] which is also a substrate of PRMT5 (Fig. 2-4).  PRMT10 
is a type I PRMT that asymmetrically dimethylates histone H4 in vitro [23].  Finally, a 
cell line lacking PRMT11 mRNA exhibited reduced levels of proteins with 
asymmetrically dimethylated arginines, suggesting that PRMT11 is a type I PRMT [24].       
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     Fig. 2-4.  PRMT substrates.  Protein substrates are listed underneath the PRMT 
isoform that performs the modification.  Many arginine methylated proteins have been 
identified since using mass spectrometry [25]; however, the enzyme responsible for the 
methylation remains unknown.  Abbreviations are as follows:  CIRP, cold inducible RNA 
binding protein; EWS, Ewing Sarcoma; ILF3, interleukin enhancer binding factor 3; 
TLS/FUS, translocated in liposarcoma; ZF5, Zn2+ finger 5; SAMT1, substrate of arginine 
methyltransferase 1; TARPP, thymocyte cyclic AMP-regulated phosphoprotein; LSm4, 
Sm-like protein 4; MBP, maltose binding protein, MBD7, methyl-DNA binding protein 
7.  PRMT2 has no reported activity. 
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Of the eleven mammalian PRMT isoforms, PRMT1 predominates performing 
an estimated 85% of all protein arginine methylations in vivo [26].  Most PRMT1 
substrates are methylated at multiple sites within the same glycine arginine rich region of 
proteins such as fibrillarin [27], heterogeneous nuclear ribonuclear proteins (hnRNPs) 
[28], and Sam68 [29].  In addition to ‘RGG’, ‘RXR’ motifs located on the surface of the 
Poly(A)-binding protein II (PABPII) are also modified by PRMT1 [30].  Although the 
predominant feature of known PRMT1 protein substrates is a glycine and arginine rich 
region, PRMT1 has also been shown to specifically methylate a single arginine residue 
on the histone H4 tail that is not embedded in an ‘RGG’ or ‘RXR’ motif [31], indicating 
that PRMT1 substrates are not limited to proteins bearing ‘RGG’ and ‘RXR’ sequences.   
Several recent studies have helped identify how PRMT1 recognizes its substrates.  
First, acidic surface residues along the substrate binding groove of PRMT1 have been 
shown experimentally to be important for PRMT1 substrate binding through a pull down 
assay [32].  Complementing this finding, positively charged residues on the substrate 
distal from the active site were shown to be important for PRMT1 catalysis [33].  The N-
terminus of PRMT1 was also shown to affect substrate specificity and activity [34].  
Finally, eleven new PRMT1 substrate motifs that go beyond the typically methylated 
‘RGG’ and ‘RXR’ motifs were identified using a fibrillarin-based peptide library screen 
[35].  This suggests that the PRMT substrate proteome is larger than previously thought. 
 
STRUCTURE OF PRMT1 
 
What is it about the PRMT1 active site that allows for the select modification of 
certain arginines but not others?  In 2003, rat His-PRMT1 was co-crystallized with 
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AdoHcy and R3, a 19 amino acid peptide substrate derived from fibrillarin 
(GGRGGFGGRGGFGGRGGFG) [36] (Fig. 2-5, A).  Due to a lack in observable 
electron density for R3, few inferences could be made concerning the substrate 
specificity of PRMT1.  The crystal structure depicted three acidic substrate binding 
grooves (P1, P2, and P3) on the surface of PRMT1 that have the ability to interact with 
substrate arginine residues (Fig. 2-5, B).  Except for the substrate arginine in the active 
site substrate binding groove (P1), the electron density of the side chains from all other 
18 amino acids of the R3 peptide was not observed and any important PRMT1-peptide 
side chain interactions went undetected (Fig. 2-5, A).  Fortunately, the majority of the 
carbon-nitrogen peptide backbone of R3 was resolved.  Because of this, the authors stated 
that the substrate could be fitted equally well in either linear orientation into the active 
site.  Electron densities from the four glycines that flank the central arginine were not 
observed and created a sequence gap in the model.  This lack in observable substrate 
electron density suggests that the sequence surrounding the substrate arginyl group does 
little to govern PRMT1 substrate selection.  Our recent studies suggest otherwise [35]. 
Importantly, the crystal structure provided much insight into the reaction 
mechanism.  First, the structure revealed that two active site glutamates (E144 and E153) 
stabilize the substrate arginine guanidino nitrogen through hydrogen bonding.  Upon 
mutating these residues to non-acidic glutamines, PRMT1 activity reduced 3,000 fold.  
Second, this study revealed that PRMT1 dimerization was essential for AdoMet binding 
and that enzymatically active PRMT1 exists as a homodimer consisting of two 42 kDa 
subunits.   
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     Fig. 2-5.  The Crystal Structure of Rat PRMT1.  (A)  PRMT1, shown in gray, was 
crystallized as a ternary complex with R3 (hot pink) and AdoHcy (red).  The guanidino 
nitrogens of the substrate arginine residue (shown in ball and sticks) are oriented toward 
the sulfur moiety in AdoHcy (yellow).  While most of the R3 peptide backbone was 
observed in the crystal structure, the electron densities from the other R3 peptide side 
chains were not observed. (B) This surface representation of PRMT1 highlights the 
negatively charged surface amino acid residues (green) located along the substrate 
binding grooves P1, P2, and P3.  The P2 and P3 grooves are found on one protein face 
while the P1 groove is on the opposite face of PRMT1.  The R3 peptide backbone 
(colored pink) is situated in the P1 substrate binding groove.  PDB ID=10R8  
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LOCALIZATION OF PRMT1 
PRMT1 is found in the nucleus, the cytoplasm, and has most recently been 
proposed to localize to the plasma membrane.  Interestingly, PRMT1 has the ability to 
heterodimerize with PRMT8, an isoform that is highly homologous in sequence to 
PRMT1.  PRMT8 has a myristolation site and has been shown to localize to the cell 
membrane when modified by a fatty acid chain.  Therefore, PRMT1 which has already 
been shown to shuttle between the nucleus and the cytoplasm [37] has now been 
proposed to localize to the plasma membrane upon the myristolation of its heterodimeric 
counterpart, PRMT8 [20].  Clearly, the cellular distribution of PRMT1 and the diversity 
of PRMT1-methylated protein substrates emphasize its physiological role as the 
dominant PRMT in the cell. 
 
MECHANISM OF PRMT1 
 
 In September 2008, the kinetic mechanism of PRMT1 was elucidated by 
Thompson and coworkers [38].  They reported that human PRMT1 utilizes a rapid 
equilibrium random sequential mechanism to methylate the histone H4 peptide.   In this 
type of reaction mechanism, the order of substrate (AdoMet and the unmodified peptide) 
binding to the enzyme and product (AdoHcy and the methylated peptide) release from the 
enzyme does not matter.   
Next, the mechanism was examined further.  Does PRMT1 1) perform 
dissociative methylation wherein the monomethylated species is released before 
rebinding and being dimethylated, or 2) perform processive methylation wherein the 
substrate binds and is mono- and dimethylated sequentially without releasing the 
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intermediate?  Interestingly, PRMT1 was found to catalyze the dimethylation of the 
histone H4 peptide in a partially processive manner [38].  PRMT1 catalyzed the 
production of MMA and ADMA containing H4 peptides in approximately equimolar 
amounts, even in the presence of excess unmethylated peptide substrate.  This ruled out a 
fully processive mechanism in which the concentration of the monomethylated 
intermediate does not rise above the concentration of the enzyme.  Additionally, the 
monomethylated histone H4 peptide was not preferred over the unmodified peptide [33].   
 
BIOLOGICAL IMPORTANCE OF PRMTs 
PRMTs play important roles in biology, yet the biological consequence of protein 
arginine methylation is not fully understood.  Studies have shown that PRMTs are 
important not only for the proteins they methylate, but also for the response that the 
modified protein elicits in the cell.  PRMT activity has been implicated in RNA 
processing, signal transduction, DNA repair, transcriptional regulation (reviewed in [11]), 
viral infection [39], chromatin remodeling [40], and neuronal cell differentiation [41].   
Arginine methylation also regulates transcription initiation and elongation.  
Specifically, PRMT4 methylates the transcription factor CBP/p300 [42] which inhibits its 
interaction with the p160 coactivator glucocorticoid receptor interacting protein (GRIP1) 
in vitro and in vivo [43].  Also, methylation of the transcription elongation factor SPT5 
by PRMT1 and PRMT5 regulates its interaction with RNA polymerase II and may be 
involved in regulating the transcriptional elongation properties of SPT5 in response to 
viral and cellular factors [44].   Although PRMT1-PRMT11 have unique biological 
functions (summarized in Table 2-1), arginine methylation ultimately regulates these and 
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other biological processes at the molecular level by altering biomolecular interactions 
such as 1) protein-protein interactions, 2) protein-RNA interactions, and 3) protein-DNA 
interactions [45].  
 
Table 2-1 Biological functions of the PRMT family 
PRMT Biological Function 
PRMT1 Transcriptional activation (H4R3), transcriptional elongation, DNA repair, signaling, chromatin remodeling, neuronal cell differentiation 
PRMT2 Viral infection, apoptosis, transcriptional coactivator, nuclear retention  
PRMT3 Ribosome assembly 
PRMT4 Transcriptional activation (H3R2, H3R17, H3R26), chromatin remodeling, muscle differentiation, T cell development, tumorigenesis 
PRMT5 
Transcriptional repression (H3R8 and H4R3), transcriptional elongation, 
RNA processing, signaling, mitosis, muscle and germ cell differentiation, 
tumorigenesis, chromatin remodeling 
PRMT6 HIV replication, DNA repair 
PRMT7 Imprinting in male germ cells (H4R3) 
PRMT8 Involved in the somatosensory and limbic systems  
PRMT9-11 Unknown 
 
Arginine (R) residues modified by each PRMT on either histone H3 or histone H4 are 
indicated in parenthesis. 
 
 
 
1.  Protein-Protein Interactions 
First, protein arginine methylation alters protein-protein interactions by either 
blocking or facilitating contact between proteins [46].  In particular, arginine methylation 
can disrupt the formation of Asp-Arg salt bridges between proteins.  For example, an 
arginine residue in Fyn (a protein involved in signal transduction and host cell activation) 
hydrogen bonds to an aspartate on the human immunodeficiency virus-1 (HIV-1) Nef 
protein stabilizing the interaction between the two proteins.  Arginine methylation of Fyn 
disrupts the Asp-Arg salt bridge and blocks further interactions between the two proteins 
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[47].  Another Asp-Arg salt bridge is disrupted when the adaptor protein Sam68 is 
methylated by PRMT1.  Arginine methylated Sam68 can no longer associate with sarc 
homology 3 (SH3) domain containing proteins; however, it can still interact with proteins 
with WW (two tryptophan) domains [48].  Finally, arginine methylation also has the 
ability to disrupt key pi-cation interactions.  Methylation of an arginine residue on the 
KIX domain of the CREB-binding protein (CBP)/p300 blocks a key pi-cation interaction 
and ultimately CREB activation by distrupting the interaction between the KIX domain 
of CBP and the kinase inducible domain (KID) of CREB [49].   
Other protein interactions are facilitated by arginine methylation.  PRMT1 
methylates NIP45, a nuclear factor of activated T-cells (NF-AT) coactivator, and 
facilitates its interaction with NF-AT.  This interaction promotes cytokine gene 
expression [50] and helps mediate the immune response.  Arginine methylation also 
strengthens interactions between the spinal muscular atrophy gene product, SMN, and 
certain small nuclear ribonucleoproteins (SmB/B’, SmD1, and SmD3) [51].  When the C-
terminus of SmB and SmD are methylated, their association with SMN is enhanced [52].  
In fact, the symmetric dimethylation of arginine residues in Sm proteins by PRMT5 and 
PRMT7 facilitates the assembly of small nuclear ribonucleoprotein particles [53].  
 
2.  Protein-RNA Interactions 
 
Second, protein arginine methylation affects interactions between proteins and 
ribonucleic acids.  The glycine arginine rich hnRNP proteins A1, A2, K, R, and U that 
assist in the processing and folding of RNA during mRNA translation are highly 
modified by the PRMTs [28].  Arginine methylation of hnRNP A1 decreases its ability to 
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bind RNA [54].  In addition to the hnRNPs, Sam68 and Hu antigen protein R (HuR) 
have arginines that hydrogen bond to the secondary and tertiary structures of RNA.  
Arginine methylation has the ability to disrupt certain protein-RNA interactions by 
preventing hydrogen bonding and/or sterically hindering van der Waals interactions [55].  
Other studies have shown that arginine methylation does not significantly affect protein-
RNA interactions [56].  So far, the effect of arginine methylation on protein-RNA 
interactions remains unclear. 
 
3.  Protein-DNA Interactions 
 
In 1967, it was recognized that histones were substrates of methyltransferases [8], 
and now it is understood that both types of PRMTs methylate histones.  In the nucleus, 
DNA is packaged around histone protein octamers forming higher ordered structures 
known as chromatin.  Histone tails that point away from the protein octamer can be 
highly post-translationally modified by methylation of arginines; acetylation, 
methylation, and ubiquitination of lysine residues; and phosphorylation of serine and 
threonine residues.  These modifications regulate the tightness of the histone-DNA 
interaction which ultimately mediates dynamic changes in gene function and expression 
[57].  Therefore, histone-DNA interactions and the proteins that modify histones are vital 
to the genetic stability of the organism.  Rett syndrome and Rubinstein-Taybi syndrome, 
inherited developmental disorders characterized by physiological deformities and a loss 
of developmental skills, result from the deregulation of gene transcription caused by 
altered histone-DNA interactions [58].   
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Both type I and type II PRMTs have been shown to methylate histones in vitro.  
PRMT4 methylates three arginine residues on the histone H3 tail while PRMT5 
methylates a single arginine (Arg 3) on both the histone H2A and H4 tails [59].  PRMT1 
has also been shown to dimethylate arginine 3 in H4 both in vitro and in vivo [40].  In 
fact, arginine methylated H4 has been shown to be a better substrate than unmodified H4 
for the histone acetyltransferase p300.  Thus, arginine methylation of H4 facilitates lysine 
acetylation of H4 by p300 which ultimately stimulates gene transcription [60]. 
  In addition to histones, other protein-DNA interactions are modulated by arginine 
methylation.  High mobility group proteins (HMGs) modulate chromatin structure and 
transcription.  HMGA1a is a PRMT1 substrate that has three positively charged motifs or 
AT hooks that bind DNA.  These AT hooks are rich in RG sequences that once 
methylated may disrupt the interactions between the HMG protein and DNA [61].  An 
increase of HMGA1a arginine methylation could be related to heterochromatin and 
chromatin remodeling of apoptotic cells [62].   
 
REGULATION OF PRMTS AND ARGININE 
METHYLATION 
 
1.  Regulation of PRMTs 
PRMT activity is regulated by a variety of factors.  Several isoforms of the PRMT 
family have different mRNA splice variants that when translated can lead to a set of 
proteins with unique activities and/or substrate specificities.  PRMT1, for example, has 
seven N-terminal splice variants in humans [15] that have different activity and substrate 
specificity [34].  In addition to splice variants, the cellular localization of the PRMTs and 
the availability of their protein substrates dictate the level of protein arginine methylation 
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that can occur.  Finally, PRMT methylation is regulated by protein interaction partners.  
For example, PRMT1 methylation is stimulated towards select substrates in vivo by the 
binding of its two protein interaction partners, BTG1 and TIS21/BTG2 [14].  Another 
protein that interacts with BTG1, hCAF1 (CCR4-associated factor 1), has been shown to 
regulate PRMT1 activity in a substrate-dependent manner [63]. 
PRMTs are also regulated by their oligomeric status.  Monomeric PRMTs 
combine to form biologically active homodimers that can bind AdoMet and methylate 
protein substrates [36].  In addition, PRMT1 and PRMT8 have the unique ability to 
heterodimerize.  Depending on the abundance of the PRMT1-PRMT8 heterodimer in 
vivo, the concentration of available PRMT1 monomers and the amount of active PRMT1 
homodimers in the cell would be reduced.  Although this could be a very important 
regulatory mechanism of PRMT1, it remains unclear how the PRMT1-PRMT8 
heterodimer affects the substrate selection or activity of PRMT1.  
 
2.  Regulation of arginine methylation  
 
Once a protein is arginine methylated, can it then be demethylated?  Protein 
arginine demethyliminase 4 (PAD4) has been shown to demethyliminate methylarginine 
residues in histones and reverse the biological consequence of methylation [64].  PAD4 is 
not a true demethylase, however, because it converts MMA into citrulline instead of 
arginine (Fig. 2-6).  Recently, a true arginine demethylase was discovered.  The Jumonji 
domain-containing 6 (JMJD6) protein is a JmjC-containing iron- and 2-oxoglutarate-
dependent dioxygenase that was shown to reverse the effects of protein arginine 
methylation on histones H3 and H4 in both biochemical and cell-based assays [65].  
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Since JMJD6 acts on mono- and dimethylated histone proteins only, is the effect of 
protein arginine methylation reversible on other methyl-arginine containing proteins in 
the cell?  The characterization of JMJD6 will help define how arginine methylation is 
regulated on histone proteins and may lead to the identification of other true protein 
demethylases.   
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     Fig. 2-6.  Reversing the effects of arginine methylation.  PRMTs methylate protein 
arginine residues to form MMA (shown here), ADMA, and SDMA.  PAD4, a protein 
arginine demethyliminase, converts MMA into citrulline but not back into arginine.  
JMJD6 is a true protein demethylase that targets methylated arginine residues on histone 
proteins.  R=(CH2)3CH(NH3+)COO- 
 
 
 
PROTEIN ARGININE METHYLATION & DISEASE 
Although PRMTs are vital to normal development and function [12], arginine 
methylation also leads to disease.  Arginine methylation has mainly been implicated in 
the progression of 1) cardiovascular disease [66] and stroke [67], 2) multiple sclerosis, 
and 3) spinal muscular atrophy [11], and 4) cancer [68].  Fortunately, the cellular 
concentration of the PRMT inhibitor AdoHcy regulates methyltransferase activity.  
PAD4 and JMJD6 reverse the effects of protein arginine methylation by demethylating 
methylated protein arginine residues.  Finally, the activity of dimethylarginine 
dimethylaminohydrolase (DDAH) helps keep free MMA and ADMA levels in check.   
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1.  Cardiovascular Disease 
Several studies have shown that free ADMA, a downstream product of the 
PRMTs, has a clear role in cardiovascular disease (reviewed in [66]) and stroke [67] by 
serving as an endogenous inhibitor of nitric oxide synthase [69].  When proteins that have 
been modified by the PRMTs are sent to the proteasome and degraded, free MMA, 
SDMA, and ADMA are released.  MMA and ADMA specifically inhibit inducible nitric 
oxide synthase (iNOS).  Since the nitric oxide produced by NOS acts as a vasodilator 
maintaining cardiovascular health, the inhibition of NOS contributes to atherosclerosis 
[70].  Free MMA and ADMA levels are controlled by dimethylarginine 
dimethylaminohydrolases (DDAHs).  Although DDAHs keep the methylarginine levels 
in check, misregulation of DDAH or the hyperactivity of PRMTs may contribute to 
cardiovascular disease [71].  In fact, PRMT1 has been shown to be overexpressed in 
myocardial tissue taken from coronary heart disease patients [72].   
Numerous studies have shown a relationship between elevated ADMA 
concentration and cardiovascular disease (CVD).  Elevated ADMA concentration is 
highly prevalent in hypercholesterolemia, hyperhomocysteinemia, diabetes mellitus, 
peripheral arterial occlusive disease, hypertension, chronic heart failure, and coronary 
artery disease (reviewed in [66]).  Although these studies were case studies and did not 
provide insight into exactly how ADMA was involved in promoting CVD, the 
observation that ADMA levels increase early in the development of atherosclerosis 
suggests that ADMA has the potential to be not only a marker but a mediator of vascular 
lesions [73].  In addition to CVD, elevated levels of ADMA increase the risk for ischemic 
stroke in the elderly [67].   
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2.  Multiple Sclerosis 
PRMT5 methylation of myelin basic protein (MBP) is involved in the progression 
of multiple sclerosis (MS), a demyelination disease of the central nervous system that 
targets myelin sheaths that surround and protect nerve axons.   The demyelination of this 
protective coat contributes to the pathogenesis of MS.  A recent study showed that myelin 
basic protein, which accounts for 35% of all protein in the myelin sheath, is a PRMT5 
substrate.  Arginine 107 on all three MBP isoforms was found to be mono- and 
symmetrically dimethylated in MS patients, and increased arginine methylation of MBP 
was shown to precede symptoms of MS in mice [74].  In addition, methylated MBP may 
also serve as an autoantigen, as is the case with methylated Sm and collin in lupus 
erythematosus [75].  
 
3.  Spinal Muscular Atrophy 
 
Arginine methylation also plays a role in spinal muscular atrophy (SMA), an 
autosomal recessive disease that results from deletions or loss-of-function mutations 
within the SMN1 gene.  A lack in the survival motor neuron (SMN) protein leads to 
motor neuron axonal guidance failure contributing to the progression of SMA [76].  SMN 
has been shown to be required for proper ribonucleoprotein assembly, a process that also 
requires arginine methylation [77].  Recently, point mutations were identified in the SMN 
Tudor domain in patients with SMA.  This domain normally associates with SDMA on 
spliceosomal Sm proteins D1, D3, and B/B’ [50] aiding in the proper localization of the 
Sm proteins.  Mutations in the Tudor domain in SMA patients cause the mislocalization 
of the Sm proteins and the improper assembly of ribonucleoproteins [78]. 
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4.  Cancer 
 PRMTs have also been directly linked to oncogenesis and may act as novel 
therapeutic targets in human cancer.  PRMT1 has been shown to be an essential 
component of the mixed lineage leukaemia (MLL) oncogenic transcriptional complex 
that has both histone acetylation and H4-R3 methylation activities.  An oncogenic MLL 
fusion complex that mediates step-wise histone modifications may facilitate an open 
chromatin structure for active gene expression and promote oncogenic transformation.  In 
fact, the direct fusion with MLL to PRMT1 or SAM68, a bridging molecule in the 
complex for PRMT1 interaction, enhanced self-renewal of primary haematopoietic cells.  
Furthermore, the specific knockdown of SAM68 or PRMT1 expression suppressed MLL-
mediated transformation.  Taken together, PRMT1 plays an essential role in a novel 
protein arginine methyltransferase-dependent oncogenic pathway [68]. 
PRMTs are also known coactivators for nuclear receptors and are likely to be 
overexpressed in hormone-dependent cancers such as prostate and breast cancer.  In fact, 
an increase in PRMT4 expression correlates with androgen independence in human 
prostate carcinoma [79].  Importantly, however, small molecules that inhibit both PRMT1 
and PRMT4 suppress estrogen and androgen receptor-mediated transcriptional activation 
[80].   
 
CONCLUSION 
 
 Protein arginine methyltransferases play an important role in a diverse set of 
biological processes.  PRMTs methylate a variety of protein substrates including 
histones, RNA-binding proteins, and various enzymes.  Protein arginine methylation 
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alters protein-protein, protein-RNA, and protein-DNA interactions.  PRMT1 performs 
over 85% of all protein arginine methylation and is critical for survival.  Yet, PRMTs 
have been linked to heart disease, spinal muscular atrophy, multiple sclerosis, and cancer.  
While PRMT biology has remained in the forefront, much of the biochemistry for this 
class of enzymes has received little attention until recently.  Once the substrate specificity 
and mechanism of PRMT1 become clear, more specific, novel therapeutic targets can 
then be developed.  Inhibiting PRMT activity could potentially slow the progression of 
cardiovascular disease and cancer in certain patients.  It will be interesting to see how an 
increased biochemical understanding these enzymes will impact biology and medicine.   
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CHAPTER 3 
AN ENZYME-COUPLED CONTINUOUS SPECTROPHOTOMETRIC ASSAY FOR 
S-ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES1 
 
ABSTRACT 
 
 Modification of small molecules and proteins by methyltransferases impacts a 
wide range of biological processes.  Here we report an enzyme-coupled continuous 
spectrophotometric assay to quantitatively characterize S-adenosyl-L-methionine 
(AdoMet/SAM)-dependent methyltransferase activity. In this assay, S-adenosyl-L-
homocysteine (AdoHcy/SAH), the transmethylation product of AdoMet-dependent 
methyltransferases, is hydrolyzed to S-ribosylhomocysteine and adenine by recombinant 
S-adenosylhomocysteine/5’-methylthioadenosine nucleosidase (SAHN/MTAN, EC 
3.2.2.9).  Subsequently, adenine generated from AdoHcy is further hydrolyzed to 
hypoxanthine and ammonia by recombinant adenine deaminase (EC 3.5.4.2).  This 
deamination is associated with a decrease in absorbance at 265 nm that can be monitored 
continuously.  Coupling enzymes are recombinant and are easily purified.  The utility of 
this assay was shown using recombinant rat protein arginine N-methyltransferase 1 
(PRMT1, EC 2.1.1.125) which catalyzes the mono- and dimethylation of guanidino 
nitrogens of arginine residues in select proteins.  Using this assay, the kinetic parameters 
of PRMT1 with three synthetic peptides were determined.  An advantage of this assay is 
the destruction of AdoHcy by AdoHcy nucleosidase, which alleviates AdoHcy product  
 
1Coauthored by K.M. Dorgan, W.L. Wooderchak, D. Wynn, E.L. Karschner, J.F. Alfaro, Y. 
Cui, Z.S. Zhou, J.M. Hevel, An enzyme-coupled continuous spectrophotometric assay for S-
adenosylmethionine-dependent methyltransferases. Anal. Biochem. 350 (2006) 249-255. 
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feedback inhibition of S-adenosylmethionine-dependent methyltransferases.  Finally, 
this method may be used to assay other enzymes that produce AdoHcy, 5’-
methylthioadenosine, or compounds that can be cleaved by AdoHcy nucleosidase. 
 
INTRODUCTION 
 
S-Adenosyl-L-methionine (AdoMet/SAM)-dependent methyltransferases play an 
important role in biological systems, including signal transduction, protein repair, 
biosynthesis, chromatin regulation, and gene silencing [1,2].  Small molecule, RNA, 
DNA, lipid, and protein methyltransferases exist [2-5].  More recently, data supporting 
the idea that protein arginine methylation plays a more dynamic role in the histone code 
has been put forth [6-9].  Defining how the protein methyltransferases work and what 
determines which proteins/residues will become methylated is pivotal for understanding 
the role these enzymes play in biology. 
The majority of methyltransferase activity assays currently used are based on 
radioactive labeling using the AdoMet substrate labeled with 14C or 3H [10-12].  This is 
because there is very little detectable spectral change between the AdoMet substrate and 
its common transmethylation product, S-adenosylhomocysteine (AdoHcy/SAH).  
However, radioactive assays require subsequent separation of the product and substrate, 
which is often time-consuming.  Another problem associated with this technique is that in 
many cases, the AdoHcy product acts as a potent feedback inhibitor to the 
methyltransferase, adding to the overall margin of error experienced in determining its 
kinetic parameters [13-16].  Two recently developed discontinuous assays make use of 
recombinant coupling enzymes that hydrolyze AdoHcy to homocysteine, which is 
detected by either chromogenic [15] or fluorescent [17] thiol-reactive reagents.  
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We report here a continuous enzyme-coupled photometric assay for AdoMet-
dependent methyltransferases.  As shown in Figure 3-1, AdoHcy can be converted to S-
ribosylhomocysteine and adenine by AdoHcy nucleosidase.  Earlier studies demonstrated 
that AdoHcy nucleosidase effectively cleaves the AdoHcy transmethylation product 
[15,16], eliminating the error associated with product inhibition.  The adenine product of 
the reaction is then converted to hypoxanthine by adenine deaminase, resulting in an 
absorbance decrease at 265 nm that can be easily detected by UV spectrometry.  The 
rapid and continuous detection of the conversion of substrate to product also helps to 
improve the accuracy over discontinuous assaying.  We demonstrate the utility of this 
assay by characterizing the activity of recombinant rat PRMT1, a protein 
methyltransferase known to methylate a variety of proteins including histone 4, fibrillarin 
and RNA binding proteins (for a review, see [18]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Fig. 3-1.  Continuous assay scheme used to detect AdoMet-dependent 
methyltransferase activity.  AdoHcy is converted into adenine and S-ribosylhomocysteine 
via AdoHcy nucleosidase.  The deamination of adenine into hypoxanthine by adenine 
deaminase is associated with a decrease in absorbance at 265 nm, which can be 
monitored continuously using a spectrophotometer. Nu, nucleophile. 
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MATERIALS AND METHODS 
 
Materials 
AdoMet p-toluenesulfonate salt and AdoHcy were purchased from Sigma.  
Hypoxanthine was purchased from the California Foundation for Biochemical Research.  
Amylose resin was purchased from New England BioLabs.  Adenine was purchased from 
Acros Organics.  Recombinant AdoHcy nucleosidase containing a histidine tag was 
expressed and purified as previously described [19].  All other chemicals were of ACS 
grade or better.  
 
Expression and purification of 
MBP-adenine deaminase 
 
The DNA encoding Bacillus subtilis adenine deaminase was PCR-amplified from 
the pHH1010 plasmid [20] and ligated into a pMAL-c2x plasmid vector (New England 
BioLabs) between EcoR1 and SalI sites.  Escherichia coli TB-1 cells were transformed 
with the resulting plasmid and grown aerobically in 1 L LB broth at 37oC for 11 hours.  
Expression of maltose binding protein (MBP)/adenine deaminase fusion protein was 
induced with 0.8 mM IPTG for 10 hours.  Cells were harvested by centrifugation and re-
suspended in ~30 mLs column buffer (20 mM Tris-HCl pH 7.4, 200 mM NaCl, 1 mM 
EDTA, and 0.2 mM DTT).  Cells were lysed via sonication using four 2 min 
discontinuous cycles on ice using, and the cell debris and unbroken cells removed by 
centrifugation at 55,000 x g, 4oC for 25 minutes.  The supernatant was filtered through a 
0.45 μm filter and incubated with 10 mL amylose resin slurry (New England BioLabs) at 
4oC for 90 min with gentle agitation.  After washing the resin with 30mL column buffer, 
MBP-adenine deaminase was eluted in 5 mL fractions with column buffer containing 10 
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mM maltose.  Fractions demonstrating >95% purity by SDS-PAGE were concentrated 
by Centricon-Plus Concentrators (30,000MWCO, Amicon) and the buffer exchanged to 
column buffer as per the manufacturer’s instructions.  The purified protein was stored at -
80oC in 25% glycerol.  Protein concentration was determined spectrophotometrically 
using ε280nm=85,770 M-1cm-1.  Approximately 18mg of purified protein was obtained 
from 1L of broth. 
 
Purification of His-PRMT1 
 
The DNA encoding rat PRMT1 was PCR amplified from the GST-PRMT1 vector 
with Pfu polymerase and ligated into a pET28b vector (Novagen) to yield an N-terminal 
His-tagged PRMT1 construct.  E. coli BL21(DE3) cells carrying the pET28b/PRMT1 
plasmid were grown in LB broth at 37ºC.  Protein expression was induced with 1.2 mM 
IPTG for 5 h.  Cells were harvested by centrifugation and resuspended in wash buffer (50 
mM sodium phosphate pH 7.5 and 20 mM imidazole). Cells were lysed by sonication 
using three 15s cycles and centrifuged at 100,000 x g at 4ºC for 1 h.  The resulting crude 
supernatant was incubated with Ni Sepharose™ High Performance resin (Amersham 
Biosciences) for 4 h at 4ºC. The slurry was loaded into a 1.7 x 13 cm column, and the 
flow through was collected. The column was washed with 65 mL wash buffer, and the 
protein was eluted with 10 mL of wash buffer containing 250 mM imidazole. The eluate 
was concentrated in Centricon-Plus Concentrators (30,000 MWCO, Amicon), the buffer 
exchanged to 50 mM sodium phosphate buffer pH 7.5, and 10% glycerol was added to 
the pure protein before storing it at -80ºC.  Approximately 5.4 mg pure protein was 
obtained from 1 L of broth and was >95% pure by SDS-PAGE. 
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Procedure for the enzyme-coupled 
photometric assay 
 
Assays were performed in thermostatted 1cm quartz cuvettes at 37oC.  Manganese 
sulfate (MnSO4) was added to a final concentration between 10 to 1050 µM.  Between 10 
to 1050 µM of manganese, the same activity was observed.  Manganese or other divalent 
ions (e.g., zinc) are required for the deaminase activity ([21] and Dorgan & Zhou, 
unpublished results).  The assay involving the conversion of adenine to hypoxanthine was 
run using adenine at various concentrations, 1050 µM MnSO4, and 0.02 µM adenine 
deaminase buffered in 200 mM Tris pH 8.0.  The assay monitoring the conversion of 
AdoHcy to hypoxanthine contained 54.3 μM AdoHcy, 1050 µM MnSO4, 0.02 µM 
adenine deaminase, and 17.3 nM AdoHcy nucleosidase buffered in 200 mM Tris pH 8.0.  
Between 3.0 to 20.0 nM adenine deaminase, the same rate was observed.  Measurement 
of PRMT1 activity was performed in 50 mM sodium phosphate pH 7.0 with 168 µM 
AdoHcy nucleosidase, 0.02 µM adenine deaminase, 10-1050 µM MnSO4, and various 
concentrations of PRMT1.  Use of AdoHcy nucleosidase at concentrations ranging from 
10 nM - 168 μM yielded the same methyltransferase rate.  Reactions were initiated with 
differing amounts of peptide substrates as indicated in the figures. 
 
Radioactive assay used to determine 
PRMT1 activity  
 
 Methyltransferase assays were equilibrated at 37 ºC for 15 minutes before 
initiating with 211 µM R3 peptide.  Each 65 µL reaction contained S-adenosyl-L-
[methyl-3H] methionine (specific activity 79 µCi/µmol, Amersham Biosciences), 4 µM 
PRMT1, 250 µM AdoMet, 100 µM MnSO4, 0.02 µM adenine deaminase, 168 µM 
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AdoHcy nucleosidase, and 100 mM sodium phosphate pH 7.0.  Aliquots of 10 µL were 
spotted directly onto P81 paper (Whatman) under vaccum in a S&S Minifold® I Slot Blot 
System (Schleisher & Shuell) at specific time points and washed three times with 500 µL 
50 mM sodium phosphate buffer pH 7.5.  After the filter paper dried, each piece was 
placed in 5 mL Scintisafe™ cocktail (Fisher) and counted (Beckman LS 6500). 
 Internal tritium standards were used initially to examine counting efficiency; 
however, we determined that the presence of protein had a profound effect on counting 
efficiency.  Instead, various volumes of the control reaction, which did not contain 
peptide substrate, were spotted onto P81 membranes and counted.  Linearity between 
observed cpms and volume spotted was demonstrated.  Counting efficiency was 4-6% 
and all calculations were adjusted accordingly.  Data were plotted against time and fitted 
using linear regression. 
 
High-performance liquid chromatograph (HPLC) 
analysis of reaction products 
 
HPLC analysis of the hypoxanthine product formed during peptide methylation 
by PRMT1 was performed on an Apollo C-18 reverse-phase column (4.6 mm x 25 cm, 
Alltech, Deerfield, Il).  The column was eluted with an isocratic mixture from 0-3 
minutes of 100 mM ammonium bicarbonate (A) at pH 7.8 (90%) and methanol (B) 
(10%).  A gradient mixture was used from 3-8 minutes where the composition changed 
from 90% A and 10% B to 10% A and 90% B.  From 8-10 minutes a gradient mixture 
was used and changed the composition from 10% A and 90% B to 90% A and 10% B.  
Finally, an isocratic mixture was used from 10-15 minutes.  A 1.0 mL/min flow rate was 
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used and the analytes (AdoMet, AdoHcy, adenine, and hypoxanthine) were monitored 
at 245 nm. 
 
RESULTS AND DISCUSSION 
 
Conversion of AdoMet to hypoxanthine  
using the coupling enzymes 
 
 In order to yield valid kinetic parameters in the coupled assay, the coupled 
enzymes used should not be rate limiting, so that the measured rate is determined solely 
by the methyltransferase activity.  The kinetics for the conversion of adenine to 
hypoxanthine via adenine deaminase were investigated first.  Adenine absorbs maximally 
at 260 nm with an extinction coefficient of 13,400 M-1 cm-1 [22].  Upon adding adenine 
deaminase, an absorbance decrease at 265 nm was observed as adenine was converted to 
hypoxanthine rapidly in a stoichiometric fashion (Fig. 3-2).  The kcat for adenine 
deaminase in 100mM Tris pH 8.0 was 35.2 ± 0.92 sec-1.  The difference spectrum shown 
in Fig. 3-2B shows the maximal change in absorbance at 265 nm.  In the presence of 13.3 
μM adenine, concentrations of hypoxanthine ranging from 3.5 μM to 142 μM did not 
inhibit adenine deaminase (data not shown).  Complete conversion of AdoHcy to 
hypoxanthine using both the coupling enzymes, AdoHcy nucleosidase and adenine 
deaminase, was accompanied by a similar absorbance change (data not shown).  The 
reaction, like that of adenine deaminase was found to be very rapid. The kcat for AdoHcy 
nucleosidase in 100mM Tris, pH 8.0 was 4.12 ± 0.10 sec-1.  In comparison, most 
AdoMet-dependent methyltransferases display kcat in the 0.016 sec-1 (1 min-1) range.  The 
two coupling enzymes are over 100-fold more active than most of the methyltransferases, 
and thus are well suited for kinetic analysis described in this paper.  The relationship 
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between AdoHcy concentration and absorbance change at 265 nm was linear and 
yielded a Δε265 of 6,700 ± 150 M-1cm-1 based on the ε260 of 15,400 M-1 cm-1 for AdoHcy 
[22] (Fig. 3-3).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Fig. 3-2.  (A)  Absorbance change associated with the conversion of adenine to 
hypoxanthine catalyzed by adenine deaminase over 5 minutes.  The reaction mixture 
contained 54.3 µM adenine, 1050 µM MnSO4, and 0.02 µM adenine deaminase buffered 
in 200 mM Tris pH 8.0 and 37 ºC.  The reaction was completed in 5 minutes.  The arrow 
indicates the decrease in absorbance at 265 nm with time.  In (B) the spectrum of the 
original solution of adenine (dotted line), the reaction at completion (bold solid line) and 
difference spectrum (thin solid line) are shown. 
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     Fig. 3-3.  Linear correlation between the absorbance change at 265nm and AdoHcy 
concentration.  The assay monitoring the conversion of AdoHcy to hypoxanthine was 
performed using varying amounts of AdoHcy, 110 μM MnSO4, 28 nM adenine 
deaminase, and 17.3 nM AdoHcy nucleosidase in 50 mM potassium phosphate pH 7.4. 
 
 
 
Investigation of PRMT1 Activity Using 
the Coupled Assay 
 
We next investigated the proposed coupled methyltransferase assay using protein 
arginine N-methyltransferase 1 (PRMT1) as our test enzyme and a peptide corresponding 
to a 19-amino acid stretch of the in vivo PRMT1 protein substrate fibrillarin [23].  
Initiation of the reaction with R3 peptide resulted in a decrease in absorbance at 265 nm 
as in the coupling enzyme control reactions (data not shown).  Figure 3-4 demonstrates 
that the reaction rate was dependent upon methyltransferase concentrations.  The rate 
obtained with 2 μM PRMT1 using this continuous spectrophotometric assay with 211 μM 
R3 (5.1 ± 0.2 μM AdoHyc formed/min) was verified by following [3H] incorporation 
from S-adenosyl-L-[methyl-3H] methionine into the R3 peptide.  The rate observed using 
the radioactive assay was 4.9 ± 0.6 μM AdoMet consumed/min.  Furthermore, the overall 
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reaction rates were independent on the coupling enzyme concentrations under our 
assays conditions.  For instance, using a different preparation of PRMT1, the rates of 
PRMT1 catalyzed methylation of 200 μM R3 peptide using 10 nM, 100 nM, and 1μM, 
168 μM AdoHcy nucleosidase were 8.71 + 0.58, 9.05 + 0.10, 9.15 + 0.16, and 8.90 + 
0.09, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Fig. 3-4.  PRMT1 activity with R3 peptide is dependent upon PRMT1 concentration.  
Reaction mixtures contained 59 µM AdoMet, 1050 µM MnSO4, 0.02 µM adenine 
deaminase, 168 µM AdoHcy nucleosidase, and 211 µM R3 peptide in 50 mM potassium 
phosphate pH 7.0.  Reactions also contained 0 (closed circles) 3.9 (open circles), 7.7 
(closed squares), 11.4 (open squares), and 14.9 (open triangles) µM PRMT1, 
respectively.  The inset shows that activity (ΔAbs 265 nm/min) is a function of protein 
concentration.   
 
 
Formation of hypoxanthine and the lack of intermediate build-up during 
methylation of R3 by PRMT1 were confirmed using HPLC.  Standards of 80 μM 
hypoxanthine, AdoMet, AdoHcy, and adenine were used for comparison, and were found 
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to elute at 6.0, 8.5, 9.7, and 10.1 minutes, respectively.  The formation of hypoxanthine 
with a corresponding disappearance of AdoMet was observed in the assay, with no 
detectable accumulation of the adenine or AdoHcy intermediates (Fig. 3-5).  
 
  
     Fig. 3-5.  HPLC chromatogram to confirm reaction products.  The top trace shows an 
HPLC chromatogram of a mixture of authentic 80 µM samples of AdoMet, AdoHcy, 
adenine (Ade), and hypoxanthine (Hxan).  The middle trace is an HPLC chromatogram 
of an aliquot of the reaction mixture prior to the addition of R3 peptide.  The bottom trace 
is the chromatogram of an aliquot of the reaction mixture when there was a change at 265 
nm.  An impurity from AdoMet (I) is seen in the bottom two traces.  All traces were 
monitored at 245 nm. 
 
 
 Using this assay we investigated the kinetic parameters of PRMT1 with R3 
peptide from fibrillarin, an R3 analog peptide containing only one substrate arginine 
residue (JMH1), and H4 peptide from histone 4 (Table 3-1).  The R3 peptide contains 
three possible arginine methylation sites, each capable of being mono and/or 
dimethylated (6 potential methylation events).  The JMH1 peptide lacks the additional 2 
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substrate arginine residues of R3 but maintains the positive charge at these positions.  
Although Vmax for R3 and JMH1 were similar, the Km for R3 could only be estimated to 
be under 10 µM with this assay.  A few peptide substrates have previously been used to 
study native PRMT1 activity and have yielded values for  
Km of 0.2 - 60 μM [24, 25].  We believe that the dramatic increase in V/K for R3 is a 
result of processive methylation at multiple arginine residues on the same peptide 
substrate and are currently investigating this further.  Compared to the JMH1 peptide, the 
H4 peptide also contains only one arginine residue and demonstrated a Km,app of 745 + 70 
μM and Vmax of 5.7 + 0.2 μM min-1.  These results are consistent with reports that 
substrates containing the RGG repeats, such as hnRNPA1 and fibrillarin, are better 
(catalytic efficiency) PRMT1 substrates than histone 4 [26]. 
 
Table 3-1  Kinetic parameters for peptide substrates of PRMT1 
Peptide Sequence Km (μM) Vmax (μM min-1) #Arg
R3 AcGGRGGFGGRGGFGGRGGFG <10 10.7 ± 0.8 3 
JMH1          AcKGGFGGRGGFGGK 450 ± 90 14.8 ± 1.7 1 
H4  AcSGRGKGGKGLGKGGAK 745 ± 70 5.7 ± 0.2 1 
  
Reactions were performed at 37º C in 50 mM potassium phosphate, pH 7.0, using 250 
μM AdoMet, 4 μM PRMT1, 1050 μM MnSO4, 168 μM AdoHcy nucleosidase, 0.02 
adenine deaminase, and various amounts of peptide.  Initial rates (< 10% product 
formation) were plotted and the data fit with the Michaelis-Menton equation using non-
linear regression.  Vmax is expressed as μM AdoHcy min-1. 
 
 
 
 This study shows that this continuous assay can be used to characterize PRMT1 
enzyme activity and is currently being amended to other AdoMet-dependent-
methyltransferases (personal communication, Zhou).  This assay system is similar to that 
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described by Coward and co-workers in 1973 for catechol-O-methyltransferase [27] 
which uses adenosine deaminase from Aspergillus oryzae to convert AdoHcy to S-
inosylhomocysteine.  However, the fungal adenosine deaminase has not been cloned, so 
purification of the enzyme from Taka-Diastase is achieved with a multi-step/multi-
column procedure [28].  In comparison the present assay utilizes recombinant fusion-
tagged coupling enzymes that are easily purified in large amounts in a single day.  More 
importantly, the structures of S-inosylhomocysteine and S-adenosylhomocysteine only 
differ by one atom (an oxygen versus a nitrogen), thus are very similar to each other.  
Hence, the use of MTA nucleosidase and adenine deaminase avoids potential product 
inhibition by S-inosylhomocysteine [29], the product of the fungal adenosine deaminase 
reaction.   
 Despite the versatility of the assay, there are some potential limitations.  For 
instance, if the methyltransferase substrates strongly absorb around 265 nm, a narrow 
range of absorbance changes will be available for activity measurement, and analysis will 
be subject to the detection limits of the spectrophotometer.  However, even with 1 mM 
each of dATP, dCTP, dGTP, dTTP we were still able to detect the change of 35 μM of 
AdoHcy to hypoxanthine (data not shown).  Use of protein substrates exhibiting a strong 
UV absorbance may not be feasible.  However, we were able to monitor 
methyltransferase activity using the small in vivo PRMT1 protein substrate histone 4 (H4) 
(Fig. 3-6).  Several methyltransferases such as catechol O-methyltransferase (COMT) 
display for the methyl acceptor of ~100 μM [27,31], but some enzymes display much 
lower Km values.  Determination of Km values lower than 10 μM may be limited by the 
small absorption changes at low substrate concentrations, but may be performed using 
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progress curve analyses [32].  In any case, the assay can be used to determine 
maximum rate.  Finally, since AdoMet contributes to the background absorbance, 
concentrations of AdoMet should be kept at or below 250 μM or smaller pathlength 
cuvettes should be used to keep the total absorption around 265 nm within the linear 
range of the spectrophotometer for accurate measurement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Fig. 3-6.  The continuous assay monitors methylation of histone 4 (H4) protein.  
Reactions containing 250 μM AdoMet, 10 μM MnSO4, 10 nM AdoHcy nucleosidase, 
0.02 μM adenine deaminase, and 0 (open circles) or 5.0 μM of purified [30] H4 protein 
(closed circles) were equilibrated to 37 ºC for 10 minutes and initiated with 4 μM 
PRMT1.  The decrease in absorbance associated with the methylation of H4 was 
monitored at 265 nm. 
 
 
The potential for this assay goes further than AdoMet-dependent-
methlytransferases.  The AdoHcy/MTA nucleosidase displays broad substrate specificity 
cleaving not only AdoHcy and MTA, but also structural analogs with hydrophobic 
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residues at the C5 position [19,33] (Cornell, Dorgan, Zhou unpublished results).  In 
addition, the adenine deaminase also shows broad substrate specificity for purine analogs 
[34,35] (Dorgan, Zhou unpublished results).  Therefore we predict that the assay will be 
applicable to a number of other enzymes whose products can be cleaved by 
AdoHcy/MTA nucleosidase to generate adenine or adenine analogs that can be used by 
adenine deaminase.  Two examples include polyamine synthesis and acylhomoserine 
lactone synthesis, both of which produce MTA [36,37].  Other enzymes can be found in a 
recent review on AdoMet utilizing this enzyme [38]. 
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CHAPTER 4 
SUBSTRATE PROFILING OF PRMT1 REVEALS AMINO ACID SEQUENCES 
THAT EXTEND BEYOND THE ‘RGG’ PARADIGM1 
 
ABSTRACT 
 
Protein arginine methyltransferase 1 (PRMT1) catalyzes the mono- and 
dimethylation of certain protein arginine residues.  Although this posttranslational 
modification has been implicated in many physiological processes, the molecular basis 
for PRMT1 substrate recognition is poorly understood.  Most modified arginine residues 
in known PRMT1 substrates reside in repeating ‘RGG’ sequences.  However, PRMT1 
also specifically methylates Arg3 of histone H4 in a region that is not glycine-arginine 
rich, suggesting that PRMT1 substrates are not limited to proteins bearing ‘RGG’ 
sequences.  Because a systematic evaluation of PRMT1 substrate specificity has not been 
performed, it is unclear if the ‘RGG’ sequence accurately represents the consensus target 
for PRMT1.  Using a focused peptide library based on a sequence derived from the in 
vivo substrate fibrillarin we observed that PRMT1 methylated substrates that had amino 
acid residues other than glycine in the ‘RX1’ and ‘RX1X2’ positions.  Importantly, eleven 
additional PRMT1 substrate sequences were identified.   Our results also illustrate that 
the two residues on the N-terminal side of the modification site are important and need 
not both be glycine.  PRMT1 methylated the eukaryotic initiation factor 4A1 (eIF4A1) 
protein, which has a single ‘RGG’ sequence.  Methylation of eIF4A1 and the similar  
 
1Coauthored by W.L. Wooderchak, T. Zang, Z.S. Zhou, M. Acuña, S.M. Tahara, J.M. 
Hevel, Substrate profiling of PRMT1 reveals amino acid sequences that extend beyond the 
‘RGG’ paradigm, Biochemistry 47 (2008) 9456-9466.  
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eIF4A3 could be affected using single site mutations adjacent to the modification site, 
demonstrating the importance of amino acid sequence in PRMT1 protein substrates.  
Dimethylation of the parent library peptide was shown to occur through a dissociative 
mechanism.  In summary, PRMT1 selectively recognizes a set of amino acid sequences 
in substrates that extend beyond the ‘RGG’ paradigm.  
 
INTRODUCTION 
 
Protein arginine methyltransferase (PRMT) enzymes perform an important 
biochemical reaction resulting in the methylation of many cellular proteins.  PRMTs 
transfer a methyl group from S-adenosyl methionine (AdoMet or SAM) onto the terminal 
guanidino nitrogen of a protein arginine residue resulting in the formation of monomethyl 
arginine (MMA) and S-adenosyl homocysteine (AdoHcy or SAH).  Type I 
methyltransferases catalyze a second methylation event onto the previously methylated 
guanidino nitrogen of MMA to form asymmetric dimethylarginine (ADMA) (Scheme 4-
1).  Type I PRMTs include PRMT1 [1], PRMT3 [2], coactivator-associated arginine 
methyltransferase 1 (CARM1/PRMT4) [3, 4], PRMT6 [5], and PRMT8 [6].  Type II 
methyltransferases catalyze the formation of symmetric dimethylarginine (SDMA) 
whereby the second methyl group is transferred onto the unmodified guanidino nitrogen 
of MMA.  Jak-binding protein 1 (JBP1/PRMT5) exhibits Type II activity [7, 8], but 
conflicting reports have been made for PRMT7.  PRMT7 has been shown to generate 
MMA with a peptide substrate [9] and both asymmetric and symmetric dimethylarginine 
residues on protein substrates [10].  The F-box only protein 11 (FBXO11/PRMT9) 
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catalyzes the formation of MMA, ADMA, and SDMA on protein arginine residues 
[11].  No methyltransferase activity has been found for PRMT2. 
 
PRMT1
MMA ADMA
+
AdoMet
AdoHcy
NH
NH2NH2
NH
NHNH2
NH
NNH2
CH3 CH3
CH3PRMT1
AdoMet
AdoHcy
+ +
 
 
    Scheme 4-1.  Reactions catalyzed by PRMT1.  All PRMT isoforms catalyze the S-
adenosylmethionine (AdoMet)-dependent methylation of protein arginine residues to 
form monomethyl arginine (MMA).  PRMT1, a type I PRMT, transfers a second methyl 
group from AdoMet onto the previously modified guanidino nitrogen to form asymmetric 
dimethylarginine (ADMA).  S-Adenosyl homocysteine (AdoHcy) is a product and 
inhibitor of this AdoMet-dependent methyltransferase reaction. 
 
 
PRMT enzymes participate in a variety of cellular processes in eukaryotes.  
PRMT activity has been implicated in development [12, 13], RNA processing, 
transcriptional regulation, signal transduction, DNA repair, and chromatin remodeling 
[14, 15, 16].  In fact, the recent discovery of a histone protein arginine demethylase, 
Jumonji domain-containing 6 protein (JMJD6), validates that protein arginine 
methylation is a reversible post translational modification on certain histone tails [17].  
Thus far, eleven putative PRMT isoforms (PRMT1-11) have been identified in humans 
with orthologs present in yeast [18], protozoa, Caenorhabditis elegans, Drosophila 
melanogaster [19], plants [20], and fish [21].  The breadth of these enzymes indicates the 
biological importance of arginine methylation across the plant and animal kingdoms.  
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Although PRMTs are vital to normal development and function, protein arginine 
methylation has also been linked to the progression of carcinogenesis, viral pathogenesis, 
multiple sclerosis, spinal muscular atrophy, lupus, and cardiovascular disease (reviewed 
in 14).  Overall, PRMTs play important roles in biology, yet much of the basic 
biochemistry for this class of enzymes remains unexplored.  Unlike the protease and 
kinase fields where substrate specificity has been studied in detail [22, 23], the molecular 
basis for substrate recognition by the PRMTs is poorly understood. 
Of the eleven mammalian PRMT isoforms, PRMT1 predominates, performing an 
estimated 85% of all protein arginine methylations in vivo [18].  The prevailing 
observation is that PRMT1 methylates a variety of proteins that are glycine and arginine 
rich within repeating ‘RG’ or ‘RGG’ motifs such as fibrillarin (GGRGRGG)2 [24] and 
the heterogeneous nuclear ribonuclear proteins or hnRNPs (GGRGGS) [25].  The ‘RGG’ 
motif is a recognized RNA-binding domain and is characterized by a variable number of 
closely spaced arginine-glycine-glycine repeats interspersed with other amino acids [26].  
It is also common to observe a ‘GG’ sequence flanking the N-terminal side of the 
modification site.  Many of these methylated proteins have been initially identified using 
commercially available anti-methyl arginine antibodies that recognize MMA or ADMA 
within the tandem ‘RGG’ context.  Although the predominant feature of known PRMT1 
protein substrates is a glycine/arginine rich region, PRMT1 has also been shown to 
specifically methylate several arginines within ‘RXR’ sequences on the surface of the 
Poly(A)-binding protein II (PABPII) [27] and the ‘MSGRGKG’ sequence on the histone 
H4 tail [28].  It should be noted, that methylated histones are not detected by the 
commercially available anti-methyl arginine antibodies (e.g. Asym24 and Asym25 from 
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Upstate are directed against peptides with ADMA-glycine or ADMA-glycine-glycine 
repeats, respectively) [29], most likely due to the specificity of antibodies for arginine–
glycine repeats [30].  Consequently, only a sub-set of methylated proteins can be 
recognized by anti-methyl arginine antibodies.  This suggests that there may be a 
diversity in PRMT1 protein substrates that has previously gone unnoticed.   
The crystal structure of PRMT1 complexed with AdoHcy and the R3 peptide 
substrate (GGRGGFGGRGGFGGRGGFG) provided insight into the reaction 
mechanism [31]; however, due to a lack in electron density afforded by the peptide 
substrate, few inferences could be made concerning the substrate specificity of PRMT1.  
Additionally, the electron densities from the four glycines that flank the substrate 
arginine of the R3 peptide substrate were not observed and created a gap in the linear 
sequence of R3.  The lack in observable substrate electron density suggests that the 
substrate specificity of PRMT1 may be much broader than the typical ‘RGG’-containing 
substrate.       
Together, these results prompted us to investigate the substrate specificity of 
PRMT1.  The goals of this work were 1) to determine if PRMT1 displays substrate 
selectivity at the amino acid sequence level and 2) to identify novel PRMT1 substrate 
sequences.  A focused directional peptide library based on the in vivo substrate fibrillarin 
was used to determine which peptide sequences are methylated by PRMT1.  Our results 
show that PRMT1 demonstrates substrate selectivity at the amino acid sequence level in 
peptide substrates.   We found that the selection of PRMT1 protein substrates is more 
complex, wherein the amino acid sequence surrounding the substrate arginyl group of the 
protein substrate is one important factor.  In summary, our data show that PRMT1 has the 
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ability to discriminate between peptide and protein substrates at the amino acid 
sequence level.  Furthermore, substrate profiling indicated that PRMT1 can methylate 
sequences that go beyond the ‘RGG’ paradigm.  
 
MATERIALS AND METHODS 
 
All chemicals used were of ACS reagent grade or better.  AdoMet was purchased 
from Sigma as a chloride salt (≥80%, from yeast).  The custom PepScreen peptide library 
was ordered from Sigma Genosys using AcKGGFGGRGGFGGKW as the parent peptide.  
The two glycines C-terminal to the arginine (underlined) were substituted with all other 
amino acids except arginine one at a time to give rise to 36 unique peptides.  The 
tryptophan on the C-terminus was added in order to accurately determine the 
concentration of each peptide in solution by UV-vis spectrometry.  Peptides were 
analyzed by MALDI mass spectrometry to confirm their molecular weight and sampled 
by HPLC to assess purity.   
 
Peptide Library Kinetics 
 
  A continuous spectrophotometric assay for AdoMet-dependent methyltransferases 
(see Chapter 3) was used to assay PRMT1 with peptides from the peptide library.  
Briefly, recombinant AdoHcy nucleosidase (MTAN) was used to hydrolyze the AdoHcy 
generated from methyltransfer.  The resulting adenine was deaminated by recombinant 
adenine deaminase.  Importantly, this strategy alleviates any product inhibition that could 
occur from AdoHcy.  Each 110 µL reaction contained 4 µM His-PRMT1 (purified as 
described in Chapter 3), 0.02 µM adenine deaminase (purified as described in Chapter 3), 
250 µM AdoMet, 10 nM MTAN (purified as in [32]), 100 µM MnSO4, and 50 mM 
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sodium phosphate buffer pH 7.1.  Reactions were equilibrated at 37 ºC for 10 minutes 
before they were initiated with various amounts of peptide.  The decrease in absorbance 
at 265 nm was monitored continuously using a Cary 300 Bio UV-visible 
spectrophotometer.  Initial rate data representing no more than 10% of product formation 
were fit to the Michaelis-Menten equation [33] to obtain kcat, app values.  Mass 
spectrometry results with the parent peptide (Fig. 4-1) indicate that the time frame 
utilized in fitting the raw spectrophotometric data is representative of a single 
methylation event.  Apparent kinetic parameters are listed due to technical limitations of 
the spectrophotmetric assay; that is, concentrations of AdoMet >250 μM were not 
feasible due to high background absorbance in the assay (see Chapter 3).  However, the 
AdoMet concentration in the assay did not support Vmax conditions (Km, AdoMet= 38 ± 12 
μM when using the parent peptide as the methylacceptor).  Each reaction was performed 
at least in duplicate, and at least two enzyme preparations were used to confirm trends in 
substrate utilization. The limit of detection for the spectrophotometric assays was 0.1 μM 
CH3/min corresponding to a kcat of 0.025 min-1.  A radioactive assay (see Chapter 3) was 
also used to confirm the methylation rates of peptides at saturating conditions.  The 
formation of MMA or ADMA was also confirmed using amino acid analysis [34].  
Briefly, peptides were hydrolyzed in 6 M HCl, derivatized with AccQ-Fluor™ (Waters 
Corporation) and separated by reverse phase HPLC.  This method provides base-line 
separation of MMA, ADMA, and SDMA. 
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Construction of FLAG-eIF4A1 and 
His-eIF4A1 plasmids 
 
N-terminal FLAG epitope eIF4A1 fusion proteins were constructed by amplifying 
the DNA encoding mouse eIF4A1 from pc4A1 [35] using a sense primer 
5’GGCGCCATATGTCTGCGAGTCA3’ and an antisense primer 
5’CCCCGAATTCAAATGAGGTCAGC3’.  The FLAG-eIF4A1 (pST020 in Table 4-1) 
was created when this PCR product was digested with NdeI and EcoRI and inserted into 
the pAED4FLAG vector [36].  Mutation of the eIF4A1 Gly363 codon was accomplished 
by PCR amplification [37] with complementary oligonucleotide primers (see 
supplementary table 1) spanning the desired site of mutation using pST020 as template.  
In particular, G363Sforward and G363Sreverse were the primers used along with the pST020 
template to give FLAG-eIF4A1(G363S) (pST202 in Table 4-1).   
 
 
Table 4-1  eIF4A1 Plasmid Constructs 
Name 
pST020 
Description 
FLAG-eIF4A1 in pAED4FLAG 
pST202 FLAG-eIF4A1(G363S) in pAED4FLAG 
pST210 6XHis-eIF4A1(G363A)  in pET20b 
pST211 6XHis-eIF4A1(G363H)  in pET20b 
pST212 6XHis-eIF4A1(G363Y)  in pET20b 
pMA300 6XHis-eIF4A1 (wt) in pET20b 
pMA301 6XHis-eIF4A1(G363S)  in pET20b 
 
The eIF4A1 constructs used in this work are listed followed by their descriptions.  The 
pET20b vector was used to create the N-terminal histidine tagged eIF4A1 constructs, and 
the pAED4FLAG vector was used to generate the N-terminal FLAG tagged eIF4A1 
constructs. 
 
 
  
73
Construction of the N-terminal His-eIF4A1 and His-eIF4A1(G363S) plasmids 
(pMA300 and pMA301, respectively in Table 1) was performed by PCR amplifying 
pST202 with the following primers: sense= 
CCCATATGCATCATCATCATCATCACATGTCTGCGAGTCAG GATTC and 
antisense= GGGATCCTCAAATGAGGTCAGCAACGTTGAGGGGCA.  PCR 
products were digested with NdeI and BamHI and ligated into the pET20b vector 
(Novagen) to yield N-terminal His-tagged eIF4A1 constructs.  Next, N-terminal His-
eIF4A1(G363A), His-eIF4A1(G363H), and His-eIF4A1(G363Y) constructs were 
obtained using pMA301(G363S) as the template and the corresponding primers.  In 
particular, the G363H and G363Y mutations were made simultaneously using a sense 
oligo with YAT mismatch replacing WT G363 to create either a His or Tyr codon. The 
complementary antisense primer had a purine (A/G) at the position corresponding to the 
C/T in the sense primer.  All plasmid inserts were sequenced in their entirety to confirm 
insert junctions and desired base substitutions.  
 
Purification of FLAG-eIF4A1 proteins 
 
FLAG-eIF4A1 proteins expressed in BL21(DE3) CodonPlus cells (Stratagene, La 
Jolla, CA)  were incubated overnight at 4 °C with 0.5 μg M2 antibody (Sigma-Aldrich, 
St. Louis, MO) in radio-immunoprecipitation assay (RIPA) buffer [38]. Immune 
complexes were collected by incubation with protein G-agarose (Pierce Chemicals, 
Rockford, IL) for 1 hou at room temperature. Unbound proteins were removed by 
resuspension in RIPA buffer followed by brief centrifugation to collect bound proteins.  
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Samples were washed with RIPA buffer two more times followed by a single wash in 
1X HMT (20 mM Tris-HCl (pH 8.0), 0.2 M NaCl, 0.4 mM EDTA).  
 
Fluorography 
 
Methylation was performed by adding 1.1 μCi [3H]-AdoMet (76.4 Ci/mmol, 
Perkin-Elmer, Boston, MA) to the adsorbed FLAG-eIF4A proteins (0.8 μg) and 0.5 μg 
His-PRMT1 in a total liquid volume of 30 μL HMT buffer.  Reactions were allowed to 
incubate for 1 hour at 37 °C and were stopped by adding sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) Laemmli sample buffer.  Proteins were 
resolved in 12.5% polyacrylamide gels, treated with Enlightning (Perkin-Elmer), dried 
and exposed to X-ray film (RPI, Mt. Prospect, IL) for 2-7 days as indicated.   
 
His-eIF4A1 protein purification 
 
E. coli BL21(DE3) cells carrying the wild type (WT) and mutant eIF4A1 plasmid 
vectors were grown in Luria-Bertani (LB) broth at 37 ºC.  Protein expression was induced 
with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 5 hours, and cells were 
harvested by centrifugation and re-suspended in wash buffer (50 mM sodium phosphate 
[pH 7.5] with 20 mM imidazole).  Cells were lysed by sonication, and the crude 
supernatant was obtained by centrifugation.  His-eIF4A1 was purified using Ni2+-
sepharose high performance resin (Amersham Biosciences) according to the 
manufacturer’s instructions.  Purified protein was eluted with wash buffer containing 250 
mM imidazole, and the eluate was concentrated in a Centricon-Plus Concentrator (30,000 
MWCO, Amicon).  The buffer was exchanged to 50 mM sodium phosphate buffer (pH 
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7.5) and the pure protein was stored at -80 ºC.  Proteins were > 95% pure as judged by 
SDS-PAGE.  
 
Rates of in vitro methylation of eIF4A1 protein 
 
Reactions were performed using the same conditions that were used to test the 
peptides from the peptide library with the following modifications: 50 nM His-PRMT1, 
500 μM AdoMet with 0.3 μM [H3]-AdoMet (Specific activity=83 μCi/μmol), and 50 mM 
sodium phosphate buffer (pH 8.0).  After equilibrating at 37 ºC for 10 minutes, reactions 
were initiated with 25 μM WT or mutant histidine tagged eIF4A1 protein.  Various time 
point aliquots were taken out and quenched with an equal volume of cold 20% 
trichloroacetic acid (TCA).  These time points were then loaded onto glass fibers (1.2 
μm) in a UniFilter-96 well plate using a filter mate harvester (Perkin Elmer) and washed 
to rid the samples of remaining [H3]-AdoMet.  Radiolabeled eIF4A1 protein was counted 
using Ultima Gold F scintillation cocktail and a TopCount NXT (Perkin Elmer).  Rates of 
protein methylation were corrected by subtracting the background counts associated with 
the control reaction that lacked eIF4A1.  
 
Analysis of products by mass spectrometry 
 
A reaction prepared as described in the peptide kinetics methods was initiated 
with 300 μM WT-eIF4A1 peptide (YIHRIGRGGR), 300 μM eIF4A1-S peptide 
(YIHRIGRSGR), or 400 μM eIF4A1-Y peptide (AcYIHRIGRYGR).  After 120 minutes, 
the reactions were terminated 1:1 with 20% TCA.  Precipitated protein was removed by 
centrifugation, and the peptide samples were analyzed for methyl incorporation using MS 
and MS/MS analysis.  For MALDI analysis, peptide samples were diluted in HPLC grade 
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water to a final concentration of 0.5-5 µM.  Diluted peptide samples (0.5 μL) were 
spotted on a polished standard 192-well stainless steel MALDI sample plate followed by 
an alpha-cyano-4-hydroxy cinnamic acid (CHCA) matrix solution (0.4 μL, 10 mg/mL in 
a mixture of acetonitrile/water/TFA, v:v:v, 50:50:0.05).  The resulting mixtures were air 
dried and analyzed using an AB 4700 MALDI-TOF/TOF Proteomics Analyzer (Applied 
Biosystems, Framingham, MA).  MS and MS/MS spectra were acquired in reflector 
positive mode.  A peptide standard, human angiotensin I ([M+H]+=1296.67), was used 
for the external calibration.  Data were analyzed using Data Explorer software 4.6.  In 
addition, unmodified, mono, and dimethylated peptides were analyzed by LC/MS using a 
Surveyor HPLC system coupled to a LCQ Deca XP mass spectrometer (Thermo Fisher, 
Waltham, MA).  The peptides were diluted to 1 µM in 0.1% formic acid and a 2 µL 
aliquot was injected into a self-packed reversed phase column (75 µm i.d. × 15 cm, 
Magic C18 resin, 3 µm particle size, 200 Å pore size, Michrom Bioresources, Auburn, 
CA) and eluted at 200 nL/min with a linear gradient from 99:1 solvent A:B to 5:95 
solvent A:B.  Solvent A was water containing formic acid, 0.1%, v/v.  Solvent B was 
acetonitrile containing formic acid (0.15, v/v).  Data were processed using Xcalibar Data 
System 2.0 (Thermo Fisher, Waltham, MA).   
 
RESULTS 
 
Design of the peptide library 
 In order to determine if PRMT1 displays substrate selectivity at the amino acid 
sequence level, and if PRMT1 can methylate peptidyl arginine residues that are not 
present in either ‘RGG’ or ‘RXR’ sequences, we constructed a peptide library based on a 
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peptide (R3 in the literature) derived from the in vivo substrate fibrillarin.  Although the 
R3 peptide has been widely used to study PRMTs and has been co-crystallized with 
PRMT1 [31], it contains three arginine residues, each of which can be methylated.  In 
order to simplify the kinetics, the two flanking arginines of the R3 peptide were replaced 
with positively charged lysines.  This fibrillarin-based peptide (KGGFGGRGGFGGKG) 
displayed saturation kinetics (data not shown) and was both mono- and dimethylated in a 
dissociative fashion as deduced by the lag in dimethylated product formation (Fig. 4-1).  
In order to allow for more accurate peptide quantification, a tryptophan was added to the 
C-terminus.  The resulting peptide, AcKGGFGGRGGFGGKW, was used as the parent 
substrate in the peptide library.  This peptide demonstrated saturation kinetics (data not  
 
 
     Fig. 4-1.  Time-dependent formation of monomethylarginine and dimethylarginine by 
PRMT1.  A reaction was performed with 100 μM fibrillarin-based peptide 
(KGGFGGRGGFGGKG), 250 μM AdoMet, and 2.5 μM PRMT1.  At 0.2, 2, 4, 12, and 
16 minutes, 120 μL aliquots were terminated with TFA (0.8% final) and analyzed by 
LC/MS.  Substrate and product peak intensities were normalized for ionization 
differences between time points using an internal standard peptide with a similar amino 
acid composition as the fibrillarin-based peptide.  The ratio of the intensity of peptide 
product(s) peak(s)/substrate peak is plotted as a function of time.  Solid lines connecting 
(●) or (○) indicate ratios of mono- and dimethylated peptide product/substrate, 
respectively.  The data support a distributive, or dissociative, mechanism. 
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shown).  As an initial step to ascertain the importance of the amino acid sequence 
adjacent to the methylation site, two residues C-terminal to the arginyl group (underlined 
in the sequence above) were independently altered to all of the other amino acids except 
arginine to generate 36 peptides.  Of the 36 peptides in the library, 26 peptides were 
soluble in sodium phosphate buffer and were tested for their methyl acceptor activity 
with PRMT1. Such a screen is important for determining the ability of PRMT1 to 
methylate sequences outside the ‘RGG’ paradigm. 
 
PRMT1 demonstrates amino acid sequence 
selectivity with peptide substrates 
 
Soluble peptides were incubated with PRMT1 and AdoMet to determine if 
methylation could occur at sequences other than ‘RGG’ and ‘RXR’.  Peptides were 
examined kinetically using PRMT1 and a continuous spectrophotometric assay for 
AdoMet-dependent methyltransferases (see Chapter 3).  Peptides that were methylated by 
PRMT1 displayed a linear decrease in absorbance at 265 nm which was monitored 
continuously with time.  Initial rates (first 10% of product formation) were used to obtain 
Michaelis-Menten kinetic parameters, which are shown graphically in relation to the 
parent peptide which had a Km, app= 89 ± 35 μM and a kcat, app= 3.0 ± 0.5 min-1 (Fig. 4-2).  
For comparison, the R3 peptide (GGRGGFGGRGGFGGRGGFG) had a Km= <10 μM 
and a kcat= 2.7 ± 0.2 min-1 (see Chapter 3). 
Table 4-2 and Fig. 4-2 summarize the kinetic data (kcat, app and kcat/Km values) 
obtained when PRMT1 was assayed with peptides modified from the parent peptide in 
the X1 (Fig. 2, A) or the X2 (Fig. 4-2, B) positions.  Overall, PRMT1 was capable of 
methylating less than half of the peptides tested that possessed an amino acid other than 
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glycine in the X1 position (Fig. 4-2A).  Peptides containing ‘RLG’, ‘RYG’, ‘RFG’, 
‘RTG’, and ‘RKG’ sequences were PRMT1 substrates (see Table 4-2).  Importantly, the 
maximum velocity for each peptide substrate and incorporation of a methyl group was 
confirmed using a [3H]-AdoMet radioactive assay [21] (data not shown).   
 
A                            B                                                                     
 
     
 
 
    Fig. 4-2.  PRMT1 methylates sequences that extend beyond ‘RGG’.  kcat, app values 
were obtained for soluble peptides in the peptide library.  The library was constructed 
based on a peptide sequence (AcKGGFGGRGGFGGKW) derived from the in vivo 
PRMT1 substrate, fibrillarin.  Kinetic parameters were obtained using a continuous 
spectrophotometric assay.  Reactions containing 4 µM PRMT1 and 250 µM AdoMet 
were initiated with 25-2000 µM peptide.  PRMT1 substrates displayed a linear decrease 
in absorbance at 265 nm that was monitored continuously with time.  Initial rate data was 
fit to the Michaelis-Menten equation to determine kinetic constants.  (A) kkat, app values 
for peptides that varied in the X1 position (X in ‘RXG’), (B) kkat, app values for peptides 
that varied at X2 are represented in bar graphs.  The letter under each bar indicates the 
amino acid that ‘X’ is equivalent to in either the X1 or X2 position.  Peptides containing 
boxed amino acid residues in either position were very poor PRMT1 substrates.  Peptides 
with residues in the X1 or X2 positions labeled (*) were not methylated by PRMT1.  
 
 
 
We also confirmed that MMA was formed by performing amino acid analysis on 
acid-hydrolyzed peptide products [34].  Using reverse phase HPLC, all PRMT1 peptide 
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substrates displayed a peak that co-eluted with authentic MMA (data not shown).  
Peptides bearing an aspartate, alanine, glutamate, or asparagine directly C-terminal to the 
substrate arginine were classified as very poor PRMT1 substrates.  The maximum 
velocity exhibited by PRMT1 for each of these peptides using radiolabel incorporation 
was only slightly above the control reaction rate.  The limit of detection for the 
radioactive assay was 0.05 μM CH3/min corresponding to a kcat of 0.013 min-1.  
Methylation of peptides bearing serine or histidine in the X1 position was not detected 
using either kinetic assay. 
 
 
Table 4-2  Peptide Library Kinetics 
Name Sequence kcat/Km (M-1sec-1) 
G-X1 KGGFGGRGGFGGKW 560 
L-X1 KGGFGGRLGFGGKW 34 
Y-X1 KGGFGGRYGFGGKW 62 
F-X1 KGGFGGRFGFGGKW 130 
T-X1 KGGFGGRTGFGGKW 710 
K-X1 KGGFGGRKGFGGKW 160 
G-X2 KGGFGGRGGFGGKW 560 
A-X2 KGGFGGRGAFGGKW 430 
L-X2 KGGFGGRGLFGGKW 160 
F-X2 KGGFGGRGFFGGKW 50 
T-X2 KGGFGGRGTFGGKW 95 
K-X2 KGGFGGRGKFGGKW 1.0 x 103 
S-X2 KGGFGGRGSFGGKW 220 
 
Peptide names are listed followed by their sequences and catalytic efficiencies (kcat/Km 
(M-1s-1)). 
 
 
 
PRMT1 was also able to methylate peptides with amino acids other than glycine 
in the X2 position.  The kcat, app values for PRMT1 with peptides modified in the X2 
position (X in ‘RGX’) are shown in Fig. 4-2, B.  Although PRMT1 preferentially 
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methylated the ‘RGG’ containing parent peptide over all other X2 position modified 
peptides, new PRMT1 substrate sequences were identified.  Peptides harboring leucine, 
phenylalanine, threonine, lysine, alanine, or serine in the X2 position were shown to be 
PRMT1 substrates (also see Table 4-2).  Peptides with ‘RGP’, ‘RGI’, ‘RGW’, ‘RGQ’, 
and ‘RGE’ sequences were very poor PRMT1 substrates; i.e., kcat values were only 
slightly above the limit of detection.  Finally, PRMT1 did not tolerate tyrosine, aspartate, 
or methionine in the X2 position (kcat values were lower than the limit of detection).  
Overall, the data from the peptide library shows that 1) PRMT1 methylates sequences 
that go beyond the glycine arginine rich paradigm and 2) PRMT1 prefers certain amino 
acids over others in either the X1 or X2 positions.   
 
PRMT1 demonstrates amino acid sequence 
selectivity with a protein substrate 
 
In order to determine if PRMT1 demonstrates the same sequence selectivity at the 
protein level as it does at the peptide level, a model protein substrate was chosen and the 
sequence C-terminal to the substrate arginyl group was modified.  Since many known 
PRMT1 protein substrates contain multiple arginine residues that can be methylated, we 
searched for a protein substrate that was methylated by PRMT1 at a single arginine 
residue to use as a model protein substrate.  We observed that eIF4A was specifically 
methylated by PRMT1 (Bochinski et al., in preparation).  The eukaryotic initiation factor 
4A (eIF4A) family of DEAD-box proteins, of which several structures have been solved 
[39], has seven motifs characteristic of nucleic acid helicases, including a 14 amino acid, 
arginine-rich motif VI located towards the C-terminus.  eIF4A1, an eIF4A isoform that 
has an ‘RGG’ sequence located in motif VI (ENYIHRIGRGGR) of the DEAD-box 
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domain, was chosen as our model protein substrate.  Wild-type eIF4A1 incorporated 
tritium from [3H]-AdoMet when incubated with PRMT1 (Fig. 4-3) in a time-dependent 
manner (data not shown).  An R362K-eIF4A1 mutant did not incorporate radiolabel from 
[3H]-AdoMet in the presence of PRMT1 (data not shown).  These results suggest that 
eIF4A1 is methylated at a single arginine residue and will serve as a good model 
substrate.  
In order to examine if the amino acid sequence surrounding the substrate arginyl 
group affects the ability of PRMT1 to methylate protein substrates, mutants of eIF4A1 at 
the X1 position were examined as PRMT1 substrates.  Mutations were selected based on 
either the results of the fibrillarin-based library or forthcoming experiments as discussed 
below.  Mutants bearing ‘RYG’ (G363Y), ‘RAG’ (G363A), and ‘RSG’ (G363S) 
sequences were incubated with PRMT1 and [3H]-AdoMet.  As Fig. 4-3 shows, none of 
the mutant proteins incorporated radiolabel.  These results show that amino acid sequence 
in both peptides and proteins is an important factor dictating PRMT1 substrate selection.  
 
 
     Fig. 4-3.  Effect of single site mutations in the PRMT1 protein substrate eIF4A1.  0.83 
µM eIF4A1 protein was incubated with 0.69 µM [3H]-AdoMet and 5 µM PRMT1. 
Reactions were quenched with SDS loading dye and run on an SDS-PAGE gel that was 
stained with Coomassie (CB panel) and later exposed to film (3H panel).  Lanes contain 
the following proteins:  WT, G363A, G363S, and G363Y-eIF4A1, respectively.  Lanes 
containing G363S-eIF4A1 and G363Y-eIF4A1 were purposely overloaded in this 
particular gel but no radiolabel incorporation was observed in these mutants.  
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Discrimination of eIF4A isoforms by PRMT1 
A sequence alignment was performed for eIF4A1 against other DEAD-box 
domain containing proteins.  Two human eIF4A isoforms, eIF4A2 and eIF4A3, were 
most similar in sequence to eIF4A1, with eIF4A2 and eIF4A1 sharing 90% sequence 
identity.  Although eIF4A3 shares 66% sequence identity with eIF4A1, eIF4A1 and 3 
share over 80% structural similarity (blue residues in Figure 4-4).  The single amino acid 
difference between eIF4A1 and 3 in motif VI (boxed amino acids in Figure 4-5A) occurs 
at G368 in eIF4A1 (S368 in eIF4A3), directly C-terminal to the methylation site. We 
asked if PRMT1 could methylate the eIF4A3 protein, which has an ‘RSG’ instead of an 
‘RGG’ sequence at the same position.   
 
 
     Fig. 4-4.  Sequence conservation of eIF4A isoforms.  The crystal structure of the yeast 
eIF4A1 protein (PDB accession 1FUU_1) highlights the proposed site of PRMT1-
methylation, Arg362, shown in ball and stick representation on a flexible loop.  Yeast 
eIF4A1 was aligned with human eIF4A3 sequence (NCBI accession# P38919) using the 
Dali Server.  Strictly conserved residues are shown in blue while functionally conserved 
residues are shown in dark gray.  Functionally distinct, non-conserved residues are shown 
in orange.  The conserved arginine is blue while the non-conserved amino acid directly 
C-terminal to it is orange.  
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Based on previous results with the G363S mutant of eIF4A1, we predicted that 
eIF4A3 would not be a good PRMT1 substrate.  No tritium incorporation into eIF4A3 
protein was observed upon incubation with [3H]-AdoMet and PRMT1 (Fig. 4-5, B) 
indicating that the eIF4A3 protein is not a PRMT1 substrate.  However, an S368G-
eIF4A3 mutant did incorporate tritium when incubated with [H3]-AdoMet and PRMT1 
(data not shown).  Thus, despite the high sequence and structural similarity between the 
two isoforms, the eIF4A1 protein is a PRMT1 substrate while the eIF4A3 protein is not.  
Furthermore, a single change in the amino acid residue adjacent to a substrate arginyl 
group dictates whether or not the eIF4A1/3 proteins are methylated.  
 
A 
eIF4A1  NRENYIHRIGRGGR 365 
eIF4A3  NRELYIHRIGRSGR 370 
                             
 
B  
 
 
 
 
    Fig. 4-5.  Comparison of eIF4A1 and eIF4A3 isoforms as PRMT1 substrates.  (A)  The 
sequences from the human eIF4A1 (accession# NP_001407) and eIF4A3 (accession# 
P38919) isoforms were aligned using CLUSTALW and were shown to be 66% identical.  
Residues 352-365 from motif VI (boxed residues) of the eIF4A1 DEAD box domain are 
shown.  The proposed site of PRMT1-methylation is bolded.  Position 363, the glycine 
residue immediately C-terminal to the eIF4A1 substrate arginine residue (R362), is 
indicated by an arrow.  Instead of glycine at this position in motif VI, eIF4A3 has a 
serine.  In (B), eIF4A3 protein was examined as a PRMT1 substrate using conditions 
described in Fig. 4-2.   
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Effect of substrate sequence context 
on PRMT1 activity 
 
The amino acid sequence surrounding the substrate arginine residue is different 
between the G363Y eIF4A1 protein (…YIHRIGRYGR…) and the fibrillarin-based 
‘RYG’ peptide (AcKGGFGGRYGFGGKW).  It is possible that the inability of PRMT1 to 
methylate the ‘RYG’ sequence in the eIF4A1 mutant could be due to sequence context.  
That is, amino acids in one position affect whether or not amino acids in a second 
position are favored.  We therefore examined PRMT1 catalyzed methylation of peptides 
which were based on the wild-type and mutant eIF4A1 sequences.  PRMT1 was capable 
of methylating all eIF4A1-peptides tested (Table 4-3).  The eIF4A1-Y peptide was 
methylated (kcat/Km, app= 80 ± 18 M-1s-1) albeit at a much slower rate than wild-type 
(kcat/Km, app= 610 ± 18 M-1s-1).  This result suggests that the inability of PRMT1 to 
methylate the G363Y eIF4A1 protein was not due to sequence context.  Additionally, 
these results show that while the sequence surrounding the reactive arginyl group is 
important (e.g., eIF4A1 mutant proteins which are not PRMT1 substrates), other factors 
also contribute to protein substrate selection.  For example, we note that the loop in 
which eIF4A1 is methylated consists of only six amino acid residues.  This loop is 
restrained by a beta sheet and alpha helix at its termini and may display limited flexibility 
compared to a peptide substrate.  The ability of peptides corresponding to the loop region 
or single amino acid mutants of the loop region to be PRMT1 substrates while the 
corresponding proteins were not PRMT1 substrates may be related to decreased 
flexibility within the protein loop.  
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Table 4-3  eIF4A peptide kinetics with PRMT1 
 
Peptide sequences and kinetic parameters (Km, app and kcat/Km, app) are listed for peptides 
derived from eIF4A1 and eIF4A3.  The peptide arginine residue that gets methylated by 
PRMT1 is bolded.   Kinetics were performed as described in Fig. 4-2.   
 
 
We also noted that the ‘RSG’ sequence presented within the fibrillarin context 
(AcKGGFGGRSGFGGKW) was not a PRMT1 substrate while the same sequence 
presented within the eIF4A1 context (YIHRIGRSGR) was a PRMT1 substrate.  The 
eIF4A1-S peptide was in fact, a better substrate than the eIF4A1-Y peptide (Table 4-3).  
This suggests that PRMT1 substrate specificity is contextual with respect to the amino 
acid sequence surrounding the substrate arginyl residue.   
Because the eIF4A1 peptides have three arginine residues, it was possible that 
changing the peptide sequence shifted the methylation site.  In order to address this issue, 
we determined the methylation site in each peptide by MS/MS.  Analysis of the WT-
eIF4A1 peptide after incubation with PRMT1 and AdoMet showed that only the arginine 
within the ‘RGG’ sequence (bolded R7 in AcYIHRIGRGGR) was both mono and 
dimethylated (Fig. 4-6 and Fig. 4-7, A).   
The eIF4A1-S peptide, AcYIHRIGRSGR, with an ‘RSG’ sequence was also 
methylated at R7 (data not shown).  Mass spectrometry analysis of the eIF4A1-Y mutant 
Name Peptide sequence Km, app (μM) kcat/Km, app (M-1s-1)
eIF4A1 YIHRIGRGGR 39 ± 2.4 610 ± 99 
eIF4A1-Y YIHRIGRYGR 250 ± 28 80 ± 18 
eIF4A1-S (eIF4A3) YIHRIGRSGR 47 ± 3.9 170 ± 22 
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peptide, AcYIHRIGRYGR, housing an ‘RYG’ sequence showed a +14 peak 
corresponding to monomethylation, which could not be ascribed to R4 or R10 
methylation (Fig. 4-7, C).  The presence of MMA in PRMT1 reaction mixtures using 
each of the three eIF4A1-derived peptides was confirmed by amino acid analysis via 
HPLC (data not shown).  Importantly, these results suggest that the methylation site did 
not shift when the eIF4A1 peptide sequence was altered.  In summary, all eIF4A1- 
derived peptides were methylated by PRMT1. 
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     Fig. 4-6.  MALDI-TOF/TOF-MS/MS spectra of (A) 1184.68 (1184.68 calculated) 
[M+H]+ precursor ion corresponding to the unmodified WT-eIF4A1 peptide, (B) 1198.62 
(1198.69 calculated) [M+H]+ precursor ion corresponding to the monomethylated WT-
eIF4A1 peptide, confirms the modification site to be Arg7, and (C) 1212.64 (1212.71 
calculated) [M+H]+ precursor ion corresponding to the dimethylated WT-eIF4A1 peptide, 
confirms the modification site to be Arg7.  The peptide sequence is labeled with observed 
b and y ions. 
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     Fig. 4-7.  MALDI-MS spectra of methylation reactions of (A) WT-eIF4A1, (B) 
eIF4A1-S and (C) eIF4A1-Y peptides.  Labeled peaks are for the unmodified (native), 
mono-methylated (+14 Da) and dimethylated (+28 Da), sodium adduct (+22 Da), 
disodium adduct (+44 Da), and dimethylated plus sodium adduct (+50 Da) peptides, 
respectively.   
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DISCUSSION 
PRMT1 substrate selectivity goes beyond 
the ‘RGG’ paradigm 
 
When PRMT1 was crystallized with the R3 peptide and AdoHcy, the electron 
density for the two amino acid residues C-terminal to the fully resolved substrate arginine 
was not observed.  Because no stabilizing interactions were observed in the enzyme-
substrate complex between PRMT1 and substrate side chains, one might predict that the 
active site residues of PRMT1 have little influence over which substrate sequences can 
interact with the enzyme.  The results from the peptide library show that PRMT1 
substrate selectivity exists (Fig. 4-2, the X1 and X2 positions); however, the variety of 
sequences that are methylated extends beyond the ‘RGG’ paradigm. 
Our results show that the ‘RGG’ sequence is not a necessity of a PRMT1 
substrate.  We confirmed the PRMT1-dependent methylation of several novel sequences 
using a coupled spectrophotometric assay, radiolabel incorporation, and amino acid 
analysis.  The ability to methylate a variety of peptide sequences indicates that PRMT1 
has evolved a certain degree of flexibility with regard to substrate binding and/or 
catalysis.  The arginine of all PRMT1 substrates must be recognized, and PRMT1 
residues that fulfill this function can be seen in the crystal structure [31].  This 
recognition appears strict as even a peptide where the arginine has been replaced with a 
citrulline, (where one of the guanidino nitrogens has been replaced with a carbonyl 
group) does not compete with substrate peptides (data not shown), suggesting that 
citrulline does not bind in the active site.  Of the eleven peptide sequences that were 
methylated by PRMT1, the amino acid residues allowed in either the X1 or X2 positions 
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possess a diverse range of chemical properties including residues with aromatic rings 
and/or hydroxyl groups, hydrophobic amino acids, and positively charged residues.   
Even though the experimental design of this study was geared toward substrate 
profiling using a peptide screen, certain observations from the screen are worthy of 
noting.   In addition to the ‘RGG’ and ‘RXR’ PRMT1-methylation sequences identified 
prior to this study, peptides containing leucine, phenylalanine, threonine, or lysine in 
either the X1 or X2 positions were methylated by PRMT1 (Fig. 4-2).  Surprisingly, 
alanine was not favored by PRMT1 in the X1 position despite its resemblance to glycine 
in size and charge but was favored in the X2 position.  Interestingly, tyrosine and 
phenylalanine, both larger amino acids, were allowed in the X1 position. 
Serine was favored in the X2 position (‘RGS’) within the context of the fibrillarin 
sequence.  We note that the R3 peptide substrate which was complexed with PRMT1 in 
the crystalline state could be modeled into the substrate binding groove in either 
orientation.  Therefore, our data is consistent with the possibility that the fibrillarin-based 
‘RGS’ peptide and a peptide derived from histone H4 that is methylated by PRMT1 in an 
‘SGR’ sequence [40] bind PRMT1 in opposite orientations.  This data suggests that a 
hydrogen bond afforded by serine in this position (‘RGS’ or ‘SGR’) may contribute to 
binding/catalysis.  However, in order for us to be able to describe specific PRMT1-
substrate interactions between the newly discovered substrate sequences and PRMT1, 
more structural information about positions of substrate side chain residues and 
directionality of the peptide substrate are needed.   
Our study reveals that directional peptide libraries are useful to begin 
characterizing the substrate selectivity of PRMT1, but they are not the end-all approach 
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because PRMT1 displayed contextual recognition of peptide substrates.  Specifically, 
the ‘RSG’ containing peptide modeled from eIF4A3 was a PRMT1 substrate while the 
‘RSG’ containing fibrillarin-based peptide was not.  Compensatory interactions have also 
been observed in the deacetylase SIRT1 [41].  Alternatively, the ability of PRMT1 to 
differentially methylate peptides containing the ‘RSG’ sequence (eIF4A3 peptide versus 
fibrillarin-based peptide) may reside in the ability of PRMT1 to bind peptide substrates in 
either an NT to CT or CT to NT orientation.  This characteristic would be consistent with 
the crystal structure.  Since it is expected that the binding mode of protein substrates 
would be fixed in one orientation, it would follow that not all peptide sequences (NT to 
CT) which are PRMT1 substrates may be PRMT1 protein substrates.   
 
Selection of PRMT1 protein substrates 
 
          Our results with the eIF4A proteins show that even at the protein level, the amino 
acid sequence of the substrate protein surrounding the reactive arginine group is one 
factor that dictates PRMT1 substrate selectivity.  Even proteins bearing remarkable 
sequence and structural similarity can be distinguished by a single amino acid difference 
near the substrate arginyl group.  Comparison of the eIF4A1 proteins and corresponding 
peptides as PRMT1 substrates illustrates that recognition of protein substrates is not 
governed by amino acid sequence alone.  Nonetheless, the peptide data suggest the 
possibility of a more diverse methylarginine proteome than the previously recognized 
‘RGG’-containing proteins.  Using the MSDmotif server at EMBL-EBI 
(http://www.ebi.ac.uk/msd-srv/msdmotif/), the pdb was queried for structures harboring 
potential PRMT1 methylation sites.  A PSI-BLAST on loop sequences yielded several 
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proteins with ‘GRYG’, ‘GRFG’, and ‘GRGF’ sequences (Table 4-4).  Human protein 
and human pathogens with diverse functions are represented.  The structures of these 
proteins confirm that the target arginine is present on an accessible region of the protein.  
Presently, a more diverse PRMT1 recognition sequence is also supported by the 
methylation of histone 4 and HNF4 [42] in ‘RGK’ and ‘RYG’ sequences, respectively.   
 
 
Table 4-4  Potential PRMT1 Targets 
Sequence PDB ID UniProt ID. Protein Class 
GRFG 2CS5 P29074  Hydrolase, Tyrosine phosphatase, pdz domain 
GRYG 2YQP Q5T1V6 Hydrolase, RNA helicase ddx59 
GRYG 2HTV Q6XV46 Hydrolase, influenza A virus 
GRYG 1DTD P48052 Hydrolase, Carboxypeptidase a2. 
GRGF 2PIE O76064 Ligase, E3 ubiquitin-protein ligase rnf8. 
GRGF 1W8K O61130 Antigen, Plasmodium vivax 
GRGF 1X4L Q14192 Metal-binding portein, lim domain 
GRGF 1N9D P01236 Hormone, prolactin 
GRGF 2C35 P62487 Polymerase, rpb7  
 
The sequences indicated were queried against the pdb using the MSDmotif server as 
discussed in the text.  All protein listed are either human or are human pathogens. 
 
 
Although the amino acid sequence of a protein substrate may play a role in 
PRMT1 substrate recognition and catalysis, PRMT1 substrate selectivity may not be 
limited to the PRMT1 active site and its ability to distinguish between different 
sequences.  It has already been shown that peptide length and the presence of positively 
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charged peptidyl residues distant from the PRMT1 active site chemistry affect substrate 
binding and catalysis [40].  This feature is also illustrated in the eIF4A1 methylation site 
which is flanked by five positive residues. In addition to interactions within the PRMT1 
active site, PRMT1 may also take advantage of specific protein-protein interactions distal 
from the methylation site, a type of “proximity-induced catalysis” that has been observed 
in ERK2 [43].   
 
Mono- and dimethylation of substrates 
 
          Using mass spectrometry, we demonstrated that the dimethylation of a fibrillarin-
based peptide substrate occurs through a dissociative mechanism (Scheme 4-2) based on 
an observable lag in the formation of the dimethylated product (Fig. 4-1).  Our results are 
consistent with Frankel and co-workers [44], but are different from the findings of 
Thompson and co-workers [40] who defined a partially processive dimethylation of a 
histone 4 peptide by PRMT1.  Because the mechanism of methyltransfer is dissociative, 
formation of the dimethylated peptide product depends upon how easily PRMT1 can 
recapture the monomethylated product.  Frankel and co-workers [44] have reported that 
the monomethylated peptide substrate is a better substrate for PRMT6 than the naked 
peptide.  We have observed similar results with PRMT1 and a fibrillarin-based peptide 
(Wooderchak and Hevel, manuscript in preparation) and suggest that sequence 
differences between a fibrillarin-based peptide and a histone 4-based peptide may be the 
basis for the different observations.   
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     Scheme 4-2.  Dissociative reaction mechanism catalyzed by PRMT1.  PRMT1 binds a 
single arginine containing peptide substrate and catalyzes methyl group transfer from 
AdoMet.  The monomethylated product is released before re-binding PRMT1 and being 
dimethylated.  R=arginine 
 
Conclusion 
Limited studies and selective tools have promoted the idea that PRMT1 substrates 
conform to an ‘RGG’ sequence with a few rare exceptions [25, 27, 28, 45].  Importantly, 
our data clearly show that PRMT1 is capable of methylating sequences that go beyond 
the ‘RGG’ paradigm.  Additionally, our results suggest that residues N-terminal to the 
arginyl modification site are also important in substrate recognition.  This suggests that 
the methyl arginine proteome may be larger and more diverse than previously thought.  It 
will be interesting to see if any of the candidate proteins identified in our study are indeed 
methylated by PRMT1. 
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CHAPTER 5 
 
EXAMINING THE FORMATION OF ADMA BY PRMT11 
 
ABSTRACT 
 
Protein arginine methyltransferase 1 (PRMT1) performs over 85% of all protein 
arginine methylation in the cell having the ability to both mono- and asymmetrically 
dimethylate protein arginine residues.  Interestingly, many PRMT1 protein substrates are 
dimethylated instead of monomethylated on multiple arginines of certain proteins such as 
the hnRNPs, SAM68, and fibrillarin.  Consequently, we sought to understand how 
PRMT1 preferentially asymmetrically dimethylates protein arginine residues in vivo 
using kinetic and mass spectrometry analysis.  PRMT1 may have evolved a way to 
ensure the formation of a dimethylated product through 1) preference for the 
monomethylated substrate over the nonmethylated substrate or 2) processive methylation.  
We show here that PRMT1 did not processively methylate a single arginine-containing 
peptide substrate.  PRMT1 preferred to methylate a peptide substrate that had already 
been monomethylated over an unmodified peptide substrate.  A multiple arginine-
containing peptide was found to be dissociatively dimethylated at a single arginine 
residue using a modified pulse-chase experiment analyzed by mass spectrometry.  
Interestingly, methylation of a multiple arginine-containing peptide was systematic (not 
random).  Based on these results, the predominance of dimethylated protein substrates in 
vivo is likely due to PRMT1 preferentially methylating monomethylated substrates over 
naked substrates. 
 1Coauthored by W.L. Wooderchak, D. Chen, J.M. Hevel, Examining the formation of 
ADMA  by PRMT1, Biochemistry (2009), manuscript in preparation.  
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INTRODUCTION 
Protein arginine methyltransferases (PRMTs) post-translationally modify a 
number of protein arginine residues.  Targeted methylation of these proteins affects a 
variety of cellular processes including RNA processing, transcriptional regulation, signal 
transduction, and DNA repair (reviewed in [1]).  Type I PRMTs (PRMT1, 3, 4, 6, and 8) 
catalyze the formation of monomethylarginine (MMA) and asymmetric dimethylarginine 
(ADMA) via the transfer of a methyl group from S-adenosyl methionine (AdoMet/SAM) 
onto protein arginine residues (Scheme 5-1) [2-7].  Type II methyltransferases (PRMT5 
and PRMT7) catalyze the formation of symmetric dimethylarginine (SDMA) where the 
second methyl group is transferred onto the unmodified guanidino nitrogen of MMA [8, 
9]. 
 
NH
Type I & II PRMTs
NH
H2N N
CH3
CH3
Type I
Type II
ADMA
SDMA
NH
NH
CH3
HN+
CH3
+
AdoMet
AdoHcy
MMA
AdoMet
AdoMet
AdoHcy
AdoHcy
H2N NH2
+
NH
H2N NH
CH3
+
 
     Scheme 5-1. Reactions catalyzed by PRMTs.  PRMTs catalyze the S-
adenosylmethionine (AdoMet) dependent methylation of a protein substrate arginine 
residue to form monomethyl arginine (MMA).  Type I methyltransferases, PRMT1, 3, 4, 
6, and 8 dimethylate arginine asymmetrically to form asymmetric dimethyl arginine 
(ADMA).  Type II methyltransferases, PRMT5 and PRMT7 catalyze the formation of 
symmetric dimethyl arginine (SDMA).  
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Thus far, nine PRMT isoforms (PRMT1-11) have been identified in humans 
with orthologs present in yeast [10], protozoa, Caenorhabditis elegans, Drosophila 
melanogaster [11], plants [12], and fish [13].  Of the eleven isoforms, PRMT1 
predominates, performing an estimated 85% of all protein arginine methylation in vivo 
[10].  PRMT1 has the ability to methylate protein substrates at multiple sites within a 
single protein.  Even though PRMT1 is capable of forming both MMA and ADMA, most 
PRMT1 substrates are found dimethylated in vivo.  Fibrillarin [14], hnRNPs [15], and 
Sam68 [16] are asymmetrically dimethylated by PRMT1 at multiple sites within the same 
protein.   
Although PRMTs are vital to normal development and function [17, 18], protein 
arginine methylation has also been linked to carcinogenesis [19], viral pathogenesis [20], 
multiple sclerosis [21], and spinal muscular atrophy (reviewed in [1]).  In addition, 
several studies have shown that free ADMA, a downstream proteolytic product of PRMT 
substrates, has a clear role in cardiovascular disease [22] and stroke [23] by serving as an 
endogenous inhibitor of nitric oxide synthesis [24].   ADMA competitively inhibits nitric 
oxide synthase which generates the vascular smooth muscle relaxant, nitric oxide.  Only 
20% of ADMA is excreted in urine while approximately 80% of ADMA is cleared by 
dimethylarginine dimethylaminohydrolases (DDAHs).  DDAHs convert ADMA to 
citrulline and dimethylamine.  However, the misregulation of DDAHs or the 
hyperactivity of PRMTs may contribute to cardiovascular disease [22].  In fact, PRMT1 
has been shown to be overexpressed in myocardial tissue taken from coronary heart 
disease patients [25].  In addition to contributing to cardiovascular ailments, 
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pathophysiological concentrations of ADMA have also been shown to elicit 
significant changes in coronary artery endothelial cell gene expression [26].   
It was discovered early on that ADMA was the most abundant of the three 
possible PRMT modifications.  Two percent of all protein arginine residues are 
asymmetrically dimethylated in rat liver nuclei [27], and approximately 12% of all 
arginine residues isolated from heterogeneous nuclear ribonucleoproteins (hnRNPs) are 
asymmetrically dimethylated [28].  Most methylated proteins derived from cellular 
extracts have a far greater amount of dimethylated arginine residues than 
monomethylated arginine residues.  Yet, the mechanism that the Type I PRMTs use to 
ensure ADMA formation is unclear.  Because ADMA is an important molecule that 
mediates a variety of cellular processes [26], it is important to understand how ADMA is 
formed.   
In order to understand how ADMA is the major biological product of PRMT1-
methylation, we investigated the enzymatic mechanism of PRMT1.  We hypothesized 
that this biological phenomenon is achieved by the nature of PRMT1 preferentially 
methylating monomethylated substrates rather than naked substrates.  Alternatively, 
PRMT1 could perform processive arginine methylation wherein the substrate binds to the 
enzyme and is not released until the arginine residue is fully dimethylated (see Scheme 5-
2).  We show here that PRMT1 dissociatively dimethylates peptides containing a single 
arginine residue using mass spectrometry (MS) and HPLC analysis.  Further kinetic 
analysis revealed that PRMT1 prefers to methylate monomethylated peptide substrates 
over their non-methylated counterparts.  Methylation of a multiple arginine-containing 
peptide (R2) was systematic (not random), and the analysis of the R2 peptide using a 
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modified pulse-chase experiment and MS revealed that PRMT1 dissociatively 
methylates fibrillarin-based peptides.   
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     Scheme 5-2.  Dissociative versus processive methylation.  Dissociative and processive 
mechanisms are depicted for PRMT1.  In a dissociative mechanism, PRMT1 (or 
E=enzyme) monomethylates the arginine-containing peptide and releases it.  When the 
monomethylated species re-binds, another methyl group is transferred from AdoMet onto 
the monomethylated peptide to yield the fully dimethylated product.  In a processive 
mechanism, PRMT1 mono- and dimethylates the single arginine-containing peptide 
without releasing the monomethylated species from the active site. 
 
 
 
MATERIALS AND METHODS 
All chemicals used were of ACS reagent grade or better.  AdoMet was purchased 
from Sigma as a chloride salt (≥80%, from yeast).  JMH1-long 
(GGKGGFGGRGGFGGKGGFG) was synthesized by Sigma Genosys.  N-terminally 
acetylated peptides based on the in vivo PRMT1 substrate fibrillarin, JMH1 
(AcKGGFGGRGGFGGK), JMH1W (AcKGGFGGRGGFGGKW), JMH1W-CH3 
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(AcKGGFGGRmethylGGFGGKW), and R2 (AcGGRGGFGGKGGRGGFG), were 
synthesized and purified by the Keck Institute (Yale University).  Two peptides based on 
the in vivo PRMT1 substrate eukaryotic initiation factor 4A1 (eIF4A1), the eIF4A1 
peptide (YIHRIGRGGR) and the eIF4A1-CH3 peptide (YIHRIGRmethylGGR), were 
synthesized and purified by the Keck Institute.  All peptides used in this study are listed 
in Table 5-1.   
 
 
Table 5-1  Peptides used to study PRMT1 formation of ADMA 
Name Peptide Sequence 
JMH1                        KGGFGGRGGFGGK 
JMH1-long                  GGKGGFGGRGGFGGKGGFG 
JMH1W                        KGGFGGRGGFGGKW 
JMH1W-CH3                        KGGFGGR(CH3)GGFGGKW 
eIF4A1                          YIHRIGRGGR 
eIF4A1-CH3                          YIHRIGR(CH3)GGR 
R2                  GGRGGFGGKGGFGGRGGFG 
 
Peptide names with their corresponding sequences are listed.  Arginine residues that are 
methylated by PRMT1 are shown in bold. 
 
 
 
HPLC analysis of a single arginine-containing peptide 
HPLC analysis was used to analyze the formation of MMA and ADMA with time 
[29].  Briefly, a reaction containing 2.5 µM PRMT1, 250 µM AdoMet, 100 nM AdoHcy 
nucleosidase (purified as in [30]) in 50 mM sodium phosphate buffer (pH 7.5) was 
initiated with 100 µM eIF4A1 peptide (see Table 5-1) at 37 ºC.  Time points were taken 
out and quenched in 10% TFA (final).  Precipitated protein was removed through 
centrifugation.  Soluble eIF4A1 peptide in the supernatant was hydrolyzed in 6 M HCl, 
derivatized with the AccQ-Fluor™ reagent (Waters Corporation), and separated by 
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reverse phase HPLC.  This method provides base-line separation of arginine, MMA, 
ADMA, and SDMA [29].  The area under the MMA and ADMA peaks were integrated.  
Standard curves of known MMA and ADMA concentrations were used to calculate the 
amount of MMA and ADMA in each sample. 
 
Mass spectrometry analysis of a single 
arginine-containing peptide 
 
A reaction with 2.5 µM PRMT1, 250 µM AdoMet, and 100 nM MTAN in 50 mM 
sodium phosphate buffer (pH 7.5) was initiated with 100 µM JMH1-long peptide (see 
Table 5-1).   At various times points, 10 µL aliquots were quenched with TFA (10% 
final) and analyzed by LC/MS.  The intensities of substrate and product peaks were 
normalized for ionization differences between time points using an internal standard 
peptide with a similar amino acid composition as the fibrillarin-based peptide.   
 
Kinetic analysis 
 
A continuous spectrophotometric assay for AdoMet-dependent methyltransferases 
(see Chapter 3) was used to assay PRMT1 with several fibrillarin-based methyl-accepting 
peptides and two eIF4A1-based peptides (eIF4A1 and eIF4A1-CH3).  Briefly, 
recombinant AdoHcy nucleosidase (MTAN) was used to hydrolyze the AdoHcy 
generated from methyltransfer.  The resulting adenine was deaminated by recombinant 
adenine deaminase.  This strategy alleviates any product inhibition that could occur from 
AdoHcy.  Each 110 µL reaction contained 4 µM His-PRMT1 (purified as in Chapter 3), 
0.02 µM adenine deaminase (purified as in Chapter 3), 250 µM AdoMet, 10 nM MTAN 
(purified as in [30]), 100 µM MnSO4, and 50 mM sodium phosphate buffer pH 7.1.  
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Reactions were equilibrated at 37 ºC for ten minutes before they were initiated with 
various amounts of peptide.  The decrease in absorbance at 265 nm was monitored 
continuously using a Cary 300 Bio UV-visible spectrophotometer.  All rates were well 
above the limit of detection of 0.1 μM CH3/min corresponding to a kcat of 0.025 min-1, 
and the time frame utilized in fitting the raw spectrophotometric data was representative 
of a single methylation event (see Chapter 4).    
For calculation of kinetic constants, the concentration of peptide was varied at 
several fixed concentrations of AdoMet (40 µM - 250 µM).  The average initial velocity 
representing no more than 10% of product formation was obtained from two 
measurements for each pair of substrate concentrations and was used to construct 
Michaelis-Menten plots.  The data were graphed as Lineweaver-Burk plots, and linear 
regression was employed to construct slope and intercept replots [31].  These replots 
were linear and were used to calculate the values of the kinetic parameters.  
 
Intrinsic fluorescence 
 
An RF-5301PC spectrofluorophotometer (Shimadzu) was used for fluorescence 
measurements.  For peptide affinity determinations, an excitation wavelength of 290 nm 
was used and emission spectra from 300-420 nm were collected.  The change in 
fluorescence intensity at the maximum emission (333 nm) was monitored.  The excitation 
and emission slit was 5 nm and the scan speed was 100 nm/min using 1325 µL of 0.7 µM 
PRMT1 in 150 mM sodium phosphate buffer pH 7.1.  Increasing concentrations from 1 
to 50 µM peptide ligand were added at 2-3 min intervals.  Data from at least two 
titrations were averaged and analyzed using a Stern-Volmer plot [32].  The linearity of 
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the Stern-Volmer plot suggests that cofactor binding is the dominant fluorescence-
quenching phenomenon over the range of concentrations tested.  Data were evaluated by 
least squares linear regression analysis to obtain the slope which corresponds to the 
dissociation constant (KD). 
 
HPLC analysis of multiple arginine- 
containing peptides 
 
HPLC analysis was used in order to determine the time frame of the mass 
spectrometry pulse-chase experiment and to quantify the amount of MMA produced at 
various time points over the course of the reaction [29].  Reactions containing various 
concentrations of PRMT1, 1200 µM AdoMet, 100 nM AdoHcy nucleosidase in 150 mM 
sodium phosphate buffer (pH 7.1) were initiated with 200 µM R2 peptide on ice.  Time 
points were taken out and quenched in 10% TFA (final), and precipitated protein was 
removed through centrifugation.  The R2 peptide in the resulting supernatant was 
hydrolyzed in 6 M HCl, derivatized with the AccQ-Fluor™ reagent (Waters 
Corporation), and the individual amino acids were separated by reverse phase HPLC 
[29].  The area under the MMA peak was integrated, and a standard curve of known 
MMA concentrations was used to calculate the amount of MMA formed in each reaction 
mixture. 
 
Mass spectrometry peptide methylation analysis 
and De Novo sequencing study 
 
A reaction with 4 µM PRMT1, 800 µM AdoMet, and 100 nM MTAN in 50 mM 
sodium phosphate buffer (pH 7.1) was initiated with 200 µM R2 peptide.   At various 
times points, 10 µL aliquots were quenched with TFA (10% final) and analyzed by 
 111
LC/MS followed by MS/MS of the desired peaks.  Peptides with and without 
methylation were analyzed using nano-LC-MS-MS on a Q-Tof Primer tandem mass 
spectrometer (Waters, Manchester, UK). Peptide samples were loaded (3 µl) using a 
NanoACQUITY Sample Manager (Waters, Manchester, UK) onto a trapping column 
(Symmetry® C18, 180µM x 20mm) (Waters, Manchester, UK).  Samples were washed 
with 99% H2O and 1% acetonitrile for one minute at 15 µl/min to a waste container and 
then eluted with a 30 min gradient (1-4% B in 0.1 minutes, 4-60% B in 20 minutes, 60-
85% B in 3 minutes,  85-1% B in 1 minute, and 1% B for 6 minutes where A = 99.9% 
H2O, 0.1% formic acid and B = 99.9% acetonitrile, 0.1% formic acid) at 800nL/min 
using an NanoACQUITY UPLC (Waters, Manchester, UK) over a 100 µm x 100 mm 
BEH 130 C18 column.  MS survey and product ion MS/MS scan times were 1.0 second.  
The collision offset was automatically determined based on precursor mass and ion 
charge state. MS/MS data was used for the De Novo sequencing of methylated peptides 
by Waters BioLynx software (Waters, Manchester, UK). 
 
Modified pulse-chase experiment to test 
processivity of mono- to dimethylated R2 
 
A reaction with 4 µM PRMT1, 1200 µM AdoMet, and 100 nM MTAN in 50 mM 
sodium phosphate buffer (pH 7.1) was initiated (or pulsed) with 200 µM R2 peptide on 
ice.  At t=5.5 minutes, a 10 µL time point was quenched with TFA (10% final) to verify 
that only monomethylation of R2 had taken place.  At t=6 minutes, the reaction was 
chased with 1 mM JMH1W-CH3 peptide.  Note, a methylated chase peptide was used 
instead of an unmodified peptide in order to design a fair competition experiment.  To 
determine if this portion of the reaction was processive, subsequent time points (t=6.5, 9, 
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12, 15, and 20 minutes) were taken out and quenched in TFA (10% final).  
Precipitated protein was removed, and soluble R2 and JMH1W-CH3 peptides (and their 
methylated products) were analyzed using the MS analysis techniques described 
previously.  The sum of all peak intensities associated with the R2 peptide was used to 
normalize each product peak intensity; e.g. the data point plotted for trimethylated R2 
=peak intensity of trimethylated R2/sum of all peaks associated with R2. 
 
Modified pulse-chase experiment to test  
processivity of di- to trimethylated R2   
 
A reaction with 4 µM PRMT1, 1200 µM AdoMet, and 100 nM MTAN in 50 mM 
sodium phosphate buffer (pH 7.1) was initiated (or pulsed) with 200 µM R2 peptide at 37 
ºC.  At t=59.5 minutes, a 10 µL time point was quenched with TFA (10% final) to verify 
that only mono- and dimethylation of R2 had taken place.  At t=60 minutes, the reaction 
was chased with 1 mM JMH1W-CH3 peptide.  To determine if this portion of the reaction 
was processive, additional time points (t=60.5, 70, 80, 100, 120, 150, and 200 minutes) 
were taken out and quenched in TFA (10% final).  Precipitated protein was removed, and 
the soluble R2 peptide and JMH1W-CH3 peptide (and their methylated products) were 
analyzed using the MS and data analysis techniques described previously.   
 
RESULTS  
 
PRMT1 dissociatively methylates a single 
arginine-containing peptide 
 
Many PRMT1 protein substrates are observed to have multiple methylated 
arginines.  Yet, it is unclear why or how the enzymatic conversion of all designated 
arginines within a protein substrate is accomplished without generating diversity.  If all 
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designated arginines are required to be dimethylated for the biological effect, how 
does PRMT1 accomplish this?  One way to ensure a dimethylated product is to perform 
processive methylation.  Previously, we showed by mass spectrometry analysis that 
PRMT1 methylates a single arginine-containing fibrillarin-based peptide substrate 
(AcKGGFGGRGGFGGK) in a dissociative manner (see Chapter 4).  Here we show data 
that suggests that PRMT1 dissociatively methylates another arginine-containing peptide 
(YIHRIGRGGR) based on the eukaryotic initiation factor 4A1 (eIF4A1) protein based on 
an initial lag in the formation of the dimethylated product (Fig. 5-1, A).  Kinetic analysis 
revealed that 4.7 ± 1.0 μM AdoHcy was generated in 45 seconds, a time in which mass 
spectrometry results suggest no presence of dimethylated peptide. This amount was 
higher than the concentration of enzyme (2.5 μM).  In a processive mechanism, the 
concentration of MMA would never exceed the concentration of enzyme in the reaction.  
These data suggest that PRMT1 methylates the eIF4A1 peptide in a dissociative manner.  
Note, only the central arginine (R7) of the eIF4A1 peptide is methylated by PRMT1 (see 
Chapter 4). 
Previous studies [33, 34] have shown that PRMT1 activity increases with peptide 
length.  In order to determine if peptide length also influences the manner in which the 
substrate is methylated, we next increased the length of the dissociatively methylated 
fibrillarin-based peptide (see Chapter 4) by six amino acids (AcKGGFGGRGGFGGK→ 
AcGGKGGFGGRGGFGGKGGFG) to see if the longer peptide could be processively 
methylated.  Despite an increase in length, mass spectrometry analysis of a reaction with 
the longer peptide displayed an obvious lag in the formation of dimethylated product 
(Fig. 5-1, B) suggesting that methylation was dissociative.  Kinetic analysis revealed that 
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3.6 ± 1.1 μM AdoHcy was generated in 1 minute, a time in which mass spectrometry 
results suggest no presence of dimethylated peptide.  Because this amount was higher 
than the concentration of enzyme (2.5 μM), the results support a dissociative mechanism.   
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     Fig. 5-1.  Time-dependent formation of mono- and dimethylarginine.  Reactions 
containing 250 μM AdoMet and 2.5 μM PRMT1 in 50 mM sodium phosphate buffer (pH 
7.5) were initiated with 100 μM eIF4A1 peptide (YIHRIGRGGR) in (A) or 100 μM 
fibrillarin-based peptide (GGKGGFGGRGGFGGKGGFG) in (B).  Aliquots were 
quenched in TFA (10% final) at various times, analyzed by LC/MS, and peak intensities 
of peptide product peaks were plotted as a function of time.  Substrate and product peak 
intensities were normalized for ionization differences using an internal standard peptide 
with a similar amino acid composition as the fibrillarin-based peptide.  Solid (●) and 
dashed (○) lines indicate ratios of mono- and dimethylated peptide product/substrate, 
respectively.  The data support a distributive, or dissociative, mechanism.  
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PRMT1 preferentially methylates monomethylated 
substrates   
 
As an alternative to processive methylation, another way to ensure the formation 
of a dimethylated product biologically is if PRMT1 were to preferentially methylate a 
substrate that has already been methylated.  To test this, we compared how well PRMT1 
could methylate the monomethylated peptide substrates (JMH1W-
CH3=AcKGGFGGRmethylGGFGGKW; eIF4A1-CH3=YIHRIGRmethylGGR) versus the 
naked peptide substrates (JMH1W=AcKGGFGGRGGFGGKW; eIF4A1=YIHRIGRGGR) 
using a continuous spectrophotometric assay for AdoMet-dependent methyltransferases 
(see Chapter 3).  Kinetic data were collected and analyzed as described in the methods 
section.  Michaelis-Menten plots for the JMH1W-CH3 and JMH1W peptides with 
PRMT1 show that the peptides were able to saturate PRMT1 at a variety of fixed 
AdoMet concentrations (data not shown).  A Lineweaver Burk plot of the data indicated 
that PRMT1 performs a sequential reaction mechanism with the JMH1W-CH3 and 
JMH1W peptides (data not shown).  This type of reaction mechanism is consistent with 
the PRMT6 reaction mechanism [34, 35].  PRMT1 preferentially methylated the 
monomethylated substrate, JMH1W-CH3 (see Table 5-2).  The Km was smaller (Km, 
peptide= 5.78 µM) and the catalytic efficiency was higher (kcat/Km= 4890 M-1s-1) for the 
monomethylated substrate in comparison to the values obtained for the unmodified 
JMH1W peptide (Km, peptide= 54.7 µM; kcat/Km= 1640 M-1s-1).  
The same trend was observed with an additional peptide substrate pair (Table 5-2) 
based on the PRMT1 protein substrate eIF4A1 (see Chapter 4).  Michaelis-Menten plots 
for the eIF4A1-CH3 and eIF4A1 peptides with PRMT1 showed that peptides were able to 
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saturate PRMT1 at a variety of fixed AdoMet concentrations.  A Lineweaver Burk 
plot of the eIF4A1-CH3 and eIF4A1 peptide data indicated that PRMT1 performs a 
sequential reaction mechanism with each peptide (data not shown).  PRMT1 preferred to 
methylate the monomethylated eIF4A1 substrate (kcat/Km= 2610 M-1s-1) versus the 
unmodified substrate (kcat/Km= 1960 M-1s-1) (see Table 5-2).  Such a preference for 
arginine residues that have already been monomethylated by PRMT1 would lead to an 
increasing amount of asymmetrically dimethylated protein arginine residues.  
 
 
Table 5-2  Kinetic constants for PRMT1 with naked and monomethylated peptides 
 Peptide Sequence Km, SAM 
(μM) 
Km, 
peptide 
(μM) 
Vmax 
(μM 
CH3/min) 
kcat/Km 
(M-1s-1) 
JMH1W KGGFGGRGGFGGKW 117 54.7 21.5 1640 
JMH1W-CH3 KGGFGGR(CH3)GGFGGKW 15.1 5.78 6.79 4890 
eIF4A1   YIHRIGRGGR 35.3 52.4 21.4 1960 
eIF4A1-CH3   YIHRIGR(CH3)GGR 49.1 28.2 17.7 2610 
 
All kinetic constants were obtained using a continuous spectrophotometric assay for 
AdoMet-dependent methyltransferases (see Chapter 3).  Substrate arginine residues are 
bolded.  
 
 
 
Peptide binding 
In order to discern if the preference for PRMT1 to modify monomethylated 
arginine residues was also due to preferential binding, we measured the dissociation 
constants between PRMT1 and the eIF4A1 peptide substrate pair.  The PRMT1 crystal 
structure depicts two tryptophans at positions 145 and 294 which lie in the catalytic 
region near the substrate arginine residue opposite the AdoMet binding region [36].  The 
intrinsic fluorescent-properites of PRMT1 were exploited in a fluorescence-quenching 
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assay to determine the dissociation constants for the eIF4A1 and eIF4A1-CH3 
peptides with PRMT1.  The Stern-Volmer plot [32] was used to analyze the quenching 
data (Fig. 5-2, A).  A Stern-Volmer plot for the eIF4A1 and eIF4A1-CH3 peptides (Fig. 2, 
B) revealed that both the methylated and nonmethylated eIF4A1 peptides had nearly the 
same affinity for PRMT1 as judged by the similar Kd values (Table 5-3).  These results 
indicate that preference for the monomethylated substrate is not due to binding.   
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     Fig. 5-2.  Naked and monomethylated substrates bind similarly to PRMT1.  (A) 
Steady-state fluorescence emission spectra of PRMT1 with the eIF4A1-CH3 peptide 
where buffer (○), enzyme (●), 1 μM peptide (Δ), and 15 μM peptide (▲) are shown.  (B)  
Stern-Volmer plot of quenching of PRMT1 fluorescence by the eIF4A1-CH3 peptide. 
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Table 5-3.  Peptide dissociation constants. 
Peptide Ligand KD (nM) Fluorescence quenching (%) 
eIF4A1 51 ± 7.2 30 ± 2.0 
eIF4A1-CH3 41 ± 5.0 25 ± 4.7 
Dissociation constants were obtained using intrinsic fluorescence quenching assays 
(performed at least in duplicate) as described in the methods section.  The quenching 
observed was consistent with the number of active site tryptophans relative to the total 
number of tryptophans. 
 
 
 
Methylation of a multiple arginine-containing 
substrate is systematic 
 
Most PRMT1 protein substrates harbor regions that contain multiple sites of 
arginine methylation.  It is unknown which of these sites undergoes methylation first.  Is 
one site preferentially methylated on a substrate containing multiple arginine residues 
(systematic methylation), or is there no preference for which arginine on a multiple 
arginine-containing substrate gets methylated first (random methylation)?  To examine 
how PRMT1 methylates substrates containing multiple arginine residues (random versus 
systematic methylation), we designed another fibrillarin-based peptide substrate, 
R2=AcGGRGGFGGKGGFGGRGGFG.  The R2 peptide was first assessed by mass 
spectrometry to assess purity (bottom spectrum, Fig. 5-3, A).  The R2 peptide was then 
purified (top spectrum, Fig. 5-3, A) and used in all experiments thereafter.   
First, we analyzed the product formation of the purified R2 peptide with time 
using mass spectrometry.  This technique allowed us to identify the methylated products 
at various time points and distinguish which arginine residue that had been modified.  A 
reaction containing 4 µM PRMT1, 800 µM AdoMet, and 10 nM MTA-nucleosidase was 
initiated with 200 µM purified R2 peptide.  The bottom mass spectrum of Fig. 5-3, B 
shows that R2 (561.9 m/z) was monomethylated (566.6 m/z) within seconds of initiating 
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the reaction.  MS/MS analysis was used to further analyze the dimethylated peptide 
product peak (571.3 m/z) (top spectrum, Fig. 5-3, B).  We observed that only the N-
terminal arginine of the R2 peptide had been di-methylated.  MS/MS sequencing data 
shown in Fig. 5-3, C gave the following sequence: GGR(2-
methyl)GGFGGKGGFGGRGGFG.  No methylation of the C-terminal arginine of R2 was 
detected (Fig. 5-3, C).  This indicates that the N-terminal arginine of R2 was first mono- 
and then dimethylated.  After an extended reaction (8 hours), MS/MS analysis was used 
to confirm the location of methylation of the tetramethylated R2 peptide.  MS/MS 
analysis of the tetramethylated peptide peak (581 m/z) (MS data not shown) revealed that 
R2 had also been dimethylated on the C-terminal arginine (Fig. 5-3, D).  MS/MS 
sequencing data shown in Fig. 5-3, D gave the following sequence: GGR(2-
methyl)GGFGGKGGFGGR(2-methyl)GGFG.  Scheme 5-3 summarizes the series of 
methylation events and indicates that methylation of R2 was systematic and not random.  
Like R2, preliminary MS/MS data suggests that the R3 peptide that has an additional 
arginine residue is also methylated at its N-terminal arginine first 
GGR(methyl)GGFGGRGGFGGRGGFG (data not shown).  Altogether, these results 
demonstrate that 1) one arginine is preferentially methylated over another, 2) both arginyl 
groups in R2 can be converted to ADMA, and 3) methylated product species can be 
effectively separated and detected using MS.  
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     Scheme 5-3.  Methylation of R2 is systematic, not random.  The Nterminal arginine of 
R2 (AcGGRGGFGGKGGFGGRGGFG) is monomethylated first.  Dimethylation of this 
modified arginine occurs next followed by the mono- and subsequent dimethylation of 
the Cterminal arginine.   
 
 
 
Methylation of a multiple arginine-containing 
substrate is dissociative 
 
One way to ensure dimethylated product formation would be to perform 
processive methylation.  Although we have shown that PRMT1 methylates substrates 
containing a single arginine residue in a dissociative manner (Fig. 5-1 and Chapter 4), it 
is possible that multiple arginine-containing substrates are processed differently.  
Because most PRMT1 protein substrates are found to be dimethylated on multiple 
arginine residues within the same protein, we examined how PRMT1 methylates a 
multiple arginine-containing substrate (processive versus dissociative methylation) at two 
different levels.  First, examined how a single arginine residue in a multiple arginine-
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containing substrate was methylated.  Second, we examined if methylation from one 
arginine residue to the next arginine residue on the same substrate was processive.   
Using the R2 peptide, which we have shown is first mono- and then dimethylated 
at the N-terminal arginine (Fig. 5-3), we tested if PRMT1 could processively dimethylate 
the N-terminal arginine residue (GGRGGFGGKGGFGGRGGFG → 
GGRdimethylGGFGGKGGFGGRGGFG).  First, reverse phase HPLC analysis [29] of the 
acid-hydrolyzed product R2 peptide was used to verify the reaction time in which only 
monomethyl arginine was present (Fig. 5-4).  This method along with a standard curve of 
MMA was then used to quantify the amount of MMA generated up until the time that the 
reaction was quenched with TFA.  At 20 minutes, approximately 4.2 μM MMA had been 
formed.  This amount was greater than the 10 nM enzyme in the reaction.  Since R2 is 
monomethylated at the N-terminal arginine first followed by the dimethylation of that 
same arginine residue (and not the monomethylation of the C-terminal arginine residue), 
a higher concentration of MMA than enzyme in the reaction indicates that methylation is 
dissociative.  If the mechanism had been processive, the concentration of MMA 
(monomethylated-R2) would have never exceeded the concentration of enzyme.   
A modified pulse-chase experiment (Fig. 5-5, A) coupled to mass spectrometry 
analysis was used to verify that the dimethylation of the N-terminal arginine 
(GGRGGFGGKGGFGGRGGFG → GGRdimethylGGFGGKGGFGGRGGFG) was 
dissociative.  A reaction containing 4 µM PRMT1 and 1200 µM AdoMet was pulsed 
with 200 µM R2 peptide substrate at 37 ºC.  At 6 minutes, a time point where only the 
monomethylated product peak was detected by mass spectrometry (bottom spectrum in  
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     Fig. 5-4.  HPLC chromatogram verifies the presence of arginine and MMA only.  A 
reaction containing 10 nM PRMT1, 1200 µM AdoMet, and 10 nM MTA-nucleosidase in 
150 mM sodium phosphate buffer pH 7.1 was initiated with 200 µM R2 peptide on ice.  
Time points were taken out and quenched 1:1 in 20% TFA.  Precipitated protein was 
removed through centrifugation, and the resulting supernatant containing the modified 
peptide was hydrolyzed with concentrated HCl.  Samples were derivatized with the 
AQFluor reagent and analyzed by HPLC.  The HPLC chromatogram indicates that only 
arginine (Arg) and monomethylated arginine (MMA) at 24.5 min and 31.7 min, 
respectively, were present after a 5 minute reaction on ice (bold line).  MMA and ADMA 
standards injected separately are shown in gray.   
 
 
 
Fig. 5-5, B), the reaction was chased with an excess amount (1 mM) of JMH1W-CH3 
peptide (KGGFGGR(CH3)GGFGGKW).  Time points were taken out at 6.5, 9, 12, 15, 
and 20 minutes (Fig. 5-5, C) and compared to time points from a control reaction that had 
been pulsed with R2 and chased with water at 6 minutes (data not shown).  Fig. 5-5, C 
shows that the chase peptide (475.88 m/z) was dimethylated (479.9 m/z) with time.  On 
the other hand, the peak intensity of the dimethylated R2 peptide product (571.29 m/ z) 
did not increase as much with time when the reaction was chased with the JMH1W-CH3 
peptide (Fig. 5-5, D) when compared to the control reaction containing the R2 pulse only.  
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Importantly, a sample of the chase peptide alone verified that the dimethylated chase 
peptide peak was not present in the JMH1W-CH3 peptide standard (data not shown). 
Furthermore, the peak intensities obtained from the raw mass spectrometry data 
were plotted against time (as described in the methods section) in Fig. 5-5, E  for the R2 
only control reaction (left panel) and the chase reaction (right panel).  Dimethylation of 
R2 was clearly influenced by the chase peptide.  The dimethylated R2 peak increased 
0.08 from 6.5-20 minutes in the control reaction but only increased 0.03 from 6.5-20 
minutes in the chase reaction (Fig. 5-5, E).  Because the chase peptide was methylated 
almost immediately in this experiment, the monomethylated R2 peptide had to have been 
released from the PRMT1 active site.  These results indicate that dimethylation of a 
single arginine residue is dissociative on a substrate containing multiple arginine 
residues. 
Finally, we examined if methylation from one arginine to the next arginine 
residue on the same substrate was processive.  In a separate modified pulse chase mass 
spectrometry experiment (Fig. 5-6, A), we tested if the mechanism going from 
dimethylated-R2 (at the N-terminal arginine) to trimethylated-R2 
(GGRdimethylGGFGGKGGFGGRGGFG → GGRdimethylGGFGGKGGFGGRmethylGGFG) 
was processive.  A reaction containing 4 µM PRMT1 and 1200 µM AdoMet was pulsed 
with the 200 µM R2 peptide substrate at 37 ºC.  At 60 minutes, a time point where only 
the mono- and dimethylated product peaks were detected by mass spectrometry (see 
bottom trace of Fig. 5-6, B), the reaction was chased with an excess amount of JMH1W-
CH3 peptide (1 mM).  Later time points were quenched and analyzed by MS.  The data 
showed that the chase peptide was dimethylated with time (479.9 m/z in Fig. 5-6, C). 
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     Fig. 5-5.  PRMT1 performs dissociative methylation of a single arginine residue on a 
multiple arginine-containing substrate.  (A) Modified pulse chase mass spectrometry 
experimental design.  PRMT1 was allowed to methylate the R2 peptide (pulse) for a 
period of time wherein the first methylation event could occur.  A time point is taken out 
to verify the presence of the monomethylated species.  The reaction is then chased with 
an excess of JMH1W-CH3 peptide.  Subsequent time points are taken out and analyzed 
by mass spectrometry to identify if the chase peptide gets methylated immediately, a 
result indicative of a dissociative mechanism.  (B) MS samples of the R2 peptide control 
reaction at 6, 9, 12, and 15 minutes where the native (R2), monomethylated (mono), and 
dimethylated (di) R2 peaks are labeled at 561.9 m/z, 566.6 m/z, and 571.3 m/z, 
respectively.  (C-D)  At 6 minutes, a reaction that had been pulsed with 200 µM R2 was 
chased with 1 mM JMH1W-CH3 peptide.  Subsequent time points (6.5, 9, 12, 15, and 20 
minutes) were quenched and analyzed by MS to identify if the chase peptide (475.88 
m/z) or the R2 peptide was dimethylated.  (C) Mass spectrums reveal that the chase 
peptide was dimethylated (di-chase=479.9 m/z) with time while the R2 peptide was not 
dimethylated (R2-di=571.29 m/z) with time (in D).  The bottom mass spectrum from the 
59.5 minute time point (in both C and D) was taken out before the chase peptide was 
added.  (E) Time dependent formation of mono- and dimethylated R2 from the R2 only 
control reaction (left panel) and chase reaction (right panel).    Peak intensities associated 
with each product were normalized as discussed in the materials and methods section and 
were plotted as a function of time.  Filled circles (●), open circles (○), and triangles (▲) 
represent monomethylated-R2, dimethylated-R2, and the dimethylated-chase peptide, 
respectively. 
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The peak intensities of trimethylated-R2 grew slower (Fig. 5-6, D) than the peak 
intensities from the R2 only pulse reaction (raw data not shown).  The ratios of the peak 
intensities obtained from the raw MS data were plotted against time (as described in the 
methods section) in Fig. 5-6, E for the R2 only control reaction (left panel) and chase 
reaction (right panel).  Both the di- and trimethylated R2 peak intensities did not increase 
as much with time when the chase peptide was added.  PRMT1 preferentially methylated 
the chase peptide over both the mono- and dimethylated R2 peptides.  In fact, the 
dimethylated R2 peak increased 0.27 from 60-200 minutes in the control reaction but 
increased only 0.02 during the chase reaction (Fig. 5-6, E).  The trimethylated R2 peak 
increased 0.14 from 60-200 minutes in the control reaction but only increased 0.02 from 
60.5-200 minutes in the chase reaction (Fig. 5-6, E).  Our results indicate once again that 
the catalytic event going from mono- to dimethylated R2 is dissociative 
(GGRmethylGGFGGKGGFGGRGGFG → GGRdimethylGGFGGKGGFGGRGGFG).  
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However, these results do not definitively prove that going from di- to trimethylated 
R2 (GGRdimethylGGFGGKGGFGGRGGFG → 
GGRdimethylGGFGGKGGFGGRmethylGGFG) is dissociative.  In order to prove whether 
this event was truly dissociative, the reaction was chased at 200 minutes instead of 60 
minutes wherein a larger buildup of the dimethylated-R2 product had been generated.  
Unfortunately, the activity of the enzyme used to perform this chase experiment had 
decreased upon storage at 4 ºC for days.  The buildup of dimethylated-R2 product was 
comparable to the previous 60 minute chase experiment.  Despite any experimental 
complications, the preliminary data suggest a dissociative mechanism wherein PRMT1 
releases the N-terminally dimethylated-R2 product before it rebinds and monomethylates 
the Cterminal arginine.   
 
DISCUSSION 
 
PRMT1 preferentially methylates monomethylated 
substrates dissociatively 
 
Previously, we demonstrated that the dimethylation of a single arginine-
containing fibrillarin-based peptide substrate occurs through a dissociative mechanism 
based on an observable lag in the formation of the dimethylated product using mass 
spectrometry (see Chapter 4).   Mass spectrometry analysis suggests that the eIF4A1 
peptide was also dissociatively methylated by PRMT1 (Fig. 5-1, A).  Our results are 
consistent with Frankel and coworkers who also observed dissociative methylation of a 
minimal peptide (WGGYSRGGYGGW) by PRMT6 [35], but are different from the 
findings of Thompson and co-workers who defined a partially processive dimethylation 
of a histone 4 peptide (AcSGRGKGGKGLGKGGAKRHRKV) by PRMT1 [33, 34].   
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     Fig. 5-6.  PRMT1 may dissociatively dimethylate multiple arginine residues.  (A) 
Modified pulse chase mass spectrometry experimental design.  PRMT1 methylates the 
R2 peptide (pulse) for a period of time wherein only two methylation events have 
occurred.  The reaction is chased with JMH1W-CH3 peptide in excess.  Subsequent time 
points are quenched and analyzed by MS.  If the chase peptide gets methylated 
immediately (before R2 trimethylation), PRMT1 is dissociative.  (B) MS samples of the 
R2 peptide control reaction at 59.5, 60, 70, 80, 100, 120, 150, and 200 minutes where the 
native (R2), monomethylated (mono), dimethylated (di), and trimethylated (tri) R2 peaks 
are labeled at 561.9 m/z, 566.6 m/z, 571.3 m/z, and 576.3 m/z respectively.  Only the top 
spectrum is labeled for clarity.  (C-D) At 60 minutes, the reaction with 200 µM R2 was 
chased with 1 mM JMH1W-CH3 peptide.  Time points (60.5, 70, 80, 100, 120, 150, and 
200 minutes) were quenched in TFA (10% final).  Mass spectrums revealed that the 
chase peptide was dimethylated (di-chase=479.9 m/z) with time in (C) while the R2 
peptide underwent little trimethylation (R2-tri=576.3 m/z) (D).  The 59.5 minute sample 
(bottom spectrum in C and D) was taken out before the chase peptide was added.  (E) 
Time dependent formation of mono-, di-, and trimethylated R2 from the R2 only control 
reaction (left panel) and chase reaction (right panel).  Peak intensities associated with 
each product were normalized as discussed in the materials and methods section and were 
plotted as a function of time.  The mono- (●), di- (○), and trimethylated (▲) R2 peptides 
along with the dimethylated chase peptide (□) are shown.   
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Because the fibrillarin-based substrates (see Chapter 4 and [35]) and the eIF4A1-
based substrate (Fig. 5-1, A) were 12-13 amino acids long and the histone 4 peptide was 
21 amino acids long, substrate length could influence the PRMT1 mechanism.  However, 
despite an increase in peptide length, our results suggest that the longer fibrillarin-based 
peptide substrate was dissociatively dimethylated as indicated by a lag in the formation of 
the dimethylated product (Fig. 5-1, B).  In a dissociative mechanism, the formation of the 
dimethylated peptide product depends upon how easily PRMT1 can recapture the 
monomethylated product.  Frankel and co-workers have reported that the 
monomethylated peptide substrate is a better substrate for PRMT6 than the naked peptide 
[35].  We observed similar results with two fibrillarin-based peptides (JMH1W and 
JMH1W-CH3) (Table 5-2).  PRMT1 preferentially methylated the monomethylated 
substrate versus the naked peptide 3 to 1.   
In order to understand if the sequence differences between a fibrillarin-based 
peptide and a histone 4-based peptide may be the basis for the different mechanistic 
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observations, we examined the kinetic parameters of an additional peptide substrate 
pair (eIF4A1 and eIF4A1-CH3) derived from eIF4A1, another PRMT1 protein substrate.  
This time, we observed that the monomethylated peptide substrate was a better substrate 
for PRMT1 than the naked peptide (Table 5-2), but the preference for the 
monomethylated eIF4A1 substrate versus the naked peptide was not as significant (1.33 
to 1).  The mechanistic basis for the observed preference for the monomethylated 
substrate is not due to binding as evidenced by the similar dissociation constants between 
eIF4A1 and eIF4A1-CH3 (Table 5-3).  A slight preference for the monomethylated 
substrate must be due to other factors in the kinetic mechanism.   
Perhaps the methylated peptides examined adopt a conformation in the active site 
that facilitates a better SN2 attack of the methyl group on AdoMet than the nonmethylated 
peptide.  Alternatively, the central position of the substrate arginine in the peptides tested 
may structurally constrain the arginine only allowing for a more restricted mechanism 
where the peptide has to dissociate from the enzyme before dimethylation can occur.  An 
arginine located towards the N or C-terminal end of the peptide (as in the case of the H4 
peptide [33, 34]) may have more flexibility allowing a second methyl group to transfer to 
the substrate arginine resulting in more of a semi-processive mechanism.  A crystal 
structure of PRMT1 with a monomethylated peptide would allow us to visualize how a 
monomethylated substrate interacts with PRMT1 and may help us understand the 
mechanism. 
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PRMT1 methylation of substrates containing 
multiple arginine residues 
 
PRMT1 methylation of substrates containing multiple modification sites was 
shown to be systematic (not random) using mass spectrometry (Fig. 5-3).  
Monomethylation of the R2 peptide occurred first at the N-terminal arginine residue.  
This monomethylated arginine was then dimethylated, a result that is consistent with the 
fact that PRMT1 prefers to methylate arginine residues that have already been 
monomethylated versus non-methylated arginine residues (Table 5-2).  PRMT1 then 
went on to trimethylate and then fully methylate R2 at the C-terminal peptidyl arginine.  
PRMT1 systematically methylated arginine residues in a multiple arginine-containing 
substrate.  Preliminary MS/MS evidence suggests that the N-terminal arginine of R3 
(GGRGGFGGRGGFGGRGGFG) is also methylated first suggesting that methylation 
does not occur randomly (data not shown).  Although these results were obtained using 
peptide substrates, PRMT may also methylate multiple arginine residues in protein 
substrates in a systematic manner.  PRMT1 methylation of multiple arginine residues on 
a protein substrate may result in different biological responses depending on the order in 
which a series of arginines is methylated.   
Next, using two carefully designed modified-pulse chase experiments, we found 
that the methylation of a substrate containing multiple arginine residues was dissociative.  
First, we found that going from monomethylated to dimethylated R2 at the N-terminal 
arginine (GGRnakedGGFGGKGGFGGRGGFG → 
GGRdimethylGGFGGKGGFGGRGGFG) was dissociative when the reaction containing 
R2 was flooded with chase peptide.  Because the chase peptide was methylated shortly 
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after its addition (Fig. 5-5, E), the R2 peptide had to have been released from 
PRMT1.  Also supporting a dissociative mechanism was the fact that the concentration of 
MMA was greater than the concentration of enzyme in the reaction when no ADMA was 
present (Fig. 5-4).  If the mechanism were processive, the concentration of MMA 
(monomethylated-R2) could never exceed the concentration of enzyme.  A dissociative 
mechanism is consistent with what we (see Fig. 5-1 and Chapter 4) and others [35] had 
already determined for peptides containing a single arginine residue.  Although the 
presence of another arginine residue in the peptide sequence could have altered how 
PRMT1 performed catalysis, the dissociative mechanism remained the same. 
Finally, preliminary results suggested that the methylation of one arginine to the 
methylation of another arginine residue on the same peptide substrate was dissociative 
(GGRmonomethylGGFGGKGGFGGRGGFG → 
GGRdimethylGGFGGKGGFGGRmethylGGFG).  The reaction was chased at a time (60 
minutes) in which most of the R2 peptide was not mostly dimethylated.  When this 
reaction was flooded with chase peptide, the chase peptide was methylated before the R2 
peptide could be di- or trimethylated (Fig. 5-6, E).  Both R2 dimethylation and 
trimethylation were substantially impeded.  These results 1) verify that R2 
monomethylation to dimethylation follows a dissociative mechanism and 2) suggest that 
PRMT1 releases the dimethylated peptide product before it can rebind and 
monomethylate the C-terminal peptidyl arginine residue.  In order to definitively prove if 
the mechanism from di- to trimethylated-R2 is dissociative, however, the reaction was 
chased at a later time point (200 minutes) wherein R2 should have been mostly 
dimethylated.  Although some trimethylation of R2 will have already occurred by this 
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time, the correct mechanistic event (methylation of one arginine to another on the 
same peptide) will be probed.   Unfortunately, the PRMT1 used to perform this 
experiment was nearly inactive due to multiple freeze/thaw cycles and the data was not 
usable.  If PRMT1 is found to methylate multiple arginine residues in a dissociative 
manner, the following scheme will be proposed (Scheme 5-4).  
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     Scheme 5-4.  Suggested reaction mechanism scheme of PRMT1 with the R2 peptide.  
PRMT1 (E=enzyme) interacts with AdoMet and the R2 peptide.  The first methylation 
event takes place, and both products (AdoHcy and R2mono-CH3) dissociate from 
PRMT1.  Monomethylated-R2 and AdoMet re-bind to PRMT1.  Dimethylation occurs, 
and both products are released.  Dimethylated-R2 and another molecule of AdoMet re-
bind to PRMT1 and trimethylated-R2 is generated.  AdoHcy and R2tri-CH3 are released.  
Finally, R2 is fully methylated when the trimethylated peptide and another molecule of 
AdoMet bind to PRMT1.  Fully methylated-R2 and AdoHcy are released from the 
PRMT1 active site.  Note, because the order of substrate binding and product release is 
not known, the rebinding event of the peptide products are not shown for simplicity. 
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We have shown that PRMT1 methylates arginine-containing peptide 
substrates in a systematic manner preferring to methylate substrates that have already 
been monomethylated.  These results may be extended to help explain how PRMT1 
methylates protein substrates; however, the structural surface of a protein substrate may 
be more restrictive (less flexible) than a peptide substrate.  Based on the fact that PRMT1 
did not methylate multiple arginines within the same substrate randomly, PRMT1 may 
exhibit directional methylation of protein substrates or even utilize a type of scanning 
mechanism.  All in all, methylation of multiple arginine residues on a protein substrate by 
PRMT1 has the potential to result in different biological responses depending on the 
order in which a series of arginines is methylated.   
 
Conclusion 
 
Many PRMT1 protein substrates such as fibrillarin, the hnRNPs, and SAM68 are 
asymmetrically dimethylated at multiple arginine residues.  In order to explain the 
biological predominance of ADMA, we investigated the catalytic mechanism of PRMT1.  
Although some methyltransferases have been shown to catalyze processive methylation 
[37-40], an enzymatic feature that would help explain the predominance of ADMA, 
PRMT1 does not catalyze processive methylation of fibrillarin-based peptides.  Instead, 
we have shown that PRMT1 methylates single arginine-containing peptides in a 
dissociative manner.  Methylation of a single arginine in a multiple arginine-containing 
peptide was shown to be dissociative.  PRMT1 preferentially monomethylated substrates 
versus the unmodified peptide substrates, a phenomenon that may result from substrate 
length, sequence, and/or the location of the substrate arginine within the substrate.  Based 
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on these results, the predominance of dimethylated protein substrates in vivo is likely 
due to the PRMT1 mechanism and the preference for monomethylated proteins. 
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CHAPTER 6 
 
DETERMINANTS OF PRMT1 PRODUCT FORMATION:  ROLES OF ACTIVE SITE 
RESIDUES1 
 
ABSTRACT 
 
Protein arginine methyltransferases (PRMTs) play important roles in biology.  
Type I methyltransferases, PRMT1, 3, 4, 6, and 8, catalyze the formation of monomethyl 
arginine (MMA) and asymmetric dimethylarginine (ADMA) on protein arginine residues 
via methyl group transfers from S-adenosyl methionine (AdoMet/SAM).  PRMT5, a 
Type II methyltransferase performs symmetric dimethylation generating symmetric 
dimethylarginine (SDMA).  Encoded in each isoform is the necessary active site 
geometry and chemical functionalities to generate SDMA or ADMA and regulate how 
much MMA versus ADMA is made.  Using the crystal structure of ratPRMT1 as our 
guide, we analyzed the effect of several active site mutations on the rate of methylation 
and the ability of PRMT1 to selectively perform asymmetric dimethylation.  Met155 has 
been proposed to play a direct role in dictating ADMA formation.  M155A-PRMT1 was 
assayed with R3, a 19 amino acid peptide derived from the in vivo PRMT1 substrate 
fibrillarin and exhibited approximately one tenth the activity of wild type PRMT1.  
Peptide products were hydrolyzed and analyzed by fluorescent derivatization via RP-
HPLC.  Only MMA and ADMA were produced.  Thus, removing steric bulk afforded by 
Met155 in the PRMT1 active site is not by itself sufficient to transform PRMT1 into a  
 
 
1Coauthored by W.L. Wooderchak, J.M. Hevel, Determinants of PRMT1 product 
formation:  Roles of active site residues, Biochemistry (2009), manuscript in preparation.  
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Type II PRMT.  Other PRMT1 mutants (M48A, M146A, S154A, W145A, Y148S, 
and M48L-PRMT1) displayed altered methyltransferase activity generating only MMA 
and ADMA.  Importantly, we show that Met48 plays a critical role in PRMT1-catalysis.   
 
INTRODUCTION 
 
Protein arginine methyltransferases (PRMTs) catalyze the transfer of a methyl 
group from S-adenosyl methionine (SAM/AdoMet) to one of the terminal guanidino 
groups of arginine generating monomethyl arginine (MMA) and S-adenosyl 
homocysteine (SAH/AdoHcy).  Type I methyltransferases, PRMT1, 3, 4, 6, and 8, 
asymmetrically dimethylate arginine on the same guanidino nitrogen and form 
asymmetric dimethylarginine (ADMA) [1-6].  Type II methyltransferases, PRMT5 and 
PRMT7, perform symmetric dimethylation wherein the guanidino nitrogens are modified 
to produce symmetric dimethylarginine (SDMA) (Scheme 6-1) [7, 8].  Selective 
formation of ADMA by PRMT1 has many biological implications [9]; specifically, Arg 3 
of histone H4 can be aymmetrically dimethylated by PRMT1 or symmetrically 
dimethylated by PRMT5 resulting in antagonistic biological consequences (reviewed in 
[10]).  Because of this, we wanted to study why PRMT1 selectively forms ADMA versus 
SDMA. 
Once a protein has been modified, it is eventually degraded in the proteasome and 
free MMA, SDMA, and ADMA are released.  Interestingly, higher levels of free ADMA 
have been linked to cardiovascular disease (reviewed in [11]) and stroke [12].  ADMA is 
also second only to age as a predictor of mortality and cardiovascular events in chronic 
renal failure patients [13].  ADMA and MMA are endogenous inhibitors of nitric oxide 
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synthase (NOS) [14] which catalyzes the formation of nitric oxide, a vasodilator that 
prevents atherosclerosis.  Fortunately, free MMA and ADMA levels are controlled by 
dimethylarginine dimethylaminohydrolases (DDAHs), but the misregulation of DDAH or 
the hyperactivity of PRMTs may contribute to cardiovascular disease [15].  In fact, 
PRMT1 has been shown to be overexpressed in myocardial tissue taken from coronary 
heart disease patients [16].  Because PRMT1 performs an estimated 85% of all protein 
arginine methylation in vivo [17], this isoform generates more ADMA than all other 
PRMT isoforms combined.  Therefore, it is important to understand how PRMTs control 
Type I (asymmetric) versus Type II (symmetric) dimethylation.   
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    Scheme 6-1.  Reactions catalyzed by PRMTs.  PRMTs catalyze the S-
adenosylmethionine (AdoMet) dependent methylation of a protein substrate arginine 
residue to form monomethyl arginine (MMA).  Type I methyltransferases, PRMT1, 3, 4, 
6, 8, and 10 dimethylate arginine asymmetrically to form asymmetric dimethyl arginine 
(ADMA).  Type II methyltransferases, PRMT5, 7, and 9 catalyze the formation of 
symmetric dimethyl arginine (SDMA).   
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The crystal structure of PRMT1 [18] has been used to offer an explanation as 
to why Type I PRMTs exclusively perform asymmetric dimethylation versus symmetric 
dimethylation.  Interestingly, all Type I PRMTs contain an active site methionine 
(Met155 for rat PRMT1) which is not conserved among Type II PRMTs.  Methionine 
155, located at the end of an alpha helix positioned near the reactive arginine of the 
substrate peptide (Fig. 6-1), has been proposed to exclude monomethylated arginine from 
binding in a conformation that would allow its symmetric dimethylation [18].  The 
residue corresponding to Met155 in the Type II PRMT5 is a serine (amino acid 446 in rat 
PRMT5 and amino acid 474 in yeast PRMT5).  PRMT7, another Type II PRMT, has an 
alanine residue in place of the bulky methionine at this location.  It was hypothesized that 
the smaller bulk of the serine and alanine side chains at this location may enable the free 
rotation of the substrate arginine about the terminal C-N bond resulting in the formation 
SDMA formation.   
 
 
    Fig. 6-1.  Active site methionines position the substrate arginine.  The active site of rat 
PRMT1 (PDB code 1OR8) is shown with AdoHcy (cyan) and the R3 peptide in orange.  
The substrate arginine of R3 is depicted in ball and stick mode with the two guanidino 
nitrogens pointing towards the sulfur atom (blue) of AdoHcy.  Met 155 (left) and Met 48 
(right) are shown in yellow as sticks with their electron densities depicted in dots.  
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In addition to Met155, we hypothesized that another active site methionine 
residue (Met48 in rat PRMT1) positioned near the reactive substrate arginine (Fig. 6-1) 
plays a role in selective ADMA formation.  This methionine residue is conserved among 
all Type I enzymes but is replaced by a proline in the Type II PRMT5.  The presence of a 
proline instead of a methionine at this position could open up the active site pocket 
enough to allow for the free rotation about the substrate arginine terminal C-N bond.  In 
addition to controlling exclusive ADMA formation, Met 155 and Met 48 may serve 
another role.  Mechanistically speaking, the pair of methionines (Met155 and Met48 
depicted in Fig. 6-1) could act as a molecular tweezer aligning the guanidino nitrogen for 
the most efficient SN2 methyl transfer among Type I PRMTs.  
The crystal structures of ratPRMT3 [19] and ratPRMT1 bound to AdoHcy and 
substrate peptide [18] have offered much insight into the PRMT reaction.  A mechanism 
has been proposed where the carboxylate of an active site glutamate (Glu153 in rat 
PRMT1) localizes the positive charge on one of the guanidino nitrogens, allowing the 
lone pair of electrons of the other guanidino nitrogen to become a better nucleophile.  The 
residue required to deprotonate the guanidino nitrogen of the substrate arginine or the 
mono-methylated product has not been identified.  Thompson and coworkers recently 
elucidated the kinetic mechanism of PRMT1 [20].  They report a different mechanism 
wherein PRMT1 utilizes a rapid equilibrium random sequential mechanism to methylate 
the histone H4 peptide.  In this type of reaction mechanism, the order of substrate binding 
to the enzyme and product release from the enzyme does not matter.  Although the 
mechanism for Type I PRMTs has become clearer, the mechanistic roles of certain 
PRMT1 active site residues have not been identified.   
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The goal of this work was to identify residues in the PRMT1 active site that 
are important for substrate binding and catalysis and may affect ADMA formation.  We 
hypothesized that two active site methionine residues (Met155 and Met48) positioned 
near the reactive substrate arginine (Fig. 6-1) enable PRMT1 to selectively form ADMA 
instead of SDMA.  M155A and M48A mutant proteins were characterized according to 
their ability to catalyze methylation of a multiple arginine-containing peptide based on 
the in vivo substrate fibrillarin.  Removing the steric bulk afforded by each of these 
residues did not allow for the formation of SDMA.  The mutation of Met48 to an alanine 
in the PRMT1 active site rendered the enzyme virtually inactive.  When this residue was 
mutated to a leucine, activity was partially restored indicating that the length of Met48 is 
critical to PRMT1 catalysis.  Our results indicate that removing the steric bulk afforded 
by either Met155 or Met48 in the active site of PRMT1 is not by itself sufficient to 
transform PRMT1 into a Type II PRMT.  Additional PRMT1 mutants (M146A, S154A, 
W145A, and Y148S-PRMT1) displayed altered methyltransferase activity generating 
only MMA and ADMA.  Interestingly, M48L-PRMT1 was capable of automethylation 
while wild type PRMT1 was not.  
 
MATERIALS AND METHODS 
 
AdoMet was purchased from Sigma as a chloride salt (≥80%, from yeast).  The 
R3 peptide, acylGGRGGFGGRGGFGGRGGFG; the JMH1W peptide, 
acylKGGFGGRGGFGGKW; and the JMH1W-CH3 peptide, 
acylKGGFGGRmethylGGFGGKW were synthesized by the Keck Institute and purified to 
≥95%. 
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Expression and purification of mutant 
PRMT1 proteins 
 
PRMT1 mutant proteins were generated using the QuikChange® Site-Directed 
Mutagenesis kit (Stratagene) with sets of complementary oligonucleotide primers 
spanning the desired site of mutation.  For each PCR reaction, the pET28b vector 
(Novagen) containing the gene that codes for N-terminal histidine tagged wild type 
PRMT1 plasmid (pET28b-PRMT1) (see Chapter 3) was used as template.  Desired 
mutations (M155A, M48A, M48L, S154A, M146A, Y148S, W145A, and M48P) were 
confirmed through DNA sequencing.  Mutant proteins were expressed and purified using 
the same methods used to express and purify wild type His-PRMT1 (described in Chapter 
3).  Each mutant protein was expressed at the same level as wild type PRMT1 in cell 
culture except for the M48A mutant which exhibited slightly lower expression levels 
when compared to wild type.  Purified proteins were ≥95% pure by SDS-PAGE.  Mutant 
protein sequences were verified using mass spectrometry.  The binding of AdoMet is 
consistent with a properly folded structure for all mutants. 
 
Kinetic assays of PRMT1 mutants 
 
A continuous spectrophotometric assay for AdoMet-dependent methyltransferases 
(described in Chapter 3) was used to assay PRMT1 mutants with arginine-containing 
peptides.  Two coupling enzymes, AdoHcy nucleosidase (MTAN) and adenine 
deaminase, were used to hydrolyze and deaminate the AdoHcy generated from 
methyltransfer, respectively.  This assay avoids any product inhibition that could occur 
from AdoHcy.  Each 110 µL reaction contained 4 µM His-PRMT1 (WT or mutant), 0.02 
µM adenine deaminase (purified as described in Chapter 3), 250 µM AdoMet, 10 nM 
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MTAN (purified as in [21]), 100 µM MnSO4, and 50 mM sodium phosphate buffer 
pH 7.1.  Reactions equilibrated at 37 ºC for ten minutes before they were initiated with 
various amounts of peptide.  The decrease in absorbance at 265 nm was monitored 
continuously using a Cary300 Bio UV-visible spectrophotometer.  Initial rate data 
representing no more than 10% of product formation were fit to the Michaelis Menten 
equation [22] to obtain Km,app and kcat, app values.  Each reaction was performed at least in 
duplicate.  The limit of detection for this assay was 0.1 μM CH3/min (which corresponds 
to a kcat of 0.025 min-1).  
 
HPLC analysis of methylated amino acids 
 
Assays containing 4 μM WT- or mutant-PRMT1 proteins, 1200 μM AdoMet, 10 
nM MTAN, and 50 mM sodium phosphate buffer (pH 7.1) equilibrated at 37 ºC for 8 
minutes.  Reactions were initiated with 200 μM R3 and were terminated after 3 hours 
with 10% TCA final.  TCA-precipitated protein was removed through centrifugation, and 
the supernatant (containing the peptide) was added to a glass vial.  An equivalent volume 
of 12.1 M HCl was added to each vial.  Vials were crimp-sealed and heated to 110 ºC for 
approximately 24 hours to carry out acid hydroloysis.  Hydrolyzed amino acids from the 
mutant catalyzed peptide product were analyzed by fluorescent derivatization 
(AccQ●Fluor reagent kit, Waters) using a well-established RP-HPLC protocol [23].  This 
method uses a gradient of acetonitrile and a C18-Luna column (Phenomenex) to separate 
MMA, ADMA, and SDMA based on their hydrophobicity.  To verify the presence and 
peak times of the methylated arginine products, subsequent runs of samples incubated 
with 0.6 μM [H3]-AdoMet (specific activity of 83 μCi/μmol) for 3 hours and analyzed via 
 157
HPLC [24].   Fractions (0.5 mL) were collected and radioactivity was counted in 4 
mL scintillation cocktail (Fisher Scientific).  MMA, ADMA, or SDMA standard amino 
acids were also used to verify the identity of the methylated products generated.  Peak 
times were 37.5, 43.65, and 48 min for MMA, ADMA, and SDMA respectively.  Shifting 
of the product peaks was observed from one run to another, so standards were run before 
and after each sample to accurately identify the presence of each arginine species.   
 
Intrinsic fluorescence 
 
An RF-5301PC spectrofluorophotometer (Shimadzu) was used for fluorescence 
measurements.  For R3 peptide and AdoMet affinity determinations, an excitation 
wavelength of 290 nm was used and emission spectra from 300-420 nm were collected.  
The change in fluorescence intensity at the maximum emission (333 nm) was monitored.  
The excitation and emission slit was 5 nm and the scan speed was 100 nm/min using 
1325 µL containing 0.7 µM PRMT1 in 150 mM sodium phosphate buffer pH 7.1.  
Increasing concentrations from 1 to 50 µM peptide ligand (or 1 to 50 µM AdoMet in a 
separate experiment) were added at 2-3 min intervals.  Data from at least two titrations 
were averaged and analyzed using the Stern-Volmer [24] or modified Stern Volmer [25] 
plots.  Data were evaluated by least squares linear regression analysis using Kaleidagraph 
in order to obtain the dissociation constant (Kd).  For the modified Stern Volmer plots, 
the following equation was used:  Fc= F (10 εcd/2) where Fc is the corrected fluorescence, ε 
is the extinction coefficient of AdoMet, c is the concentration of AdoMet, and d is the 
pathlength.  Finitial/(Finitial-Fc) was then plotted against 1/[AdoMet] and the data was fit to a 
line where the yintercept=1/fa, the slope=1/fa*KQ, and the KQ=1/KD. 
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RESULTS 
Active site methionines do not govern 
strict ADMA formation 
 
It was proposed [18] that Met155 helps determine the formation of ADMA 
because of the increased steric bulk of the residue.  If the length of Met155 is solely 
responsible for the strict formation of ADMA in the PRMT1 active site, then the 
mutation of this residue to a smaller amino acid might allow for the formation of SDMA.  
To investigate this hypothesis, we mutated Met155 to an alanine residue.  M155A-
PRMT1 was expressed, purified, and demonstrated saturation kinetics with a peptide 
derived from the in vivo substrate fibrillarin (R3=acylGGRGGFGGRGGFGGRGGFG) 
(see Fig. 6-2).  Compared to WT-PRMT1, this mutation did not affect kcat, but Km 
increased by a factor of ten (Table 6-1).  As a result of this, the catalytic efficiency 
(kcat/Km) of M155A-PRMT1 was only 10.3% the activity of WT-PRMT1 (Table 6-1) 
indicating that Met155 is important to catalysis. 
 
 
Table 6-1  Kinetic constants for mutant and WT-PRMT1 with R3 peptide 
PRMT1 Km (µM) Vmax (µM CH3/min) kcat/Km (M-1s-1) 
WT <10 10.7 ± 0.803 4460 ± 333 
M155A 118 ± 29.6 12.9 ± 1.12 457 ± 121 
M48A 303 ± 214 0.959 ± 0.470 13.2 ± 13.1 
M48L 17.6 ± 2.65 7.06 ± 0.209 1670 ± 255 
M48P 439 ± 205 6.69 ± 1.49 63.4 ± 30.2 
 
Activity was assessed using various concentrations of R3 peptide (25-1000 µM), 250 µM 
AdoMet, 4 µM His-PRMT1 (WT or mutant), 10 nM MTAN, 10 µM MnSO4, and 50 mM 
NaPO4 buffer pH 7.1 at 37 °C.  Reactions were performed at least in duplicate, and initial 
reaction rates were used to assess activity.  
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     Fig. 6-2.  M155A-PRMT1 methylates R3.  Various concentrations of R3 peptide [25-
1000 µM] were used to initiate reactions containing 4 µM M155A-PRMT1, 250 µM 
AdoMet, 10 nM MTA nucleosidase, 10 µM MnSO4, and 50 mM NaPO4 buffer pH 7.1 at 
37 °C.  Initial rates were used to plot the Michaelis-Menten curve.   
 
  
Next, we analyzed the products generated from an extended reaction between 
M155A-PRMT1 and R3 to determine if mutating M155 to a smaller alanine residue 
converted PRMT1 into a Type II PRMT.  Using a reverse phase-HPLC method that 
provides baseline separation between MMA, ADMA, and SDMA [23], we show that 
similar to wild type (Fig. 6-3, A), M155A-PRMT1 catalyzed the formation of only MMA 
and ADMA (Fig. 6-3, B).  Interestingly, an additional peak whose identity is unknown 
was found to incorporate radioactively labeled AdoMet and eluted at approximately 39 
minutes (between MMA and ADMA) in the M155A-PRMT1 sample.  All in all, 
removing the steric bulk afforded by Met155 in the PRMT1 active site was not enough to 
transform the Type I PRMT into a Type II PRMT that is capable of catalyzing the 
formation of SDMA.    
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     Fig. 6-3.  M155A-PRMT1 catalyzes the formation of MMA and ADMA.  Acid 
hydrolyzed amino acids from reactions that had been initiated with 200 µM R3 and 
catalyzed by wild type in (A), or M155A-PRMT1 in (B), were derivatized using the 
AccQFluor reagent.  HPLC [23] was used to separate the methylated products based on 
their hydrophobic properties (solid lines).  3H-AdoMet was used as a tracer to verify the 
presence of the methylated species in each reaction (dashed lines).  MMA, ADMA, and 
SDMA standard amino acids were used to identify the methylated species in each sample.  
MMA and ADMA are labeled appropriately according to the retention times of the 
standards.  SDMA, which had a later retention time, was not generated. 
 
 
 
A 
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Because Met155 was not responsible for the strict formation of ADMA versus 
SDMA, we next examined the role of another active site methionine residue (Met48) due 
to its proximity to the substrate arginine of the R3 peptide in the PRMT1 crystal structure 
(Fig. 6-1) [18].  To determine if the bulk of this methionine is responsible for aiding in 
the strict formation of ADMA in the PRMT1 active site, we mutated Met48 to a smaller 
amino acid (alanine).  Unlike the M155A-PRMT1 mutant, M48A-PRMT1 demonstrated 
extremely low activity with the R3 peptide (Table 6-1 and Fig. 6-4, A).  When an 
extended reaction with M48A-PRMT1 and R3 was analyzed by HPLC, methylated 
arginine species may have been formed but levels were only slightly above background 
when using radioactivity (Fig. 6-4, A).  M48A-PRMT1 was not capable of methylating 
two additional single arginine-containing fibrillarin-based peptides that wild type PRMT1 
is capable of methylating (acylKGGFGGRGGFGGKW and its monomethylated 
counterpart acylKGGFGGRmethylGGFGGKW) (data not shown).  Thus, mutating Met48 to 
an alanine obliterated PRMT1-activity altogether and eliminated the catalysis of both 
arginine and monomethylarginine-containing substrates. 
Based on these findings, we proposed that the length of Met48 is critical to 
catalysis.  Perhaps mutating Met48 was too drastic of a change in length.  Therefore, we 
mutated Met48 to a leucine, a residue that was in between alanine and methionine in 
length.  Interestingly, M48L-PRMT1 displayed saturation kinetics with R3 (data not 
shown).  The catalytic efficiency of M48L-PRMT1 (1670 ± 255 M-1s-1) was 
approximately 40% of wild type (Table 6-1) indicating that the length of this active site 
residue is critical for catalysis.  Further HPLC analysis of the products generated from an 
extended reaction with M48L-PRMT1 and R3 indicated that higher levels of MMA and 
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ADMA had been generated (Fig. 6-4, B) compared to the reaction with M48A-
PRMT1.  The shape of the ADMA peak was not as defined as in other samples due to 
sample overloading.   
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     Fig. 6-4.  M48A/L-PRMT1 mutants catalyze the formation of MMA and ADMA.  
Acid hydrolyzed amino acids from reactions that had been initiated with 200 µM R3 and 
catalyzed by M48A in (A) or M48L-PRMT1 in (B) were derivatized using the 
AccQFluor reagent.  HPLC [23] was used to separate the methylated products based on 
their hydrophobic properties (solid lines).  3H-AdoMet was used as a tracer to verify the 
presence of the methylated species in each reaction (dashed lines).  Standard amino acids 
were used to identify methylarginine products in the sample.  MMA and ADMA are 
labeled appropriately according to the retention times of the standards.  SDMA, which 
had a retention time of approximately 51 minutes, was not generated in (A). 
A 
B 
 163
Like M48A-PRMT1, M48L-PRMT1 was not capable of methylating two 
additional single arginine-containing fibrillarin-based peptides 
(acylKGGFGGRGGFGGKW and its monomethylated counterpart 
acylKGGFGGRmethylGGFGGKW) (data not shown).  It is unclear why the Met 48 mutant 
proteins were unable to methylate these peptides.  Based on these results, however, 
M48L-PRMT1 may not be able to methylate arginine residues located in the center of 
peptides.   
 
Peptide substrate and cofactor binding 
 
To further investigate the role of Met48, we measured the dissociation constants 
of WT, M48A, and M48L-PRMT1 for each substrate (R3 peptide and AdoMet).  The 
PRMT1 crystal structure depicts two tryptophans at positions 145 and 294 which lie in 
the catalytic region near the substrate arginine residue opposite the AdoMet binding 
region [18].  The intrinsic fluorescent-properites of PRMT1 were exploited in 
fluorescence-quenching assays to determine the dissociation constants for the R3 peptide 
with WT and mutant PRMT1.  Stern-Volmer plots [24] were used to analyze the 
quenching data.  A representative Stern-Volmer plot for WT-PRMT1 with R3 is shown in 
Fig. 6-5, A.  These plots revealed that WT and M48A/L-PRMT1 had nearly the same 
affinity for the R3 peptide as judged by the similar Kd values (Table 6-2).  Lehrer’s 
modified Stern-Volmer plot [25] was used to interpret the fluorescence-quenching data 
from the titrations of WT and M48A/L-PRMT1 with AdoMet.  A representative modified 
Stern-Volmer plot for WT-PRMT1 with AdoMet is shown in Fig. 6-5, B.  The results in 
Table 6-2 indicate that the diminished activity of M48A-PRMT1 or M48L-PRMT1 is not 
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due to differences in AdoMet binding.  The affinity of WT-PRMT1 and both mutants 
for AdoMet was nearly the same.  Importantly, results obtained from isothermal titration 
calorimetry (ITC) were consistent with the dissociation constant values obtained using 
intrinsic fluorescence.  When WT-PRMT1 was titrated with AdoMet, a value of 4.2 ± 1.5 
µM was obtained using intrinsic fluorescence (Table 6-2) versus 2.5 µM from ITC (data 
not shown). 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Fig. 6-5.  Stern Volmer and modified Stern Volmer plots.  In (A), a Stern Volmer plot 
is shown for the titration of WT-PRMT1 with R3.   The slope of the line is equivalent to 
the dissociation constant.  In (B), a modified Stern Volmer plot is shown for the titration 
of WT-PRMT1 with AdoMet.  The data was fit to a line where the yintercept=1/fa, the 
slope=1/fa*KQ, and the KQ=1/KD. 
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Table 6-2  Dissociation constants for mutant and WT-PRMT1 for AdoMet and R3 
PRMT1  Kd, peptide  (nM) Fluorescent 
quenching (%) 
Kd, AdoMet 
(µM) 
Fluorescent 
quenching (%) 
WT 36 ± 11 36 ± 19 4.2 ± 1.5 17 ± 0.13 
M48A 47 ± 8.2 47 ± 2.0 7.1 ± 1.8 15 ± 0.17 
M48L 49 ± 18 39 ± 7.8 7.1 ± 0.94 29 ± 4.2 
 
Dissociation constants were obtained using intrinsic fluorescence quenching assays 
(performed at least in duplicate) as described in the methods section. 
 
 
 
Active site residues affect PRMT1 
substrate processing 
 
Because the active site methionine mutations did not govern the strict formation 
of ADMA versus SDMA, the roles of several additional active site residues that were 
conserved among Type I PRMTs but not among Type II PRMTs were evaluated.  The 
following mutations to the PRMT1 sequence were verified by DNA sequencing:  Y148S, 
S154A, W145A, and M146A-PRMT1.  Proteins were overexpressed and purified to 
homogeneity before being assayed with the R3 peptide.  All mutants demonstrated 
saturation kinetics with R3 (data not shown).  However, each mutant PRMT1 protein 
resulted in a substantial decrease in catalytic activity (kcat/Km, app) when compared to wild 
type PRMT1 except for S154A-PRMT1 (Table 6-3).   
Next, we analyzed the peptide product generated from extended reactions with the 
four mutant PRMT1 proteins and R3.  Mutant proteins did not generate a detectable 
amount of SDMA but were able to catalyze monomethylation and asymmetric 
dimethylation of the R3 peptide (data not shown).  These results are summarized in Table 
6-3.  Thus, the strict formation of ADMA versus SDMA in the PRMT1 active site is not 
governed by Tyr148, Ser154, Trp145, or Met146.  
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Table 6-3  PRMT1-mutant activity and product formation 
PRMT1  Catalytic efficiency 
(M-1s-1) 
MMA ADMA SDMA 
WT  4458 ± 333  [22] yes yes no 
M155A 457 ± 121 yes yes no 
M48A 13.19 ± 13.05 yes yes no 
M48L 1668 ± 255 yes yes no 
Y148S 151 ± 39.5 yes yes no 
S154A 4406 ± 1366 yes yes no 
W145A 139 ± 20.8 yes yes no 
M146A 463 ± 162 yes yes no 
M48P 63.4 ± 30.2 yes yes no 
 
Activity was assessed using various concentrations of R3 peptide (25-1000 µM), 250 µM 
AdoMet, 4 µM His-PRMT1 (WT or mutant), 10 nM MTAN, 10 µM MnSO4, and 50 mM 
NaPO4 buffer pH 7.1 at 37 °C.  Reactions were performed at least in duplicate, and initial 
reaction rates were used to assess protein activity.  HPLC analysis [23] and a radioactive 
tracer (3H-AdoMet) were used to confirm the presence or absence of MMA, ADMA, and 
SDMA formation for each PRMT1 protein reaction with the R3 peptide.     
 
 
 
DISCUSSION   
PRMT1 mutants catalyze the formation of MMA 
and ADMA at varying efficiencies 
 
The purpose of this study was to identify a residue that was responsible for 
controlling the strict formation of ADMA (versus SDMA) in the active site of the Type I 
PRMT, PRMT1.  First, Met 155 was probed because this residue had previously been 
hypothesized [18] to determine ADMA formation based on its steric bulk.  Due to the 
proximity of this residue to the substrate arginine (Fig. 6-1) and the fact that it was 
conserved among Type I PRMTs but not Type II PRMTs, this residue was mutated to a 
smaller amino acid residue to see if SDMA could be generated.  M155A-PRMT1 did not 
form SDMA (Fig. 6-2) and displayed a decrease in catalytic activity when compared to 
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WT-PRMT1 (Table 6-1).  Thus, reducing the size of this methionine to an alanine at 
this active site location did not allow for the free rotation about the terminal C-N bond of 
the arginine residues in R3 and the formation of SDMA.  Met 48, the methionine on the 
other side of the substrate arginine (Fig. 6-1), was shown by HPLC analysis not to alter 
Type I versus Type II product formation either (Fig. 6-4).  In fact, all mutations made to 
the PRMT1 active site (M155A, M48A, M48L, M146A, W145A, S154A, and Y148S) 
did not result in a detectable amount of SDMA but did result in the formation of both 
MMA and ADMA (Table 6-3).  When Met 48 was mutated to a proline, the 
corresponding residue found in the Type II PRMT5 active site, activity dropped 
dramatically (kcat/Km= 63.4 ± 30.2 M-1s-1) (Tables 6-1 and 6-3).  No detectable amount of 
SDMA was detected by HPLC after an extended reaction (data not shown).  Ultimately, 
these results indicate that transforming a Type I PRMT into a Type II PRMT is more 
complex than previously thought and may extend beyond the composition of the active 
site.  Alternatively, the mutation of other residues or a combination of active site residues 
(such as an M48L/M155A-PRMT1 double mutant) could govern ADMA versus SDMA 
formation. 
PRMT1 mutants utilized R3 as a peptide substrate but did so at varying 
efficiencies.  All PRMT1 mutations resulted in a substantial decrease in catalytic activity 
(kcat/Km, app) when compared to wild type PRMT1 except for S154A-PRMT1 (Table 6-3).  
Interstingly, M48A-PRMT1 had very little to no activity with the R3 peptide, the most 
kinetically competent fibrillarin-based peptide substrate suggesting that this methionine is 
critical to catalysis (Table 6-1).  Further kinetic analysis of Met 48 with the M48L-
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PRMT1 mutant and R3 (Table 6-1) proved that the length of this amino acid residue 
is important to catalysis. 
Surprisingly, the M48L-PRMT1 mutant methylated the R3 peptide with nearly 
half the activity of WT-PRMT1 but would not methylate two single arginine-containing 
peptides, acylKGGFGGRGGFGGKW and its monomethylated counterpart 
acylKGGFGGRmethylGGFGGKW (data not shown).  This inactivity may be due to the 
central position of the arginine in the substrate.  Perhaps M48L-PRMT1 methylated the 
R3 peptide on the two terminal arginines in bold (acylGGRGGFGGRGGFGGRGGFG) 
but was unable to access the central arginine residue.  MS/MS analysis of the R3 peptide 
product from this reaction will reveal if this hypothesis is true. 
Although it is unclear how Met 48 affects PRMT1 catalysis, this residue may help 
position AdoMet or the substrate arginine so that a more direct SN2 attack of the methyl 
group of AdoMet can be made (Fig. 6-6).  The active site appears to ‘open up’ more 
when Met 48 is replaced with a leucine (Fig. 6.6).  Because the M48L-PRMT1 mutant 
was unable to methylate two central single arginine-containing peptides but was able to 
methylate R3, Met 48 may play a significant role in substrate specificity.  Interestingly, 
M48L-PRMT1 was also capable of automethylation (described further below).  Further 
examination of this residue may provide crucial mechanistic details because of its close 
proximity to the substrate arginine.   
 
Automethylation of PRMT1 
 
M48L-PRMT1 was capable of automethylating itself when incubated with 
tritiated AdoMet (data not shown).  This phenomenon was not observed for the wild type  
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     Fig. 6-6.  Methionine 48 positions PRMT1 substrates for catalysis.  AdoMet (purple) 
was modeled into the PRMT1 active site (PDB ID, 1OR8).  The AdoMet methyl group 
(carbon shown in red) is positioned for a direct SN2 attack from the R3 peptide substrate 
arginine (yellow).  The wild type active site (M48 in gray) is depicted in the top panel 
while the M48L mutant is depicted below (gray).  
 
  
 
enzyme under the identical reaction conditions (data not shown).  PRMT6 and PRMT8 
have been shown to automethylate themselves [5, 26].  PRMT6 was found to be mono- 
and dimethylated at certain arginine residues [5].  PRMT8 automethylates two arginine 
residues (monomethylarginine 58 and dimethylarginine 73) on its N-terminal tail, an 
ability that is thought to regulate and possibly inhibit the methylation of other substrates 
[26].  Although PRMT1 and PRMT8 are highly identical in sequence, the methylated 
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arginine residues in PRMT8 do not align with arginines in PRMT1.  In the same 
study, Clarke and coworkers detected that WT-PRMT1 had also underwent 
automethylation to a lesser degree [26].  Under our reaction conditions, however, we 
could not detect WT-PRMT1 automethylation.  It will be interesting to see where M48L-
PRMT1 has been methylated.   
 
Conclusion 
 
Our results indicate that transforming a Type I PRMT into a Type II PRMT is 
more complex than previously thought and may extend beyond the composition of the 
active site.  Importantly, our study identified PRMT1 active site residues that are critical 
to catalysis.  The mutation of Met 48 to an alanine in the PRMT1 active site rendered the 
enzyme virtually inactive.  In particular, the length of Met 48 is critical to PRMT1 
catalysis.    Further examination of this residue may provide crucial mechanistic details.  
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CHAPTER 7 
 
  ONGOING PROJECTS 
 
 
INTRODUCTION 
This chapter includes experimental results from several projects that have yet to 
be completed.  In the first section, we found that the amino acid sequence of certain 
peptide substrates directly affects the extent that a particular substrate is mono- and 
dimethylated.  We also found that two ‘RGA’-containing fibrillarin-based peptides 
demonstrated substrate inhibition at high substrate concentrations when incubated with 
PRMT1.  This indicates that substrate sequence can regulate PRMT1 activity at a higher 
level by altering the amount of dimethylation that can occur physiologically.  Together, 
these data show that the sequence around the substrate arginyl group affects how the 
substrate arginine is being modified and indicate that although many protein sequences 
may be PRMT1 substrates, the identity of the sequence and its abundance in the cell may 
dictate how the substrate arginine residue is mono- or dimethylated in vivo.   
Next, I examined the importance of interactions between the substrate and the 
conserved THW loop among PRMTs by mutating two residues (H293 and W294 to an 
alanine on PRMT1) and assessing the activity of each with several substrates.  I found 
that both residues were essential for PRMT1 catalysis.  In another section, I investigated 
how the AdoMet/AdoHcy ratio present in healthy and diseased individuals affected 
PRMT1 activity.  The AdoMet/AdoHcy ratio is higher in healthier individuals (~4-6) [1] 
and lower in patients with Type II diabetes [2], Alzheimer’s disease [3], and cystic 
fibrosis [4] (~1.4-3.5).  Interestingly, the lower the AdoMet/AdoHcy ratio, the more 
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severe the disease [2].  As expected, I found that as the concentration of AdoHcy 
increased (meaning the AdoMet/AdoHcy ratio decreased), PRMT1 activity decreased.  
Because PRMT1 performs over 85% of all protein arginine methylation in the cell, a 
decrease in PRMT1 activity due to an alteration in the AdoMet/AdoHcy ratio could cause 
a decrease in total protein arginine methylation.  This inhibition could have numerous 
biological ramifications that have yet to be fully explored.  Finally in a related 
experiment, I determined the Ki for a fibrillarin-based peptide containing ADMA.  
 
RESULTS AND DISCUSSION 
 
Effect of amino acid sequence context 
on activity and end-products   
 
In Chapter 4, we identified that PRMT1 was capable of methylating a variety of 
peptide sequences that extended beyond the ‘RGG’ paradigm using a small fibrillarin-
based peptide library.  We also observed that methylation was contextual with the ‘RSG’ 
sequence.  The ‘RSG’ sequence presented within the fibrillarin context was not a PRMT1 
substrate while the same sequence presented within the eIF4A1 context was a PRMT1 
substrate.  This suggested that amino acids in one position affect whether or not amino 
acids in a second position are favored.  To explore the effects of substrate sequence on 
PRMT1 activity further, we examined the end products generated with time from 
reactions that had been initiated with the WT-eIF4A1, eIF4A1-S, or eIF4A1-Y peptide.  
Because the eIF4A1 peptides contain three arginine residues, we employed tandem mass 
spectrometry first to prove that R7 (bolded in AcYIHRIGRGGR, AcYIHRIGRYGR, and 
AcYIHRIGRSGR, respectively) was the only modified arginine after incubating with 
PRMT1 and AdoMet (Fig. 4-6).   
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The MS analysis of the eIF4A1 peptides revealed that the proportion of the 
mono- and dimethylated arginine products observed was different in the eIF4A1 peptides 
(Fig. 7-1).  The ‘RGG’ containing WT-eIF4A1 peptide was almost fully dimethylated 
(97.3%) while the eIF4A1-peptide containing the ‘RSG’ motif was mostly not modified 
after 105 minutes.  Only 7.1% of the eIF4A1-S had been monomethylated after 105 
minutes (Fig. 7-1).  The eIF4A1-peptide containing the ‘RYG’ motif only underwent 
monomethylation (3.7%) after 105 minutes.  After an extended reaction with PRMT1, the 
‘RGG’ containing WT-eIF4A1 peptide was mostly dimethylated while the ‘RSG’ and 
‘RYG’ containing eIF4A1 peptides were mainly monomethylated.  PRMT1 and AdoMet 
were shown to be viable during the extended reaction time period (Fig. 7-2) indicating 
that the reaction conditions were such that the reaction should have gone to completion 
(i.e., peptides should have been fully dimethylated instead of partially monomethylated).  
Perhaps the reactions with eIF4A1-Y and eIF4A1-S peptides did not go to completion 
due to substrate inhibition (described more fully in the next section).  These data suggest 
that sequence differences around the substrate arginyl group in peptide substrates may 
affect whether mono- or dimethylation is the major end-product and demonstrate that the 
amino acid sequence of a PRMT1 substrate may dictate how an arginine is modified.  
Thus, many sequences may be PRMT1 substrates, but the identity of the sequence may 
dictate how the substrate arginine residue is mono- or dimethylated in vivo. 
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C  
 
 
 
 
 
 
     Fig. 7-1.  Effect of sequence on methylated product distribution.  Reactions were 
prepared as described in Fig. 4-2 and were initiated with WT-eIF4A1 in (A), eIF4A1-S in 
(B), and eIF4A1-Y in (C).  Mass spectrometry was used to identify the parent (gray 
lines), monomethylated (solid lines), and dimethylated (dashed lines) peptide products.   
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     Fig. 7-2.  PRMT1 and AdoMet are viable during extended reactions.  Continuous 
spectrophotometric assays with 4 μM PRMT1, 250 μM AdoMet, and coupling enzymes 
in 50 mM sodium phosphate buffer (pH 7.1) that had equilibrated to 37 °C were initiated 
with 300 μM eIF4A1-Y peptide.  At 105 minutes (A) and 405 minutes (B), reactions 
were spiked with 200 μM R3 peptide.  When comparing this methylation rate to the rate 
from a reaction initiated with 200 μM R3 at t=0 (with no eIF4A1 peptide), PRMT1 was 
92% active at 105 minutes and 89% active at 405 minutes.  
 
 
 
Substrate inhibition  
In another experiment, both the RGA-peptide (KGGFGGRGAFGGKW) and 
RGA-CH3 peptide (KGGFGGRmethylGAFGGKW) were tested to identify if the sequence 
context near the substrate arginine dictated how the substrate was methylated.  The RGA-
peptide (Fig. 7-3) and the RGA-CH3 peptide (data not shown) displayed substrate 
inhibition at high substrate concentrations, a phenomenon which may prove to be 
important biologically.  Protein substrates that are methylated in the context of something 
other than a glycine/arginine rich motif may undergo such inhibition in the cell.  For 
instance, an ‘RGG’-containing protein may get fully dimethylated whereas the same 
concentration of an ‘RGA’-containing protein may only get monomethylated due to 
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substrate inhibition.  If dimethylation is required to elicit the biological response, then 
the biological response will not happen.   
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     Fig. 7-3.  Peptides caused substrate inhibition at high substrate concentrations.  
Reactions containing 4 μM PRMT1, 0.2 μM adenine deaminase, 10 nM AdoHcy 
nucleosidase, 1050 μM MnSO4, and 250 μM SAM in 100 mM sodium phosphate buffer 
pH 7.1 were initiated with various concentrations of RGA-peptide 
(KGGFGGRGAFGGKW).  Higher peptide concentrations demonstrated substrate 
inhibition, an observation that may be found to be important biologically. 
 
 
 
THW loop mutations alter PRMT1 activity 
In Chapter 4, new substrate motifs were identified that went beyond the ‘RGG’ 
paradigm.  Two of these motifs (‘RYG’ and ‘RFG’) surprisingly had large, ring-
containing amino acids directly C-terminal to the substrate arginine residue.  How could 
such large amino acid residues adjacent to the substrate arginine facilitate methylation 
when several smaller amino acids such as alanine were not tolerated in the X1 position?  
Perhaps PRMT1 could tolerate phenylalanine and tyrosine in this position because they 
were ring containing and could make pi-pi stacking interactions with PRMT1.  When 
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looking at the PRMT1 crystal structure [5] and sequence alignments among the 
PRMT family, a conserved THW loop positioned near the substrate X1 position could 
potentially make pi-pi stacking interactions the substrate.  In order to test this hypothesis 
and further understand the role of the active site THW loop residues H293 and W294, 
these residues were mutated to an alanine.   
H293A and W294A-PRMT1 proteins were purified and assessed for activity with 
the R3 peptide (GGRGGFGGRGGFGGRGGFG).  H293A-PRMT1 utilized R3 (kcat= 
0.27 ± 0.11 min-1) while W294A-PRMT1 did not (data not shown).  W294A-PRMT1 was 
not active with either an ‘RYG’ or an ‘RFG’-containing fibrillarin-based peptide (data 
not shown).  Further HPLC analysis of this protein revealed that AdoMet was still able to 
bind suggesting that the AdoMet binding pocket had not been disrupted by the mutation 
and that the protein was able to fold properly (data not shown).   
The activity of H293A-PRMT1 was analyzed next with ‘RYG’ and ‘RFG’-
containing peptides.  Preliminary data suggests that H293A-PRMT1 was not capable of 
methylating the peptide housing the ‘RFG’ sequence very well as demonstrated by a low 
Vmax (Fig. 7-4, A).  These data suggest that the pi-pi interactions between enzyme and 
substrate at this location have been disturbed; however, further investigation is needed.  
Interestingly, H293A-PRMT1 was able to methylate the tyrosine-containing peptide 
(kcat/Km= 10.2 ± 8.01 M-1s-1) (Fig. 7-4, B).  H293A-PRMT1 was also able to methylate 
the ‘RYG’-containing eIF4A1-Y peptide (YIHRIGRYGR) at a catalytic efficiency of 27 
± 13 M-1s-1 (data not shown).  Although the kcat/Km values were extremely low, the rate 
of methylation increased as the concentration of peptide increased suggesting that pi-pi 
stacking interactions are not by themselves responsible for PRMT1 activity with ‘RYG’-
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containing peptides.  Perhaps the ability of tyrosine to hydrogen bond to the enzyme 
via its hydroxyl group facilitates methylation.  
Our main objective to determine if pi-pi interactions are important in substrate 
selection and catalysis remains somewhat elusive because I was unable to perform 
additional follow-up studies.  Despite this, I was able to show that each peptide tested 
with either the H293A or W294A-PRMT1 mutant proteins was not methylated very 
efficiently.  These preliminary results suggest that histidine and tryptophan from the 
conserved THW loop are necessary for PRMT catalysis.   
 
 
 
      
 
 
 
 
 
     Fig. 7-4.  Mutations in the THW loop alter PRMT1 activity.  Reactions containing 4 
μM H293A-PRMT1, 0.2 μM adenine deaminase, 10 nM AdoHcy nucleosidase, 1050 μM 
MnSO4, and 250 μM SAM in 100 mM sodium phosphate buffer pH 7.1 were initiated 
with various concentrations of ‘RFG’-peptide (KGGFGGRFGFGGKW) in (A) or 
‘RYG’-peptide (KGGFGGRYGFGGKW) in (B).  Although the reactions were 
performed in duplicate, the data remained scattered in (A). 
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AdoMet/AdoHcy ratio affects PRMT1 
activity in vitro 
 
A measurement of the AdoMet/AdoHcy ratio reflects the wellness of an 
individual [1-4].  We were interested in determining if the biologically significant ratios 
that we chose to classify as healthy (4.0), diseased (2.0), and extremely sick/near death 
(1.0) had any effect on PRMT1 activity.  We found that as the amount of AdoHcy present 
in the methylation reaction increased, PRMT1 activity decreased accordingly when 
initiating the reaction with an unmodified fibrillarin-based peptide substrate (Fig. 7-5, A) 
or a monomethylated fibrillarin-based peptide substrate (Fig. 7-5, B).  In both (A) and 
(B), addition of any AdoHcy to the reaction reduced methyltransferase activity as 
expected.  Despite the large standard deviations observed in the reactions containing 
peptide only, PRMT1 was clearly able to methylate peptides in these reactions more 
easily than in the reactions containing AdoHcy.  Although it is more apparent with the 
monomethylated substrate (Fig. 7-5, B), increasing the amount of AdoHcy diminished 
PRMT1 activity in a dose dependent manner.  Interestingly, both peptides were 
methylated by PRMT1 in AdoMet/AdoHcy conditions approaching death.  Based on 
these preliminary results, the activity of PRMT1 is reduced by biologically relevant 
AdoHcy concentrations such as those found in healthy individuals.  This implies that 
future in vitro PRMT activity studies may obtain a more biologically relevant 
measurement of kinetic parameters if a healthy AdoMet/AdoHcy ratio was included in 
the study. 
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     Fig. 7-5.  PRMT1 activity is reduced during disease states.  PRMT1 activity was 
probed under various AdoMet/AdoHcy ratios using the JMH1W peptide 
(KGGFGGRGGFGGKW) in (A) and the JMH1W-CH3 peptide 
(KGGFGGRmethylGGFGGKW) in (B).  Reactions containing 4 μM PRMT1, 0.3 μM 
[H3]-AdoMet (specific activity of 83 μCi/μmol), 50 μM AdoMet (S-isomer only) in 100 
mM sodium phosphate buffer pH 7.1 were initiated with peptide or a mixture of peptide 
and AdoHcy.  Methylation was monitored discontinuously with time using a P81 
membrane assay (as described in Chapter 3).  Reactions initiated with peptide only (●) 
exhibited the highest activity.  Reactions initiated with a mixture of peptide and AdoHcy 
decreased PRMT1 activity according to the amount of AdoHcy present.  The data 
corresponding to the following AdoMet/AdoHcy ratios: 4 to 1, 2 to 1, and 1 to 1 
represent individuals that are healthy, (○); diseased, (▲); and near death, (open triangles), 
respectively.  Control reactions (x) containing only PRMT1 and AdoMet displayed little 
activity as expected.  Reactions were performed in duplicate, and the standard deviations 
are shown.   
 
Obtaining the Ki for a fibrillarin-based 
peptide containing ADMA 
 
In order to determine which type of mechanism PRMT1 performs (random 
sequential or ordered sequential); I looked at product inhibition profiles.  First, I 
examined the JMH1W-ADMA peptide inhibitor (KGGFGGRdimethylGGFGGKW) 
kinetically because AdoHcy could not be examined using the continuous assay (see 
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Chapter 3).  Each reaction containing 4 µM His-PRMT1 and 250 µM AdoMet in 50 
mM sodium phosphate buffer pH 7.1 equilibrated at 37 ºC for 10 minutes before being 
initiated with various amounts of JMH1W-CH3 peptide or a mixture of JMH1W-CH3 and 
JMH1W-ADMA inhibitor peptide.  For calculation of kinetic constants, the concentration 
of peptide was varied at several fixed concentrations of JMH1W-ADMA inhibitor 
peptide (0 µM - 150 µM).  The average initial velocity representing no more than 10% of 
product formation was obtained from two measurements for each pair of substrate 
concentrations and was used to construct Michaelis-Menten plots (Fig. 7-6, A).  The data 
were graphed as Lineweaver-Burk plots (Fig. 7-6, B) and linear regression was employed 
to construct slope and intercept replots (data not shown).  These replots were used to 
calculate the value of the inhibition constant, Kii.  A larger Kii of 462 µM was determined 
for the JMH1W-ADMAinhibitor peptide.  Because this value is larger than both the Km 
for JMH1W and JMH1W-CH3, it is not a potent PRMT1 inhibitor.  Although the 
Lineweaver-Burk plot rules out uncompetitive inhibition, we could not conclude whether 
the peptide inhibitor was a competitive or noncompetitive inhibitor without performing 
additional product inhibition profiles.  Recently, the mechanism of PRMT1 was 
published in September 2008, so any further studies were aborted.  Using peptides 
derived from the in vivo substrate histone H4, Thompson and coworkers concluded that 
PRMT1 performs a random sequential mechanism [6].  
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     Fig. 7-6.  (A) Velocity versus μM JMH1W-CH3 plot.  The following velocities were 
plotted against μM JMH1W-CH3 substrate concentration to obtain Michaelis Menton 
parameters:  0 μM ADMA inhibitor (●), 25 μM ADMA inhibitor (♦), 50 μM ADMA 
inhibitor (crosses), 100 μM ADMA inhibitor (▲), and 150 μM ADMA inhibitor (■).  (B)  
Lineweaver-Burke plot.   The values for 1/velocity (μM CH3/min) at different ADMA 
inhibitor concentrations were plotted against 1/substrate (μM JMH1W-CH3) to obtain the 
slope and y-intercept values of each line at 0 μM ADMA inhibitor (●), 25 μM ADMA 
inhibitor (♦), 50 μM ADMA inhibitor (crosses), 100 μM ADMA inhibitor (▲), and 150 
μM ADMA inhibitor (■). 
 
 
 
Conclusion 
The purpose of this chapter was to introduce several projects that were started and 
have yet to be fully developed.  Importantly, I have shown preliminary data that suggests 
that sequence differences around peptide substrate arginyl groups may affect whether 
mono- or dimethylation is the major end-product.   Although many sequences may be 
PRMT1 substrates, the identity of the sequence may dictate how the substrate arginine 
residue is mono- or dimethylated in vivo.  I also found that certain substrates cause 
substrate inhibition at high concentrations, a factor that may have played a role in the 
inability of PRMT1 to fully methylate the eIF4A1-Y and eIF4A1-S peptides (Fig. 7-1).  
0
0.8
1.6
2.4
3.2
4
4.8
0 50 100 150 200 250
µM
 C
H
3 /
m
in
µM JMH1W-CH
3
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 0.01 0.02 0.03 0.04 0.05 0.06 0.07
1/
v 
(µ
M
 C
H
3 /
m
in
)
1/ µM JMH1W-CH
3
A B 
 187
Next, I showed that the histidine and tryptophan from the conserved THW loop are 
necessary for PRMT catalysis and that this made it difficult to probe specific pi-pi 
interactions that exist at this location between enzyme and substrate.  Finally, I showed 
that PRMT1 activity decreased when AdoHcy or a peptide housing ADMA were added.  
Interestingly, AdoHcy was a more potent inhibitor than the ADMA-containing peptide 
because the addition of a biologically relevant concentration of it regulated PRMT1 
activity.  Altogether, these studies provide good starting points for the development of 
future interesting projects.  
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CHAPTER 8 
 
          SUMMARY 
 
 
 Protein arginine methyltransferases (PRMTs) play an important role in a diverse 
set of biological processes.  PRMTs methylate a variety of protein substrates including 
histones, RNA-binding proteins, and various enzymes.  While PRMT biology has been in 
the forefront, much of the biochemistry for this class of enzymes has remained a mystery.  
The purpose of my study was to develop a biochemical understanding for how PRMT1 
substrates are recognized and modified.  I chose to characterize PRMT1 because it 
methylates over 85% of all protein arginine residues in vivo and has been implicated in 
cardiovascular disease and cancer.  Using a continuous spectrophotometric assay for 
AdoMet-dependent methyltransferases that I helped develop, we first investigated the 
substrate specificity of PRMT1.  Next, in order to understand why most methylated 
proteins are found in the fully dimethylated state in vivo, we analyzed the mechanism of 
asymmetric dimethylarginine (ADMA) formation of single and multiple arginine-
containing peptide substrates.  Finally, we probed a variety of amino acid residues in the 
PRMT1 active site to understand their role in catalysis, specifically their ability to control 
ADMA formation.    
 Defining how PRMT1 works and what the preferred substrates are is pivotal for 
understanding the role that PRMT1 plays in biology.  A major milestone of my research 
was the development of the continuous spectrophotometric assay for AdoMet-dependent 
methyltransferases.  Instead of assaying PRMT1 with radioactively labeled [H3]-AdoMet, 
I helped develop a continuous assay that enabled me to quickly and inexpensively assess 
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PRMT1 activity with a variety of peptide substrates.  In the continuous assay, 
AdoHcy the transmethylation product of AdoMet-dependent methyltransferases, is 
hydrolyzed to S-ribosylhomocysteine and adenine by recombinant AdoHcy nucleosidase 
(SAHN/MTAN).  Adenine generated from AdoHcy is further hydrolyzed to 
hypoxanthine and ammonia by recombinant adenine deaminase.  This deamination is 
associated with a decrease in absorbance at 265 nm that can be monitored continuously 
with time.   
The continuous spectrophotometric assay is robust, inexpensive, and amenable to 
high throughput when evaluating methyltransferases that have been targeted for drug 
discovery.  One main advantage of this assay is the destruction of AdoHcy by AdoHcy 
nucleosidase, which alleviates AdoHcy product feedback inhibition of S-
adenosylmethionine-dependent methyltransferases.  In the absence of enzyme inhibition, 
more accurate measurements of kinetic parameters can be made.  This method may also 
be used to assay enzymes that produce AdoHcy, 5’-methylthioadenosine, or compounds 
that can be cleaved by AdoHcy nucleosidase.   
Using the continuous assay, we made the important discovery that PRMT1 
selectively recognizes and methylates a set of amino acid sequences in substrates that 
extend beyond the ‘RGG’ paradigm.  Prior to this study, PRMT1 was thought to 
methylate substrates only within glycine arginine rich motifs such as ‘RGG’ and ‘RXR’ 
with one exception, histone H4.  Using a focused peptide library based on a sequence 
derived from the in vivo substrate fibrillarin, we observed that PRMT1 methylated eleven 
substrates that had amino acid residues other than glycine in the ‘RX1’ and ‘RX1X2’ 
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positions (Fig. 8-1).  Notably, our results illustrate that the two residues on the N-
terminal side of the modification site are important and need not both be glycine.   
 
 
     Fig. 8-1.  New model for PRMT1 substrate specificity.  Substrate profiling of PRMT1 
revealed that PRMT1 methylates a broad range of substrate motifs when compared to the 
old paradigm.  
 
 
 
This study also demonstrated the importance of amino acid sequence in PRMT1 
protein substrates.  Methylation of two eukaryotic initiation factor 4A protein isoforms, 
eIF4A1 and the similar eIF4A3, could be affected using single site mutations adjacent to 
the modification site.  After comparing eIF4A peptides and proteins, we concluded that 
recognition of protein substrates was not governed by amino acid sequence alone.  Other 
factors such as global protein-protein surface interactions may dictate protein substrate 
recognition.  Future crystallographic studies that examine specific PRMT1-protein 
substrate interactions will help identify important surface interactions. 
Before examining the substrate specificity of PRMT1, limited studies and 
selective tools promoted the idea that PRMT1 substrates conform to an ‘RGG’ sequence 
with few rare exceptions such as histone H4.  Our study clearly showed that PRMT1 is 
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capable of methylating sequences that go beyond the ‘RGG’ paradigm and suggests 
that residues N-terminal to the modification site are also important in substrate 
recognition.  This suggests that the methyl arginine proteome may be larger and more 
diverse than previously thought.  Hopefully, investigators that previously discounted 
arginine methylation as a regulatory factor in their system because the arginine of interest 
was not in a glycine arginine rich motif will now give this modification more thought. 
PRMT1 has recently emerged as a potential new target for the development of a 
novel therapeutic for heart disease because it generates the majority of cellular 
asymmetrically dimethylated arginine (ADMA).  Interestingly, most PRMT1 substrates 
are found dimethylated instead of monomethylated on multiple arginine residues within 
the same protein.  In order to understand the biological prevalence of ADMA, we 
investigated why PRMT1 preferentially asymmetrically dimethylates protein arginine 
residues.  Using kinetics and mass spectrometry analysis, we showed that PRMT1 
preferentially methylated monomethylated peptide substrates versus their unmodified 
counterparts.  PRMT1 did not processively methylate single arginine-containing peptide 
substrates.  Interestingly, methylation of a multiple arginine-containing peptide was 
systematic (not random) and dissociative (not processive).  Based on these results, the 
predominance of dimethylated protein substrates in vivo may be due to the preference 
that PRMT1 has for monomethylated substrates over unmodified substrates.  It will be 
interesting to see if PRMT1 methylates multiple arginine-containing protein substrates in 
the same manner. 
Finally, we investigated the role of several amino acid residues in the PRMT1 
active site in order to understand their role in catalysis and if they specifically controlled 
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ADMA formation.   We hypothesized that two active site methionine residues 
(Met155 and Met48) positioned near the reactive substrate arginine (Fig. 6-1) enable 
PRMT1 to selectively form ADMA instead of SDMA.  M155A and M48A mutant 
proteins were characterized according to their ability to catalyze methylation of a 
multiple arginine-containing peptide based on the in vivo substrate fibrillarin.  Removing 
the steric bulk afforded by each of these residues did not allow for the formation of 
SDMA.  The mutation of Met48 to an alanine in the PRMT1 active site rendered the 
enzyme virtually inactive.  When this residue was mutated to a leucine, activity was 
partially restored indicating that the length of Met48 is critical to PRMT1 catalysis.  Most 
importantly, our results showed that removing the steric bulk afforded by either Met155 
or Met48 in the active site of PRMT1 was not by itself sufficient to transform PRMT1 
into a Type II PRMT.  Therefore, something else about the active site of Type I PRMTs 
governs the specific formation of ADMA.  Perhaps the way in which the 
monomethylated substrate is forced to orient itself in the active site due to strict 
geometric/structural constraints of the active site as a whole facilitates ADMA formation 
and prohibits SDMA formation. 
Further analysis of the M48L-PRMT1 mutant revealed that it was capable of 
automethylation while wild type PRMT1 was not.  This is not a unique, unheard of 
phenomenon because PRMT6 and PRMT8 are capable of automethylation.  It will be 
interesting to identify which arginines of M48L-PRMT1 are methylated and how 
automethylation regulates PRMTs.  Clearly, something about having a methionine 
residue at this active site location juxtaposed to the substrate arginine in wild type 
PRMT1 1) prohibits PRMT1 automethylation and 2) is essential to catalysis.   
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Overall, the research presented in this dissertation mainly focuses on the 
development of a paradigm for understanding how PRMT1 substrates are recognized and 
modified.  First, we identified eleven new substrate motifs that are modified and go 
beyond the typically modified glycine arginine rich motifs (Fig. 8-1).  Second, single and 
multiple arginine-containing peptide substrates are modified dissociatively, and PRMT1 
prefers to methylate monomethylated substrates over their nonmethylated counterparts.  
We also showed that altering select active site residues one at a time did not convert 
PRMT1 into a Type II PRMT.  Although Met 48 was shown to be critical to catalysis, its 
exact mechanistic role has yet to be determined.   
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